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Systems biology studies are becoming increasingly important as the need to study
organisms in a holistic manner, instead of looking at processes in isolation, is be-
ing recognised. This is especially true for the study of host-pathogen interactions
where the responses from bacteria are complex and overlap extensively. This
thesis explores the application of 1H NMR metabolomics to the study of bacteria-
host interactions and seeks to identify its strengths and weaknesses with a view
to integrating this technique into a combined approach that can provide an un-
precedented, sophisticated understanding of host-pathogen interactions that we
believe is intractable by other methodologies.
The BBSRC CASE studentship that supported this work was awarded in
conjunction with Procarta Biosystems Ltd who have produced a new generation
of antibiotics with a novel mechanism of action. The final objective for the
studentship therefore, was to develop a validated systems approach capable of
defining the mechanism of action of this new class of antibiotics; transcription
factor decoys (TFDs). By understanding how the target bacteria respond to
antibiotic threats, the future development of new targets, delivery systems and
formulations can be undertaken in a rational manner. The thesis builds towards
this ultimate goal in three stages by showing, in a stepwise manner, how three
increasingly complex scenarios can be interrogated by NMR metabolomics, either
as a standalone technique or in combination with biophysical or genomic tools.
In the first stage we investigated how the growth of different Pseudomonas
aeruginosa isolates from Cystic Fibrosis patients might influence airway secre-
tions. Growth and NMR analysis of the spent media was technically challenging,
highlighting the need for improved data pre-processing techniques and exper-
imental design. Nevertheless multivariate analysis of changes in spent media
composition could be related to univariate clinical measures of respiratory dis-
iii
ease.
In the second stage we undertook a murine faecal microbiome study to show
how different gut microbial communities affect the host gut metabolome. Faecal
pellets were extracted into aqueous buffer and 1H NMR spectra obtained in the
solution state. Clear differences in the amino acid and short chain fatty acid
complement of the mouse gut were related to divergence in the gastrointestinal
microbiota in the mice. The study required comparison of two separate sets of
multivariate data and showed how, with application of Hierarchical Cluster Ana-
lysis, relationships between microbiota can be simplified to generate hypotheses
that can be tested using metabolomic approaches. In this study the metabolomic
technique was capable of identifying a link between divergence of gut microbiota
and the nutritional performance of the mouse gut.
In the third and final stage, we investigated whether a whole organism view
could provide a bacterial perspective to enable a better understanding of how bac-
teria respond to antibiotic challenges. Here we combined 1H NMR spectroscopy,
now of solid, bacterial cell samples (using high resolution magic angle spinning),
with electron microscopy and transcriptomics to characterise the effect on Es-
cherichia coli of four structurally and physically related antimicrobial peptides
with suspected differences in their mechanisms of action. Bacterial responses
characterised by the NMR metabolomic study could be detected at sub-lethal
antimicrobial peptide concentrations and were qualitatively different according
to the antimicrobial peptide. The technique was sufficiently sensitive and high-
throughput to allow both a range of antimicrobial peptide concentrations to be
probed as well as the bacterial response to be followed over time. Using the NMR
technique to identify optimal conditions for GeneChip experiments allowed the
antimicrobial peptide mechanism of action to be inferred from analysis of the
ontological profile of those genes whose expression is altered in response to the
antibiotic challenge. This study provided a fresh, novel perspective for previ-
ous functional and biophysical studies and shows that, with better integration
with transcriptomic and other systems data, 1H NMR metabolomics will have
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The human body contains 10 times more microorganisms than its own cells and
researchers now estimate that more than 10,000 microbial species occupy the
human ecosystem [3]. Some bacteria are beneficial or even vital for a healthy
population, whereas others are linked to disease and it is important to learn
how this correlates with changes in the microbiome. The study of complete sys-
tems using approaches that provide a holistic view of host-bacterial, in particular
host-pathogen, interactions is becoming an essential tool in the battle against
antimicrobial resistance. Given the complexity of host-bacterial interactions a
systems biology approach is regarded as necessary to move forward in our un-
derstanding of biological processes involved [4–6]. Host-bacterial interactions are
considered dynamic, complex and multifactorial and a combination of advanced
-omics technologies is required to access the level of detail necessary to resolve
the key interactions in their entirety. Therefore, the broad aim of this work is to
develop new ways of investigating how bacteria interact with their environment
and host: how they cope with environmental changes that confer stressful stim-
uli such as a challenge by antimicrobial peptides, but also how bacteria influence
their environment. In this chapter, and each of the results chapters, it is argued
that host-bacterial interactions are complex and deriving meaningful biological
information from such systems is challenging. This thesis suggests that metabolo-
mics techniques (here based on NMR spectra of bacteria or their products) might
be a cost-effective and high-throughput means of characterising these complex
interactions. The key advantage of metabolomics over other -omics approaches
is that it allows reduction of the overall complexity of the system, while retaining
the ability to maintain an overview of the complete system. This is due to the
fact that, in a bacterial cell, metabolites should be less abundant than genes and
proteins [7]. The challenge in applying metabolomics techniques to host-bacterial
interactions is to retain the ability to understand biological function while reduc-
ing the number of reporters from biological processes in the cell. Our ultimate
goal is to combine two existing techniques, metabolomics and transcriptomics,
in a novel approach that provides a platform to probe host-bacterial interactions
yielding mechanistic understandings that are not tractable through other means.
Our approach here has been to relate NMR metabolomic data to, first, univari-
ate measures of patient outcomes, a simplified but multivariate analysis of gut
microbiota and ultimately the highly multivariate data available from GeneChip.
At each step the strengths and weaknesses of the NMR metabolomic method are
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considered, as is the ability to effectively relate this data to a biological under-
standing of host-bacterial interactions.
Understanding the functional connections between genes, proteins and metabo-
lites is one of the greatest challenges in the postgenomic era and -omics ap-
proaches are often applied simultaneously in an integrative approach coupled
with improved performance of bioinformatics. Proteomics is a direct method of
analysing the function of genes by systematic identification and quantification
of its associated proteins. However, such studies are complex and the results
not always discriminatory, since one gene can give rise to more than one pro-
tein through alternative splicing or post-translational modifications in eukarotes.
Post-translational modifications can also lead to profound alterations in protein
activities and characteristics [8]. Another molecular strategy, transciptomics,
measures the expression level of mRNA in a given cell population. Although
transcriptome and proteome analyses provide important aspects regarding phys-
iology of a cell, much is still unknown and it has been argued that the generation
of hypotheses through these -omics data alone, is incomplete and may lead to in-
correct interpretations [8]. Recently metabolomics has emerged as an important
tool in understanding biological systems. Metabolites (small organic molecules)
are either the end products or currency of cellular processes, hence the metabo-
lome level should be an indicator of the transcriptomic and proteomic changes
and reflect the response of biological system to environmental changes [9]. Me-
tabolomics aims to define the complete set of metabolites for a biological system
at a specific time or a cellular state in a holistic approach and provides major
advantages over other -omic platforms:
• metabolomic data is easier to manage, as metabolites are less abundant
than genes, transcripts and proteins, therefore the complexity is reduced
(there are 2,700 metabolites in E.coli, ca. 5,000 genes with ten times greater
proteome size and a number of possible protein-protein interactions much
exceeding this number [10])
• metabolites offer a better way of discriminating between cellular states /
conditions as changes in concentrations of metabolites are faster than in
proteins and transcripts and sometimes changes in proteins and transcripts
do not result in pertinent changes to the phenotype or in metabolites [9, 11]
• with necessary infrastructure (having access to the equipment), analysis
of the metabolome is more cost-effective and high-throughput than of the
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proteome or the transcriptome
Regardless of the platform used, metabolomic data generation consists of five
essential steps outlined in the next chapter (Chapter 2 on page 18):
1. Sample preparation
2. Raw data generation e.g. LC-MS chromatogram or NMR spectra
3. Data pre-processing e.g. spectral calibration, baseline correction
4. Multivariate data analysis and integration into biologically relevant infor-
mation
5. Setting of the results into biological context
The importance of each of these steps are considered in the context of different
applications, of NMR metabolomics to host-bacterial interactions, which each
seek to obtain biologically relevant information from an overview of the main
metabolic variables of each system.
1.2 The complexity of host-bacterial interactions,
a role for metabolomics?
In the ’damage-response framework’ [12], which outlines the contributions of both
the pathogen and the host in the process of pathogenesis, the pathogen is defined
as a microbe that has the ability to cause host damage, virulence is the relative
ability of the pathogen to cause host damage, whereas the virulence factors com-
bine all the properties of the pathogen that can damage a susceptible host. Often,
it is properties of the host at a given time that will determine whether bacteria
are pathogenic or not, thus different hosts can respond differently to the attack
of the same pathogen. Moreover, the same host can have a differing susceptibil-
ity to the same pathogen at different times. Generally, there are four possible
outcomes of a bacterium interacting with a host: commensalism, colonisation,
persistence or disease depending on the ability of the bacterium to avoid, ma-
nipulate or disarm host defence responses. Furthermore, at any given moment of
host-bacterial interaction each of those states can occur at the same time [12]. In
order to survive stress conditions, including the host environment, and maintain
homoeostasis, bacterial cells respond through coordinated changes in gene expres-
sion and cellular metabolism via highly integrated regulatory networks. Bacteria
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have evolved to constantly monitor and counteract harmful environmental in-
sults and are equipped with stress sensing regulatory systems, which operate
predominantly at the level of transcription initiation [13]. This can be achieved
by regulation of gene expression or by using alternative sigma factors (σ), which
are specificity proteins that can redirect ribonucleic acid (RNA) polymerases and
initiate transcription from alternative promoters by substituting the primary σ
[14]. Also, the concentrations of certain metabolites can affect gene expression,
which in turn can regulate metabolic activity [15] (Figure 1.1 on page 9). For
example low levels of tryptophan in the environment induce the expression of
genes responsible for production of this amino acid. According to Vinson et al.
[16] despite Escherichia coli (E. coli) responding to the environmental changes
by regulating the level of enzyme expression to keep metabolite levels stable,
messenger RNA and protein levels do not change in response to most gene dis-
ruptants. Changes in the structure of the metabolic network keep the levels of
most metabolites stable. This is supported by another study [17], which reveals
emergence of an alternative pathway in central carbon metabolism in response
to 12 different nutrient conditions. It did not require changes in gene expression,
but rather relied on the accumulation of an intermediate metabolite. This study
demonstrated the robustness of bacterial metabolic pathways. Brooks et al. [18]
on the other hand postulates, using their data-driven models, that bacteria can
tailor transcriptional responses to environmental changes, despite a modest num-
ber of regulators. It is still to be explored, however, to what extent the changes
of metabolite concentrations and transcriptional response are related [15, 19] and
weather metabolomics and transcriptomics approaches can be combined to gain
insight into the coordination of these responses and their dynamics in the con-
text of host-bacterial interactions. It is also unknown whether metabolomics can
emerge as a stand-alone technique for this purpose.
1.2.1 The influence of host-bacterial interactions on pa-
tient outcomes, a role for metabolomics?
Bacteria are able to mount various stress responses to survive selective pressures
from their environment. Pathogenic bacteria are also capable of deploying vir-
ulence factors that allow them to successfully colonise host organisms [12, 20].
The immune system of the host organism poses many barriers for bacteria and
highly sophisticated virulence factors are required to facilitate entry, inactivate
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host defence systems and provide recovery from the damage suffered by bacteria
from host defences. Despite this large panel of stresses imposed by host cells or
the host organism, pathogens need to access new environmental niches to win
competition with other microorganisms and sustain growth [20]. Colonisation of
a host is beneficial for pathogenic microorganisms as compared with free living
bacteria, as abiotic conditions such as temperature, pH, pressure, osmolarity, hu-
midity among others as well as supply of nutrients is constant [12, 20]. Mounting
stress responses and activation of suitable virulence factors are often intercon-
nected and, in contrast to specific environmental stress responses, much more
complex. Bacteria are under assault from many different stressors simultane-
ously with even more signals to take into account in case of infection when the
host innate and adaptive immune responses are active. This hinders the direct
analysis of host-pathogen interactions using traditional, reductionist approaches.
Bacterial responses to host defence systems can be divided into defensive and
offensive [13]. Defensive responses facilitate survival when faced with challeng-
ing conditions. Offensive mechanisms are represented by the virulence factors
including an array of toxins, adhesins and invasins essential for active crossing
of barriers in a host organism and elimination of its defence mechanisms. When
considering defensive mechanisms, there are two ways in which bacteria can pro-
tect themselves from stress conditions and increase their chances of colonisation
and proliferation: biofilm formation and modifications to bacterial surface struc-
tures. Pathogens can modify themselves and their unique antigens or disguise
them by coating their surface with various host proteins, which results in inhibi-
tion of opsonising antibodies and any subsequent reactions such as phagocytosis
or complement activation [21]. Another variation of this defensive mechanism
is modifications to the composition of bacterial lipopolysaccharride or endotoxin
(LPS) in Gram-negative bacteria and secretion of extracellular material in form
of a slime layer or a capsule. Biofilms are multicellular agglomerations, struc-
tured communities where bacteria of distinct physiological states [22] attach to
each other as well as host surfaces or abiotic surfaces and are embedded in a
slimy extracellular matrix composed of proteins and/or carbohydrates [23]. Var-
ious persistent and destructive inflammatory processes are attributed to bacteria
living as biofilms, since they can reach resistance levels 10-1000 times higher
than planktonic bacteria, which are single-cells that may float or swim in a liq-
uid medium [23]. The high persistence and decreased sensitivity to antibiotic
treatment is caused by many factors. These include reduced metabolic activ-
6
ity, insufficient penetration of antimicrobial agents into biofilms and protection
against phagocytosis, binding of effector molecules, activation of signalling path-
ways and other immune responses by the extracellular matrix. The pathogen is
not recognised as potentially dangerous, therefore the host immune system can-
not elicit the necessary response to eliminate it. This survival mechanism can
be seen in cystic fibrosis patients, whose lung infections are dominated by Pseu-
domonas aeruginosa (P. aeruginosa). Secretions from P. aeruginosa potentially
play a selective role in the overall microbiota composition in the airways and also
affect CF lung function [24]. In our study (Chapter 3 on page 48) the impact
of Pseudomonal secretions on key indicators of patient outcomes has been in-
vestigated. This study serves to highlight how a limited selection of univariate
patient data can be related to the multivariate data obtained in a metabolomic
investigation and potentially identify the key effects of bacterial colonisation.
1.2.2 Microbiome and metabolome, a causal relationship?
Deleterious effects can come also from products secreted by host cells to the
extracellular environment and bacteria have to mount a survival response by up-
regulating suitable stress responses and expression of virulence factors. These
insults can include antimicrobial peptides [25] and other antibacterial agents
such as lysozymes, bile salts, fatty acids, chloridhydric acid, but also resident
microbiota. This can be seen in the specialised microbes that have evolved to
survive the insults imposed on them by the range of niche habitats within the
gastrointestinal ecosystem, such as Bacteriodetes and Firmicutes [26]. Such spe-
cialisation of microbiota to withstand the insults and adapt to the environment
presents evolutionary advantages to the host. Lederberg [27] has emphasised the
importance of having a broad, holistic view of such relationship. The existence
of microbe and human is interdependent; the phenotype of colonising bacteria
can influence the emergent properties of the community and this in turn can be a
factor modulating e.g. nutritional extraction or susceptibility to certain diseases
in some hosts [26, 28]. Metabolites, in turn, are effector molecules and can be
the reason behind the associations between microbiome and conditions such as
obesity, allergy etc., which are associated with alteration in the composition of
the microbiota. Obese and lean humans differ in microbiota compositions [29].
It was demonstrated to modulate metabolism in germ-free mice when transferred
with microbiota from obese and lean humans, highlighting the need for greater
understanding of microbiota-host metabolic interactions. A recent publication
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[30] demonstrates that microbiome disruption early in life, for example through
exposure to antibiotics, can be linked to increased risk of obesity in adulthood.
The gut microbiota has been also shown to be critical in the homeostasis of host
metabolic and immune networks. When early microbial colonisation in mice was
delayed, the gut associated lymphoid tissues (GALT) failed to develop, leading
to persistent immune dysregulation [31]. Links between changes in microbiota
due to antibiotic use, dietary changes, and other lifestyle differences and devel-
opment of allergic diseases have also been shown [32]. Worldwide, sensitisation
rates to one or more common allergens among school children are currently ap-
proaching 40 %-50 % [33]. In Europe, 87 million people suffer from allergies [33]
and the issue and its link to gut microbiome received coverage in recent news [34].
Such a relationship between microbiome and metabolome was investigated in
the mouse gut using NMR-metabolomics. We have examined faecal pellets and
were able to detect differences in their composition which related to the diver-
gence in the mice gut microbiota (Chapter 4 on page 83). The challenge here is
to relate two sets of multivariate data (microbiome and NMR metabolome) to
each other to understand how a change in gut microbiota might effect host re-
sponses manifested in diseases processes. Here the microbiome data is simplified
by using a hierarchical cluster analysis that identified groups of mice whose gut
microbiomes were closely related. This provided groups of mice whose gut faecal
metabolomes could be compared to reveal how variation in gut microbiota can
substantially alter the small molecule complement and nutritional balance of the
animal.
1.2.3 The complexity of bacterial stress responses: Com-
bining metabolomics and transcript profiling to in-
vestigate bacterial responses to antibiotics.
Biological systems are composed of functional units that interact at multiple
levels via complex network of genes, proteins and metabolites. The interaction
is regulated primarily by signalling molecules and enzymatic inhibition or acti-
vation reactions with transcription being controlled by levels of metabolic end
products (Figure 1.1 on the following page). Therefore, in order to capture such
complex and dynamic interplay, which spans so many regulatory levels, a sys-
tems biology approach is essential. To complete this task a combination of -omic
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Figure 1.1: Systems biology level of cellular organisation. Shows metabolic
network and feedback regulation in response to developmental and environmental
conditions. Modified from Carneiro, S.M A (2010). A Systems Biology approach for
the characterization of metabolic bottlenecks in recombinant protein production
processes. Ph.D. Thesis. University of Minho: Portugal.
methodologies supported by biophysical tools were used, which investigate bac-
terial systems at different organisational levels. Combined -omics strategies can
increase understanding of host-pathogen interactions by identifying biomarkers,
giving insights into metabolic and genetic network regulation and identifying
pathway bottlenecks and nutritional requirements. This knowledge will inform
rational development of prevention and control measures. However, to be able to
interpret such data and give it biological meaning, it is essential to differentiate
between different bacterial responses and the possible outcomes of host-pathogen
interactions at the transcriptome and metabolome level.
Bacterial stress responses can be classified into those induced by nutrient lim-
itation (general stress response, the stringent response), cell damage or exposure
to antibiotics (envelope stress, DNA damage, oxidative stress) or abiotic stress
(heat stress, osmotic stress). Each of these types of bacterial stress response
overlap and more than one stress response can be induced by the same stimulus
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and the same alternative sigma factor can be induced independently in different
types of stress response.
The general stress response is initiated by activation of alternative sigma fac-
tor RpoS (ς 38) in response to starvation and growth inhibition, but also growth
rate reduction, extreme temperature changes, high osmotic pressure and low pH
[35]. The RpoS regulon overlaps extensively with other global response networks
and directly or indirectly controls over 200 genes in E. coli [36]. Another aspect
of this response is induction of DNA polymerase (Pol) IV and Pol V. The activity
of Pol V is tightly controlled and targeted in E.coli in order to prevent sponta-
neous mutations which are usually detrimental [37], whereas Pol IV activity leads
to an increase in the spontaneous mutation rate of stressed cells. RpoS has also
been proposed to be responsible for down-regulating enzymes essential for mis-
match repair (MMR) [35]. Therefore, under stressful conditions bacterial cells
are primed for genetic change and accumulate the mutations that increase their
chances of survival via mutagenic phenomena referred to as adaptive mutation
[36].
The stringent response is the second type of response triggered by nutri-
tional limitation and amino acid starvation and its initiation is mediated by
the RelA/SpotT enzymes [38]. It is characterised by accumulation of guano-
sine 3‘-diphosphate 5‘-triphosphate (pppGpp) and guanosine 3‘-diphosphate 5‘-
diphosphate (ppGpp) nucleotides, collectively referred to as (p)ppGpp. The re-
sult of (p)ppGpp accumulation is the arrest of ribosomal translation and, in
E.coli, (p)ppGpp mediates this process by inhibiting replication initiation [38]
thereby shifting the expression of genes responsible for cell growth to expression
of stress-related genes. Little is known about the impact of the (p)ppGpp-induced
stress response on cellular metabolism, but it plays a key role in the adjustment
of the bacterial growth rate, therefore continuously balancing between growth
and survival. It facilitates the RpoH (below) and RpoS responses and multiple
studies suggest that it may be involved in many other cellular responses such as
DNA damage, osmotic, oxidative or SOS stresses [39].
Bacteria have evolved to have many ways to minimise lethal consequences of
exposure to DNA damaging agents. The SOS response is triggered by DNA dam-
age and is mediated by the LexA/RecA regulon [35]. Regions of single stranded
DNA (ssDNA), a result of DNA damage or DNA repair, are recognised and com-
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plexed with RelA, a bacterial recombinase, which in turn induces cleavage of
the LexA repressor. Cleavage of the LexA repressor results in increased activity
of enzymes essential for DNA repair, synthesis and recombination and tolerance
mechanisms including DNA polymerases-Pol IV (above), Pol V, encoded by the
umuDC genes, and Pol II, which is thought to be responsible for rescuing stalled
replication forks [35]. In total, 42 genes have been identified to be regulated by
LexA-RecA regulon including genes involved in eﬄux pumps, channels, mem-
brane function [40]. Other deleterious conditions activating SOS response are ex-
posure to antimicrobials, sublethal/lethal pH and hydrostatic pressure changes,
oxidative stress, metabolic intermediates and nutrient limitation [40]. Recent
studies revealed a network of genes in E.coli that play a role in modulating the
response to DNA damage whose induction is independent from LexA/RecA regu-
lon [41]. A study applying a metabolomic and transcriptomic approach to look at
the effects of agents such as antimicrobial peptides targeting DNA could perhaps
provide more insight into the regulation of those genes.
In the maintenance of homoeostasis in E.coli and other Gram-negative bac-
teria the first line of defence is the cell envelope and bacteria respond strongly
to its perturbation. Those responses are highly regulated by alternative sigma
factors and two component systems (TCSs). There are five major envelope stress
responses in E.coli : sigma factor RpoE (ς E), Cpx signalling system, Rcs (reg-
ulator of colanic acid synthesis), phage-shock protein (Psp), and Bae response
[42]. (ς E) is increased in response to a variety of conditions: heat shock, ex-
posure to ethanol, treatment with antibiotics, mutations leading to misfolding
of outer membrane (OM) and alterations in LPS. The Cpx regulon is triggered
by alterations to the composition of the inner membrane (IM) and also alka-
line pH, whereas the Rcs response is triggered by treatment with beta-lactam
antibiotics and lysosyme, which inhibit peptidoglycan synthesis [43]. Envelope
stress response pathways are therefore activated by generation and accumulation
of misfolded periplasmic or membrane proteins and loss of OM integrity and the
main aspects of the responses involve upregulation of genes encoding periplasmic
chaperones and proteases that refold or degrade those proteins alleviating the
stress response [43]. This helps in repair and biogenesis of the bacterial enve-
lope and thereby restoration of cell surface integrity. Envelope stress response
pathways also play roles in bacterial motility, colony and biofilm formation and
virulence regulation [43].
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Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are gen-
erated in the course of metabolism, exposure to antibiotics and redox-active
molecules and can also be a way of one bacterial species inhibiting growth of an-
other [44]. They can cause damage to proteins, nucleic acids, and cell membranes
and, to counter the effect of oxidative stress, bacterial cells constitutively express
a number of antioxidant enzymes that detoxify the reactive oxygen species and
repair the damage they caused. In addition to the SOS response, several ded-
icated responses to oxidative stress have been identified. Two major adaptive
responses are regulated by the redox-sensitive transcriptional activator (SoxR)
and hydrogen peroxide-inducible genes activator (OxyR) regulons in E. coli [45].
Moreover, exposure to ROS was shown to induce expression of genes required for
induction of components of multidrug eﬄux system promoting resistance devel-
opment [46]. Most of the cell death that occurs upon hydrogen peroxide exposure
is thought to be due to DNA damage [47], whereas some of the DNA damage
leads to miscoding and increased mutagenesis in aerobically growing cells [45].
The heat-shock response (HSR) is triggered upon activation of another alter-
native sigma factor-RpoH (ς 32) through a signal transduction system in response
to a temperature shift above the normal growth range [35]. The consequence of
the response is overproduction of proteins that increase the tolerance of bacte-
ria to such thermal insult-heat-shock proteins (HSPs). The sudden increase in
temperature leads to cytoplasmic stress and misfolded and unfolded proteins.
Among HSPs are chaperones and proteases that aid elimination of such damaged
proteins. Furthermore, in UV mutagenesis, molecular chaperone GroE, which is
controlled by RpoH-regulon, protect Pol V from degradation therefore controlling
the spontaneous mutation rates [48]. It has been suggested that GroE is impor-
tant for Pol IV-induced adaptive mutation by protecting Pol IV from degradation
[49]. The RpoH regulon can be induced by stimuli other than temperature shift:
depletion of amino acids and carbon source, phage infection, challenge with an-
tibiotics or heavy metals, DNA damage and oxidative stress [35].
Another form of stress, experienced by bacteria, that can alter cell structure,
chemistry and physics is osmotic stress. Bacteria attenuate external upshifts and
downshifts in osmotic pressure by accumulation (by de novo synthesis or uptake
from the environment) of electrolytes or small organic solutes such as potassium
ions, glutamate, proline or trehalose and release via mechanosensitive channels.
The main aspect of the response is maintenance of turgor pressure within the
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cells, by ensuring that the osmolarity of the cytoplasm is greater than the osmo-
larity of the medium [50].
To be able to thrive in a variety of habitats, bacteria had to evolve to respond
to fluctuations in their environment. Bacteria have to be able to not only handle
these nutritional and abiotic stresses, but also compete or share their environ-
ment with other organisms in their respective niches and hence may influence
their own environment. Recent studies have focused on characterising those in-
teractions and classifying them as cooperative, competitive or adaptive.
Therefore, in order to gain a comprehensive view of host-bacterial interactions
and regulation mechanisms a method is needed capable of probing such complex
responses.
1.3 Metabolomics
The metabolome is defined as the collective set of low molecular weight intermedi-
ates/metabolites in a biological system under particular physiological conditions
[9, 11, 51]. Metabolomics studies the changes in the biological state of the cell,
tissue, organ or the whole organism by non-biased identification and quantifi-
cation of all detectable metabolites in the system [9, 11, 51] and the term was
coined by Steve Oliver of University of Cambridge [9]. Its sister term, metabo-
nomics, is defined as the quantitative measurement of the time-related multi-
parametric metabolic response of living systems to pathophysiological stimuli or
genetic modification [52], however, the terms are often used interchangeably and
the term ”metabolomics” will be employed throughout this thesis.
Metabolites are both products and reactants of in vivo reactions and simul-
taneous characterisation of a number of metabolites provides a ’snapshot’ of the
dynamic state of an organism. Concentrations of metabolites play direct regula-
tory roles via feedback inhibition and allosteric mechanisms in rapid responses to
metabolic flux changes. Therefore, metabolites are key biomolecules that control
the cellular machinery, as elucidated by the central role they constitute in the
regulome illustrated in Figure 1.1 on page 9. Moreover, the flux of metabolites is
much faster (seconds) in comparison to turnover in proteome (minutes to hours)
[53] and being downstream of both transcription and translation, metabolites
might be better indicator of enzyme activity [54] making metabolomics more
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suited for probing environmental perturbations and enabling the most current
view of the state of an organism. Apart from scientific advantages, metabolo-
mics has also major practical advantages-it is cost effective per sample and more
high-throughput than other -omics, which makes it more suited for screening of a
large number of conditions and their effects on the organisms, tissues or cells [55].
Despite being a relatively recent scientific development, metabolomics, is al-
ready emerging as an important tool in pharmaceutical discovery and develop-
ment, the food industry, medicine, plant sciences and toxicology. It is widely
used in target identification and investigation of the mechanisms of disease and
toxicity and also characterisation of phenotypes and different metabolic states
[56]. A PubMed search for the term ’Metabolomics’ shows 1,559 entries in 2013
and 1,448 in 2014, which is over two-fold increase since 2009 largely due to re-
cent experimental and technological advances. Metabolomic analysis, however,
still faces a number of challenges due to the diverse nature and the amount of
analytes present in each sample. This requires optimised protocols, particularly
sample preparation methodologies, that take into account the chemical diversity
and wide dynamic concentration range of the metabolites in a sample, and selec-
tion of a suitable analytical platform.
The metabolome comprises organic molecules such as amino acids, fatty acids,
vitamins, carbohydrates and lipids, however interactions with inorganic species
are also a subject of research [57]. The size of each metabolome varies greatly
depending on the organism under study from over 2700 metabolites for E. coli
[58] (http://www.ecmdb.ca/), 200,000 primary and secondary metabolites es-
timated for plant kingdom [51]. The Human Metabolome Database (HMDB,
http://www.hmdb.ca) currently contains 41,818 metabolite entries and it grows
each year.
Generally, the aim of metabolomic analyses is the generation of a list of
metabolites with altered concentrations from which biological meaning can be
derived. There are two general approaches that can be applied: the non-targeted
and targeted approach. The aim of a non-targeted approach is non-biased identi-
fication of as many metabolites in a biological system as possible with no a priori
knowledge of the sample nature and composition. Further multivariate analysis
provides a list of molecular features discriminating between samples, allowing
their classification according to treatment, disease, alteration and revealing po-
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Figure 1.2: Metabolomics analysis workflow. A typical metabolomics
experiment involves sample preparation, data acquisition using MS and/or NMR and
metabolite identification and quantification. Once a set of metabolites of interest have
been identified, two types of tools can be used to gain biological insight into
experimental results: (i) mapping and visualisation of pathways and (ii) statistical
enrichment analysis of metabolite annotations.
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tential biomarkers for the condition. Targeted approaches, further divided into
metabolic target analysis, metabolic profiling, metabolic fingerprinting [51] and
metabolic footprinting [59], are used for qualitative and quantitative analysis of
one of a few preselected compounds or classes of compounds in a sample, gen-
erally related to a specific metabolic pathway/metabolic reaction by selective
analysis and specialised calibration methods. This approach is often used for
drug screening and profiling of drug metabolic products [60].
Today, metabolomics applications range from finding a relationship between
phenotype and related gene function, providing biomarkers useful for identifica-
tion of early stage of certain conditions, understanding metabolic reaction net-
works and their in vivo regulation and predicting novel metabolic pathways to
engineering of metabolite fluxes and measuring flux levels of metabolites of in-
terest under varying conditions [51, 61–63].
1.4 Research objectives and thesis organisation
The first chapter of the thesis provides an introduction into the system-level
overview of biological systems and why it is becoming a necessity to understand
the multilevelled repertoire of host-pathogen interactions in biological systems.
The overview of bacterial stress responses provided is linked with the globally
increasing problem of antimicrobial resistance to antibiotics and provides an in-
troduction to antimicrobial peptides (AMPs) and metabolomics. This is followed,
in the next chapter, by an introduction to the main concepts and bottlenecks in
NMR metabolomics and an outline of the process from data acquisition to data
analysis. In Chapter 3 liquid-state NMR has been applied to study the pathogen,
Pseudomonas aeruginosa, and its different isolates colonising the lining of lungs
of cystic fibrosis patients. It has been investigated how this pathogen affects the
host, i.e. patients lung function. In Chapter 4 both host and bacterium have
been investigated in the study of the composition of a gut microbiota in mice
and how differences in gastrointestinal bacterial makeup is linked to divergence
in the host metabolome. Chapter 5 describes the main project, where multiple
-omic approaches have been combined to measure the metabolic response of E.
coli to AMP challenge along with transcriptional response and determine the
extent of correlation between them. The chapter also provides information on
physicochemical characteristics of the peptides used in this study, which were
previously investigated in detail with circular dichroism (CD) and fluorescence
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assays [64]. The ability of bacteria to initiate and coordinate changes in gene
expression and at the metabolome level as a response to varying environmental
factors is essential for successful pathogenesis and maintenance of homeostasis.
In order to gain fundamental insight into the molecular mechanisms governing
events associated with those processes the following objectives were considered
in this thesis:
• How to investigate host-bacterial interactions in a cost efficient, repro-
ducible and high-throughput manner? What are the strengths and limi-
tations of such an approach?
• How to study antimicrobial mechanisms of action of novel therapeutics in
a cost efficient, reproducible and high-throughput manner?
• Is the method sufficiently sensitive to distinguish between different bacterial
responses to sublethal concentrations of structurally and physically related
AMPs and how does this manifest in the metabolome?
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NMR and data analysis in metabolomics: from





The key to a successful metabolomic experiment is the generation of high-quality
biological samples. The type of sample is dictated by the character of the ex-
periment, the target metabolites under study and the sensitivity of the method
used. In metabolomics one can study intracellular (endometabolome) and ex-
tracellular (exometabolome) metabolites. Analysing extracellular metabolites
provides information on what cells excrete into the intracellular matrix, particu-
larly at suboptimal growth conditions, and/or what they fail to assimilate from
their surroundings. While extracellular metabolites present in the extracellular
medium can be filtered or centrifuged to separate them from the cells, the en-
dometabolome sample preparation can involve considerable sample manipulation
for some metabolomic platforms (Figure 1.2 on page 15). This is very important
as, in order to provide meaningful results, it is crucial to minimise the experi-
mental variation that may arise from different stages of sample generation and
processing before the biochemical analysis. Heterogeneity and chemical com-
plexity of metabolites is the main challenge in the field, since sample preparation
methods must be non biased towards any group of metabolites be they volatile,
non volatile, polar, semi polar or non polar and at widely differing concentra-
tions. Generally this step involves quenching of metabolism and application of
time-consuming and sometimes inaccurate extraction and separation procedures.
Other factors that can greatly influence the reproducibility of the results are time
and method of sampling as well as the storage of samples. Nuclear magnetic res-
onance (NMR) spectroscopy sample preparation can also be problematic due to
presence of various buffers and viscous compounds in the sample and the dy-
namic concentration range of the metabolites under the analysis. The relatively
low sensitivity of the method requires a substantial amount of sample, which has
to be taken into account when planning the experiment to ensure a sufficient
number of sample replicates. Determining the sample size for metabolomic ex-
periments is a very important aspect, however currently there are no standard
ways of sample size estimation in metabolomics, due to the complex nature of
such experiment [65, 66]. The rule of a thumb is that one needs 3 times more
samples than the number of components, with components defined as ”indepen-
dent sources of variation in the data” [65]. Technical replicates inform whether an
outlier sample is actually biologically different, rather than the result of system
variability.
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2.1.2 Platforms for analytical quantification
The main efforts in metabolomics focus on the development of analytical plat-
forms for metabolome quantification. Mass spectrometry (MS) is the most com-
monly used technique [51] with its variations: liquid chromatography mass spec-
trometry (LC/MS), liquid chromatography tandem mass spectrometry (LC/MS/MS),
gas chromatography mass spectrometry (GC/MS) and capillary electrophoresis
coupled to mass spectrometry (CE/MS). Other metabolome analyses technolo-
gies include: infrared spectroscopy (IR) and thin layer chromatography (TLC).
Next to mass spectrometry NMR spectroscopy is the main metabolomics analyt-
ical platform. Since the first NMR metabolomic study over 40 years ago [67], the
approach has experienced significant advancements in both instrumentation and
analysis methodology and has become recognised and used extensively in clini-
cal and pharmaceutical applications for the analysis of biofluids and tissues and
in diagnostics for identifying biomarkers and defining pathological status. The
method is powerful enough to produce reproducible and detailed spectra that
provide a linear analytical response at the molecular level. Coupled with a high
dynamic range, this allows comprehensive identification of multiple components
within the sample simultaneously as well as providing quantitative characteri-
sation in a non-targeted and non-destructive manner [56]. The method is used
typically for biofluids where it involves little or no sample manipulation and the
acquisition of the data is rapid and noninvasive [62, 68].
2.2 NMR for metabolomics
NMR is a very powerful and versatile technique that emerged in the mid-1940s
[69, 70] and since then has seen unparalleled growth as an analytical tool for deter-
mination of molecular composition, structure, probing of dynamics and molecular
reactions in areas such as chemistry, biology, materials science, medicine and ge-
ology. It can be applied to samples in the solid, liquid as well as liquid-crystal
and gas states [71]. The application of NMR to solid samples will be discussed
in detail in Section 2.2.2 on page 24.
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2.2.1 The physical background to NMR
Nuclei in magnetic fields
NMR spectroscopy is based on the application of strong magnetic fields and radio
frequency (RF) pulses to the nuclei of atoms that posses spin. The nuclei of all
atoms can be characterised by a nuclear spin quantum number (I ). It can have
a value of zero or greater than zero, with all values being multiples of 1
2
. Any
nucleus with an odd atomic number or odd mass number such as 1H or 13C will
possess nuclear spin and be therefore amendable to NMR observation. For atoms
with I =0, NMR cannot be used, as they have no nuclear spin. When an external,
static magnetic field (B0) is applied, the nuclei align themselves in a specific
number of orientations with respect to the static field. For a spin of magnetic
quantum number I, there are 2I +1 possible spin states, whereas for a spin-1
2
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and it corresponds to
the popular image of a nucleus having two spins which align parallel (α or upper
state) or antiparallel (β or lower state), denoting lower and higher energy states,
respectively [72].
Signal in NMR
If energy, hν, is absorbed, the emitted RF signal from excited nuclear spins is
detected as a time-dependent oscillating voltage that steadily decays as a result
of spin relaxation and which, after applying the procedure of a Fourier transform
(FT), gives a signal in the frequency domain, i.e. a line in the NMR spectrum.
The differences between the two population states are in the order of 1 in 104,
even when very strong field is applied, rendering NMR a relatively insensitive
technique [72]. The nuclear spins precess around the magnetic field vector and
the ν (Lamor frequency) of this precession (Lamor precession) can be measured





where γ is the magnetogyric ratio, which is a constant for any given nuclide. The
nucleus may absorb photons whose frequency matches the difference between the
low-energy and high-energy spin states, δE, according to equation 2.2:
hν = Eupper − Elower (2.2)
where h is the Planck’s constant.
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Features of NMR spectrum
Because the atomic nuclei are present in a molecule at different positions, they
experience different interactions with the surrounding atoms. Of particular im-
portance is the presence of the electron clouds, because they shield the nuclei
from the external magnetic field. A reduced field experienced by the nucleus
reduces the precession frequency of the nuclear spin, while electron withdrawing






where (ν - νTMS) is the frequency difference between the resonance of the sig-
nal of interest and the reference resonance, which for 1H NMR is 2,2,3,3-D4-
3-(Trimethylsilyl) propionic acid sodium salt (TMSP) in aqueous solutions or
Tetramethylsilane (TMS) in organic solutions in units of hertz (Hz) and ν0 is the
operating frequency of the spectrometer expressed in megahertz (MHz). This is




), therefore the units of parts
per million (ppm) are used. TMSP/TMS signal is set by convention to 0 ppm.
The ppm value is device independent, as it is given relative to the spectrometer
frequency. The ppm values based on different references provide a relative chem-
ical shift scale, which is used to distinguish between protons in a molecule and
other nuclei such as 13C, 15N or 31P in the different amino acids providing valu-
able structural information. The chemical shifts can be then assigned to specific
metabolites.
Instrumentation and detection sensitivity
The majority of NMR applications of clinical relevance, including metabolomics,
use 1H NMR. Since the vast majority of metabolites contain hydrogen atoms,
the technique is relatively non biased towards particular class of chemicals unlike
other methods discussed above. The sensitivity of NMR, however, is relatively low
and can still present an obstacle when compared to other spectrometric methods.
1H signal-to-noise depends on many factors according to equation 2.4, however,
an improvement can usually be achieved by either increasing the signal intensity












where N is the number of molecules in the observed sample, A is a term that
represents the abundance of the nuclide, Ts is the temperature of the sample and
surrounding rf coil, T∗2 is the effective transverse relaxation time and NS is the
total number of accumulated scans. The signal intensity depends on many of the
properties of the nuclide involved, such as the natural abundance, the magneto-
gyric ratio and relaxation properties, which are independent of the instrumental
design. 1H has high magnetogyric ratio, nearly 100 % natural abundance and
favourable relaxation properties making it suited for high resolution NMR spec-
troscopy [73]. The number of molecules in the observed sample volume, N, is
directly related to the amount of sample available in the active volume region of
the coil.
In the last decade, significant advances have been made to boost the per-
formance of NMR spectrometers and increase the detection limit in NMR spec-
troscopy, which is generally in the low micromolar range for less crowded parts
of the spectrum. The magnetic field strength is one of the factors and a sig-
nificant advance has been made in the development of more powerful magnets
that also improve spectral resolution, as well as processing capabilities of new
instruments. Moreover, the introduction of cryogenically cooled probes for high-
resolution NMR spectroscopy offers 3-4 fold improvement in detection sensitivity
[74]. Cryoprobes not only reduce the thermal noise by lowering the temperature of
the rf detection coil, but also improve the signal-to-noise by amplifying the signal
detected via inbuilt preamplifier, also kept cooled [74]. Spectra of large molecules
not only suffer from excessive signal overlap, but also from poor sensitivity, be-
cause of their slow tumbling rate, which results in fast relaxation time i.e. signal
loss and effectively broader lines. The introduction of pulse field gradients allows
to selectively detect only the signal of interest and/or discard signals of no interest
improving the optimal dynamic range of the experiment. A significant improve-
ment in sensitivity has been also possible due to application of solvent suppression
techniques with excitation sculpting [75], water suppression through gradient tai-
lored excitation (WATERGATE) [76], presaturation being commonly used. In
NMR metabolomics the most common NMR pulses used for metabolomic profil-
ing are 1D nuclear nuclear Overhauser effect spectroscopy (NOESY) with presat-
uration (1D NOESY-presat) [77] and Carr-Purcell-Meiboom-Gill spin-echo NMR
sequence (CPMG) spin-echo NMR sequence [78], because of high quality water
suppression they offer. Moreover, CPMG allows removal of the broad resonances
associated with macromolecules and slow tumbling compounds, by refocusing the
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signal, therefore enhancing signal from low molecular weight metabolites. Also,
the 2D 1H-1H J-resolved (JRES) NMR pulse sequence with water presaturation
is sometimes used as it allows generation of much less congested spectrum via the
JRES projection (p-JRES). JRES projections are effectively a proton-decoupled
1D 1H NMR spectra (without the multiplicities) achieved by projecting the JRES
spectrum (composed of chemical shift-F2 and spin-spin coupling-F1) along the
F1 axis. This increases the chances of observation of better resolved peaks and
therefore metabolite identification. The limitation of the method is longer acqui-
sition times, approximately 20 min [79].
Field strength
A higher field strength of the magnet (B0) offers improvement of signal-to-noise,
but also an improvement in terms of resolution, as implied by equation 2.2 on
page 21, where the signal-to-noise in an NMR experiment is enhanced as the num-
ber of nuclei in the lower energy state relative to the upper energy state increases
and by equation 2.4 on page 22, hence the total signal-to-noise is proportional to
(B0 new/ B0 old)
3/2. Therefore, using 800 MHz NMR instead of 500 MHz NMR
doubles the signal. Even a modest increase in the field strength when comparing
800 MHz and 900 MHz instruments gives an advantage of almost 20 % in the
signal-to-noise ratio. The frequencies of peaks are also directly proportional to
the magnetic field strength. One ppm on 50 MHz NMR instrument is actually
50 Hz from resonance position of TMS, whereas on a 500 MHz NMR instrument,
1 ppm in 500 Hz from the TMS resonance position, which allows for acquisition
of spectra with much better resolution.
The theory described in this section is oversimplified and a detailed introduc-
tion to NMR theory is beyond the scope of this work, however, there are many
books that provide detailed discussion of the principles of NMR such as [73, 80]
or more advanced [72] and [81].
2.2.2 High-resolution magic angle spinning NMR
NMR can also be used in live cells and intact tissues, often giving uniquely power-
ful insights [82, 83]. The method allows for non-invasive observation of different
groups of metabolites and cellular processes. Similarly to liquid state NMR,
this knowledge can be used in diagnostic, toxicological or environmental studies
[84–87]. Tissue extracts can be analysed by high-resolution liquid state NMR
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spectroscopy or mass spectrometry, however, the information on localisation of
metabolites is destroyed, and targeting of groups of specific metabolites depends
on the selection of solvents employed. High-resolution magic angle spinning NMR
(HR-MAS NMR) spectroscopy of tissues and whole cells has shown to be valu-
able in assessing tissue metabolite profiles non-destructively.
In conventional liquid state NMR, molecules can tumble due to fast isotropic,
or orientation independent, motion and sample all possible orientations with
respect to B0 and effectively experience the same magnetic field. In (liquid-)
crystalline samples or solids, however, such motion is restricted and therefore
the Larmor precession frequency becomes orientation dependent or anisotropic.
Effectively, molecules present in the sample at different orientations will give dif-
ferent signals, where the observed spectrum is a sum of all possible orientations
for each nucleus [72]. This effect, referred to as chemical shift anisotropy (CSA),
gives rise to broad peaks with a characteristic shape and is presented in Figure 2.1.
Figure 2.1: NMR patterns simulated for different kinds of molecular
motions. B0 is the applied static magnetic field. Modified from Dr Louic Vermeer.
In solid samples there are also sources of magnetic fields internal to the sample
which may result in a number of interactions. The full NMR Hamiltonian may
therefore be expressed as:
Hˆ = HˆZeeman + HˆJ + HˆCS + HˆDD + HˆQ (2.5)
where HZeeman is the Zeeman interaction (energy level splitting in atomic nu-
cleus when placed in a magnetic field with the magnitude proportional to the
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strength of the magnetic field), HJ is the J coupling, HCS is the chemical shift
coupling, HDD is the dipolar coupling, and HQ is the quadrupolar coupling.
J-coupling, also known as scalar coupling or spin-spin coupling, is a through
bond coupling of nuclei. The chemical shift in NMR spectra can provide informa-
tion on the structure of the molecule. Since each nucleus can be thought of as a
small magnet, the orientation of that magnet has an effect on the local magnetic
field experienced by other nuclei, which is mediated through bonds. An NMR
peak will split into n+1 peaks, where n is the number of NMR active nuclei within
3 chemical bonds. Magnetically equivalent nuclei do not cause splitting. This
situation is pictured below (Figure 2.2 ) using ethyl acetate as an example. The
blue methyl hydrogens show a peak at 1.3 ppm. These 3 hydrogens are J-coupled
to the 2 red hydrogens resulting in 3 peaks (triplet) methyl peaks (blue). The
peak at 4.2 ppm for red hydrogens is split into 4 peaks, by 3 blue hydrogens
(3+1).
Figure 2.2: Simulated NMR spectrum of ethyl acetate showing the
splitting pattern due to J coupling. Modified from: Wikimedia Commons, the
free media repository.
The most important interaction between the spin and its surrounding spins
is the dipolar interaction. It is the dominant broadening factor in organic solids.
Dipolar coupling is a through-space coupling of two NMR active nuclei. It is the
magnetic effect on nucleus I due to the magnetic field generated by nucleus S. The
dipolar coupling of spins is either between two of the same nuclei (homonuclear
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dipolar coupling) or between two different nuclei (heteronuclear dipole coupling).
The natural abundance of the NMR active nuclei and the space between the
nuclei directly influence the size of the dipolar coupling in solid systems. For
less abundant nuclei, such as 13C, the dipolar coupling can be neglected as the
chance that the nuclei are close together is small. Also, as the distance between
two NMR active nuclei is increased, the interaction between them diminishes.









(1− 3 cos2 θ)(3IzSz − IS) (2.6)
where Hd is the size of the interaction, r is the inter-nuclear distance, γC is
the gyromagnetic ratio of the nuclei and the last term describes orientation of the
inter-nuclear vector. Study of tissues and intact cells becomes possible using high
resolution magic angle spinning NMR (HR-MAS NMR). The method effectively
allows use of almost any solid sample, because dipolar couplings and chemical
shift anisotropy are reduced according to the term:
(3 cos2 θ − 1) (2.7)
where θ is the angle between the long axis of the ellipsoid (principal tensor)
with the field B0, by spinning the sample about its own axis at the frequency of
3-5 KHz and at the magic angle (the diagonal through the cube) of 54.7◦ with
respect to the B0 as seen in Figure 2.3 on the next page. At this angle any vectors
aligned along the z axis will be rotated through both the x and y axes, effectively
making the x, y and z axes equivalent. The anisotropy is therefore removed and
only the isotropic chemical shift is observed.
Andrew et al. [88] and Lowe [89] were first to show that spinning solid samples
at the magic angle reduces line-broadening effect and results in highly resolved
NMR spectra as per example from our laboratory shown in Figure 2.4 on page 29.
As with liquid state NMR, simple sample preparation protocols minimise the
differences between preparations. Also, due to the rapid turnover time of some
intracellular metabolites, a simple protocol without an extraction step is of great
advantage for metabolomic study. In this thesis, high resolution magic angle spin-
ning NMR (HR-MAS NMR) has been applied to bacterial cell pellet (Chapter 5
on page 107), which is a novel way of probing the bacterial metabolome.
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Figure 2.3: The distribution of the electrons about the nucleus is
non-spherical; the magnitude of the shielding depends on the relative
orientation of the nucleus with respect to the static field. Modified from Dr
Louic Vermeer.
2.2.3 Two-dimensional NMR spectroscopy
Despite many advantages that NMR spectroscopy presents, for some samples
severe spectral congestion can hinder the analysis, the identification of spectral
features and assignment of the compounds. In NMR spectroscopy pulse sequences
can be applied to further separate 1D NMR spectra into additional dimensions,
in order to help unravel complex 1D spectra.
In two-dimensional (2D) spectroscopy, intensity is plotted as a function of two
frequencies (F1 and F2), which map out interactions within the molecules and
also between the molecules of interest. The spectrum is usually represented as a
contour map with intensity peaks represented as contour lines at chosen intervals.
The position of the peaks is dictated by the frequency coordinates correspond-
ing to F1 and F2. Depending on the method used and the interactions probed,
2D NMR methods can be divided into three categories: through-bond coupling,
through-space coupling and chemical exchange. Heteronuclear correlation exper-
iments, such as heteronuclear single-quantum correlation spectroscopy (HSQC),
are particularly useful NMR experiments where a two-dimensional spectrum is
recorded in which the co-ordinate of a peak in one dimension is the chemical
shift of one type of nucleus (e.g. 1H) and the co-ordinate in the other dimension
is the chemical shift of another nucleus (e.g. 13C) which is coupled to the first
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Figure 2.4: A comparison of a static (red) and a high speed MAS (blue)
1H NMR spectra of human breast carcinoma sample acquired at 37 ◦C on a Bruker
Avance 400 MHz spectrometer equipped with a 4 mm 1H/ 13C HR-MAS probe using
1H cpmg pulse sequence.
nucleus. Figure 2.9 on page 33 shows and example of 1H/13C HSQC spectrum
with cross peaks for amino acid valine assigned. In homonuclear experiments,
such as homonuclear correlation spectroscopy (COSY), the cross-peak indicates
the position of two interacting nuclei, e.g. 1H-1H. In COSY cross-peaks arise due
to magnetisation transfer between two nuclei that are within one to three bond
lengths through J-coupling. Figure 2.10 on page 34 shows an example of a COSY
spectrum with cross peaks assigned for the amino acid valine.
Two-dimensional 1H J-resolved NMR spectroscopy (JRES) NMR spectroscopy
has the benefits of 1H 1D NMR, but has an additional dimension which allows to
eliminate the congestion problem and overlapping signals, increasing the resolu-
tion and specificity of the spectral information. This method allows for visualisa-
tion of chemical shifts but also J-couplings along the second axis (Figure 2.5, C),
which is instrumental for identification of metabolites in overcrowded spectra, as
it provides the multiplicity and magnitude of coupling. Another advantage of
JRES over other 2D techniques is that its acquisition time is much shorter (ca
20 min) to provide the same sensitivity as a comparable 1D spectrum, making
it amendable for metabolomic study. If required an optional projection of 2D
JRES spectrum along F2 can be conducted, which is similar to 1D 1H NMR
spectrum (Figure 2.5, A), but each proton appears as singlet irrespective if its




Figure 2.5: 1H NMR data of malignant human melanoma cell extracts,
featuring: (A) 1D NMR spectrum acquired using cpmg pulse sequence; (B) the 1D
skyline projection (p-JRES) of (C) 2D JRES spectrum. All acquired at 37 ◦C on a
Bruker Avance 400 MHz spectrometer equipped with a 4 mm 1H/ 13C HR-MAS probe
with magic angle spinning applied at 5 kHz.
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Figure 2.6: 1D 1H NMR spectrum and the chemical structure of amino
acid valine with atom numbers and corresponding resonances and multiplicities
indicated. Taken from The Human Metabolome Database (HMDB).
spectra [79, 90] as can be seen in Figure 2.5, B.
2.2.4 Identification
Typically, compounds are identified by comparing the observed chemical shift to
those of known metabolites stored in databases such as the Human Metabolic
Database (HMBD, http://www.hmdb.ca/) [91], Biological Magnetic Resonance
Data Bank (BMRDB, http://www.bmrb.wisc.edu/metabolomics/query_metab.
php) [92] and the Escherichia coli Metabolome Database (ECMDB, http://
www.ecmdb.ca/) [58]. Chemical shift values, are not precise and deviations of
± 0.2 ppm or more for proton are expected. This is due to variations in the
solvent and temperature in which the spectrum is being recorded [93]. Due
to the nature of the metabolomic NMR spectra and the way the signals arise,
the spectra of biological samples can be very complex with overlapping sig-
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Figure 2.7: Overlay of the 1D 1H NMR spectra of E.coli NCTC9001
challenged with different antimicrobial peptides displaying multitude of resolved peaks.
Here are shown the pellet samples acquired at 37 ◦C on a Bruker Avance 400 MHz
spectrometer equipped with a 4 mm 1H/ 13C HR-MAS probe with magic angle
spinning applied at 5 kHz. Different colours represent different samples.
nals. As a result, unambiguous identification of all individual 1D NMR traces
such as e.g. valine signal (Figure 2.6 on the preceding page) is challenging
when looking at the recorded NMR data (Figure 2.7). Unambiguous identifi-
cation of metabolites in a sample can be difficult, however the number of avail-
able databases is increasing and becoming more comprehensive. The combina-
tion of 1D spectra and multidimensional NMR techniques provides a promis-
ing framework for assignment of spectral features. Also, several commercial
products are available to aid the process such as Chenomx NMR Suite (http:
//www.chenomx.com/software/software.php?pageID=32). Below is an exam-
ple of the assignment process using amino acid valine as an example.
Some metabolites can be assigned directly by comparing the 1D NMR spec-
tra to reference spectra from databases. This is facilitated by analysis of the
signal multiplicities from 2D J-resolved spectra and experimental chemical shifts
for 1H and 13C from 2D 13C HSQC. An example of a JRES in Figure 2.8 on
the following page, HSQC in Figure 2.9 on the next page and COSY in Fig-
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Figure 2.8: Representative contour plot of a 2D 1H J-resolved (JRES)
spectrum of E.coli NCTC9001 challenged with pleurocidin at sublethal concentration
for 30 min; acquired at 37 ◦C on a Bruker Avance 400 MHz spectrometer equipped
with a 4 mm 1H/ 13C HR-MAS probe with magic angle spinning applied at 5 kHz
using the standard pulse sequence. Valine peaks are identified with atom numbers
annotations corresponding to those from The Human Metabolome Database (HMDB).
Figure 2.9: Representative contour 1H/13C HSQC spectrum of E.coli
NCTC9001 challenged with pleurocidin at sublethal concentration for 30 min and
identified valine signals; acquired at 37 ◦C on a Bruker Avance 400 MHz spectrometer
equipped with a 4 mm 1H/ 13C HR-MAS probe with magic angle spinning applied at 5
kHz using the standard pulse sequence. Valine peaks are identified with atom numbers
annotations corresponding to those from The Human Metabolome Database (HMDB).
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Figure 2.10: Representative contour COSY spectrum of mouse
adenocarcinoma cells and identified valine cross-peaks; acquired at 37 ◦C on a Bruker
Avance 400 MHz spectrometer equipped with a 4 mm 1H/ 13C HR-MAS probe with
magic angle spinning applied at 5 kHz using the standard pulse sequence. Valine peaks
are identified with atom numbers annotations corresponding to those from The
Human Metabolome Database (HMDB).
ure 2.10 are shown with signals from valine identified and annotated according to
atom numbers given in The Human Metabolome Database (HMDB) - Figure 2.6.
The statistical total correlation spectroscopy (STOCSY) analysis method is
also used to aid identification of metabolites and confirm tentative assignments.
STOCSY identifies peaks that belong to the same compound, but can also detect
intra-molecular correlations and identify metabolites involved in the same path-
way [94]. Figure 2.11 on the next page shows correlation between the two peaks
of valine at 3.75 ppm and 0.9 ppm. The chemical shifts are in rough agreement
with the chemical shifts expected from valine and provide additional confidence
that the cross peaks assigned previously in HSQC, JRES and COSY belong to
valine.
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Figure 2.11: Representative STOCSY plot of the resonances of E.coli
NCTC9001 challenged with antimicrobial peptide pleurocidin at sub-lethal
concentration from 1H NMR spectra with two valine peaks highlighted in red, therefore
showing high correlation with each other.
2.3 Data processing and multivariate data ana-
lysis
In metabolomics, collected data sets are large, highly multivariate and challenging
to interpret and derive biological meaning. Therefore various high-performance
numeric computation and visualisation methods and tools are used, collectively
known as chemometrics. Tools are being developed in order to tackle this chal-
lenge by various groups [95–102]. While there are many tools focused on inter-
pretation of human metabolic experiments, the availability of options for other
organisms is still limited [103]. Moreover, there is no widely accepted consen-
sus on how to computationally process and interpret metabolic data [104–106].
The areas of disagreement include the strategy for model cross-validation, infer-
ence of class differences, number of samples necessary, parameters used to assess
classification or ways to choose the overall model [107].
2.3.1 Data pre-processing
Before data exploration, spectra have to be subjected to pre-processing to make
them amenable to multivariate statistical analysis. In our laboratory, software
was developed using the Python programming language with numpy and scipy
for calculations, and matplotlib for visualisation. The nonlinear iterative par-
tial least squares algorithm (NIPALS) algorithm [108] was used for orthogonal
PLSDA (OPLSDA) analysis (see Section 2.3.2 on page 42). A manual for data
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processing using our software is included in Appendix A on page 177.
First, spectra have to be calibrated to the internal reference peak which is set
to 0 ppm, phase and baseline corrected (see Appendix A on page 177), in order
to avoid distortions to data analysis and also metabolite quantification. Next,
NMR spectra are read into the software, aligned to a chosen peak and unwanted
spectral features such as solvent peaks, residual water resonance, and reference
peak are removed, by excluding the data points from the analysis. This is fol-
lowed by bucketing (binning) spectra into evenly-spaced, user defined segments
usually of 0.01-0.04 ppm size, in order to correct any minor, global peak shifts
(as opposed to local), decrease the noise and reduce the number of data points to
increase the speed. The intensities inside each bin are summed, so that the area
under each spectral region is used instead of individual intensities. The downside
of this approach is that it may reduce spectral resolution, while some peaks may
appear in two or more bins, splitting the chemical information due to a lack of
flexibility of the boundaries. This can be somewhat overcome by applying man-
ual bucketing to problematic spectral regions that are not crowded. Bucketing
is, nevertheless, a commonly applied pre-processing procedure. Various binning
algorithms have been proposed recently [109–112], however, their applicability
has not been tested in our laboratory.
Sometimes complex spectra cannot be aligned by the binning method or the
peak shifts are larger than the bin size. This can be due to instrumental in-
stabilities, temperature variations, or variations in pH and ionic strength, both
of which influence the ionisation state of basic or acidic groups and thus their
associated chemical shifts. It has been demonstrated that peak shifts can be
beneficial to discern between different groups of samples under certain circum-
stances, however, this effect is unwanted for most applications [113]. Shifting
peaks have to be corrected or excluded from the analysis as they can hamper the
discovery of patterns in the data and lead to incorrect interpretation of the re-
sults. Peak alignment methods are more elaborate than bucketing and generally
require use of commercially available software. Giskeodegard et al. [114] reviewed
the five most prominent warping methods: interval correlation shifting (icoshift)
[115], correlation optimised warping (COW) [116], fastpa [117], variable penalty
dynamic time warping (VPdtw) [118] and parametric time warping (PTW) [119].
In our laboratory a freely available COW-based method adopted for use with
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Figure 2.12: An example of 1H NMR spectra of E.coli NCTC9001
challenged with pleurocidin at sublethal concentration before (top panel)
and after (bottom panel) alignment using COW; acquired on a Bruker Avance
400 MHz spectrometer equipped with a 4 mm 1H/ 13C HR-MAS probe with magic
angle spinning applied at 5 kHz using the standard cpmg pulse sequence.
Python [120] is used (see Appendix A on page 177), based on the original paper
by Niels-Peter Vest Nielsen et al. [116]. Previous packages used in this project
have been freely available and we wanted to maintain this and the software also
allows for adjustment of many parameters in order to achieve the best results.
It uses two input parameters based on the width of the peaks-m, which is the
segment length and t, which is the amount of slack, i.e. the maximum range or
degree of warping in segment length. It has been suggested that parameter m
should be at least equal to the width of the smallest peak that has to be aligned
and that lower values may result in the alignment of noise and distortions in
peak shapes [116]. For each set of spectra, optimal combination of these param-
eters has to be established. Figure 2.12 shows an example of spectra aligned
using this method. Notably, spectral warping can distort spectra and introduce
artefacts, thus absolute quantification should be performed on unaligned spectra.
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This is followed by normalisation, in which spectra are scaled to the same
overall concentration to account for differences in amount of material per sam-
ple, overall variations in sample concentration or for technical reasons in order to
make the samples directly comparable and amendable to multivariate analysis.
Generally, normalisation involves multiplication of every row ( i.e. sample) by a
constant specific to each sample. In the total integral normalisation method the
constant is the total integrated intensity across the whole spectrum or part of it
so that each data point is expressed as a fraction of the total spectral integral.
Total integral normalisation is the standard method used in most metabolomic
studies [121–123], however, it is not optimal for spectra with extreme concen-
trations of certain metabolite in the sample, as this will skew the total integral
and hamper the subsequent scaling and analysis. This issue is overcome by the
probabilistic quotient normalisation (PQN) [124] method, which is currently the
method of choice in our laboratory. Here the spectra are normalised using the
most probable quotient. The most probable quotient can be calculated from the
distribution of signals in a spectrum divided by the reference signal (e.g. median
or mean spectrum from the study or a reference spectrum) [124] so that it is not
affected by the peaks with large changes.
The last step in data pre-processing is scaling. Metabolite intensities have to
be scaled to adjust for variations between high- and low-concentrated metabo-
lites in a sample. The more abundant metabolite will give rise to higher peak,
which will be considered more significant in data analysis, as higher intensity is
generally linked to higher variation. A number of scaling methods are in use.
Mean-centering moves the centre of the data to around zero, instead of the mean
of each intensity, calculates the average spectrum of the data set and subtracts
this from each spectrum. Mean-centering is usually insufficient, particularly for
data of bivariate/multivariate distribution and it is often used in combination
with other scaling methods, as it moves the origin of all the components in prin-
cipal component analysis (PCA) (see Section 2.3.2 on page 40) to the centroid
of the data giving a parsimonious model. Another widely used form of scaling
is autoscaling, where mean-centering is followed by division of each column (in-
tensity) by the standard deviation of that column. In some cases, autoscaling is
applied in order to amplify signals of low intensity which can carry important
information but are obscured by high intensity peaks. This process, however,
also amplifies the noise and therefore should be used with caution and the results
always checked against the original spectra. Pareto scaling is considered as a
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compromise between mean-centering and autoscaling. In the process of Pareto
scaling, data are mean-centered and divided by the square root of the standard
deviation. In this work, the input variables are preprocessed by autoscaling with
a few exceptions where Pareto scaling is used (with justification).
There is no optimum pre-processing method and a combination of processes
described above has to be applied depending on the experiment, sample origin
and analytical method used for data acquisition. The procedures described above
highlight the importance of a good sample preparation protocol due to the nature
of the NMR spectroscopy (low sensitivity, crowding of spectra, line broadening
due to viscosity of the sample) and also the need for spectral reproducibility,
which is essential for metabolomic study.
2.3.2 Model construction and data classification
Despite considerable progress made in the field of metabolomics, the extremely
large and highly correlated datasets still remain a challenge to analyse and inter-
pret. Typically, in a metabolomic dataset there are more variables than samples
(100-100,000s) and the data are highly correlated and non-normally distributed.
Unlike in e.g. microarray data, the number and identity of compounds is not
known. For these reasons different multivariate data analysis tools have been de-
veloped. They enable extraction of information from the data in order to visualise
the trends and relationships between the samples and variables and subsequent
generation of predictive models. This can determine which molecular entities are
’associated’ with specific disease, perturbation, condition etc. It is also possible
to determine which subset of thousands of chemically diverse compounds present
within a cell provides a unique signature for a specific disease, perturbation, con-
dition etc. Knowledge of how those chemical entities are functionally related and
how they respond to perturbations allows to map them onto known metabolic
pathways which can provide more comprehensive, pathway-based interpretation.
Analysis of metabolomics data involves first spectral analysis of the data
showing the overall changes in metabolite concentration. At this level, the study
is neither qualitative, nor quantitative, but should be thought of as a metabolic
fingerprint reflecting the response of the organism to the changing environment
[11]. The data is then subjected to statistical analysis and classification models
are generated. For the results of such analyses to be meaningful, they must be
reproducible over a period of time. Very often, reproducibility is degraded due to
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analytical and sample differences introduced during metabolite extraction pro-
cedure [125] therefore the simplified and straightforward HR-MAS NMR sample
preparation has an obvious advantage. Next, the changes in the metabolome are
identified and quantified. This involves dividing the datasets into classes accord-
ing to the level of variation they demonstrate and determining how well the data
fit with the predetermined classes using statistical software and identifying the
compounds that differ between classes. The final step is to assign them to spe-
cific pathways, which provides information about the intrinsic mechanisms [11].
Principal component analysis (PCA), partial least squares regression or projec-
tion to latent structures (PLS) and PLS discriminant analysis (PLSDA) are, by
and large, the most commonly used multivariate analysis methods that can be
applied to metabolomic data.
Principal component analysis (PCA)
Principal component analysis (PCA) was first introduced in 1901 by Karl Pearson
[126] and later developed and named by Hotelling [127], while a good modern
reference is Jolliffe [128]. PCA is a method used to reduce the dimensionality
of multivariate data, whilst preserving as much of the relevant information as
possible, and also to gain an initial insight into hidden patterns and relationships
in acquired data. During the PCA analysis the original measured variables are
transformed into new variables referred to as principal components (PCs), where
the greatest variance is explained by the first PC, the second greatest variance
by the second PC, and so on. Usually only two or three principle components
are sufficient to explain most of the information in the collected data. The data
can be plotted in a coordinate system based on two or three largest principle
components, that are always uncorrelated and orthogonal to each other. That
way each PC represents different type of independent information since it defines
a different direction of variance. PCA is used mainly to discern information about
the overall structure of the data i.e. similarities and differences among samples. It
is also used for identification of outliers, usually spectra of unacceptable quality
that can be potentially excluded from the analysis. PCA is an unsupervised
method, as the analysis is blind i.e. it does not require any prior knowledge, and
it relies entirely on the input data itself. This ensures an unbiased examination
of the data.
Figure 2.13 on the following page (top right panel) presents the scores plot of
PC1 and PC2 for a model with 3 classes. Each marker on the plot represents one
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Figure 2.13: A representative PCA analysis of samples containing 3 classes:
class 1 (black), class 2 (red), class 3 (blue). PC1 and PC2 account for 60.6 % of the
total variance in the data (A). PCA scores indicate the clustering pattern (B),
whereas loadings indicate the features of the NMR spectrum contributing to the
separation seen in the scores plot (C/D).
single sample. In this example, spectrum 16 is a possible outlier, as it clusters
away from other blue markers. Samples from the class 1 and 3 cluster together in
the top quadrants, therefore they influence the model in a similar way and there
is not much variation between samples of those two classes. Samples belonging
to class 2 (red markers) are separated from class 1 and 3 ( black and blue markers
along PC2 axis. The further away the sample from the origin, the more dissimilar
the sample is from samples belonging to class 1 and 3 and therefore the more
influential the sample is on the model. The loadings plot (Figure 2.13 bottom left
panel) describes the importance of the variables, which are the peaks in the NMR
spectrum. The direction in the loading plot correspond to those on a scores plot
and the loadings are the ppm values from the NMR spectrum. The loadings plot,
therefore allows interpretation of the score plot by examination of the loadings
and correlates the values to the original NMR spectra. In this example the peak
at 3.73 ppm is the main spectral feature separating classes 1 and 3 from class 2
along PC2.
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Partial least squares (PLS) and orthogonal projections to latent struc-
tures (OPLS)
PLS (also known as projection to latent structure) is the most widely used super-
vised statistical method and has been used in science and technology since 1980
[129]. The technique models the variables (X block) using a set of predictor vari-
ables (Y block), which are given by the user. PLS finds the components (latent
variables) which discriminate between two or more different groups of samples
using their covariance with the predictor variables (target class, e.g. control vs
treatment). This method is used for regression modelling when data represent
continuous variables. When variables are in a discrete form and represented as
class memberships, PLS discriminant analysis (PLS-DA) is applied. This method
is used in classification and biomarker studies. In PLS-DA the results are pre-
sented in the form of a scores plot, which gives information about class member-
ship and separation. The weights plot provides information about which peaks
in NMR spectra are responsible for the separation. PLS-DA is a latent variable
method, therefore the data can be projected onto the new space so that it max-
imises the covariance between scores in X and Y spaces, unlike in PCA, where
the algorithm is just looking at the variance in the data set. It is used for two-
class models. Orthogonal PLS (OPLS) is a modified PLS method, which divides
variation in the data into correlated and orthogonal components [107, 130]. The
predictive components are linearly related to the response, whereas orthogonal
components contain unrelated information, such as technical issues or unintended
differences in experimental conditions. The models generated using OPLS are the
same, as using PLS, and therefore the predictive power of the models is identi-
cal, however, model visualisation and subsequent interpretation of the data is
improved [131]. The method can be extended to OPLS-DA.
Hierarchical cluster analysis and generation of heatmaps
Hierarchical cluster analysis (HCA) is another unsupervised method similar to
PCA, which is routinely used to show similarities within metabolic data [132].
The samples are grouped pairwise based on the similarities between them. The
results are presented as a dendrogram where the length of the branch corresponds
to the difference between samples and their groupings. The algorithm constructs
a hierarchy from top to bottom on the basis of a self-organising tree. It dynami-
cally finds the number of clusters at each level. Figure 2.14 on the following page
shows a representative heatmap from HCA of changes in the metabolite levels in
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Figure 2.14: Representiative clustered heatmap of the metabolite yields
(columns) in E.coli NCTC 9001 challenged with different AMPs (rows).
bacteria in response to treatment with different AMPs. Different treatments are
presented in columns and in rows are metabolites that differ in yield depending
on the treatment. HCA groups metabolites based on significant differences in
relative abundance. The level and scale of clustering has to be chosen depending
on the application. Since cross-validated data is used, a Euclidean distance algo-
rithm was chosen to calculate the distance between every pair of objects in a data
set, since it computes the differences directly from the data already subjected to
the statistical analysis in the most intuitive way. Either the average linkage or
complete linkage method was used to link objects into binary clusters based on
distance information from the metric algorithm. Complete linkage computes the
distance between two clusters as the distance between the two farthest objects
in the two clusters, whereas average linkage computes the distance between two
clusters as the average distance between objects from the first cluster and objects
from the second cluster. The freely available MultiExperiment Viewer (MeV),
which is a part of the TM4 Microarray Software Suite [133], was used for hierar-
chical clustering analysis and generation of heatmaps. The details can be found
in Appendix A on page 177.
2.3.3 Model validation: OPLS cross-validation
A vital stage of classification analysis is model validation, also referred to as
cross-validation. It is a standard resampling procedure which estimates the per-
formance of a model when applied to unknown data and checks if it does not
overfit the data. It allows the overall complexity of the model i.e. the number
of PCs in a PCA model to be assessed [134]. Generally, cross-validation proce-
dures involve a series of iterations, where, in each iteration, a subset of objects
from the dataset is removed (the test set) and a model is constructed using the
remaining objects in the dataset (the model building set or training set) and
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subsequently the created model is used to predict the removed objects. Typical
cross-validation involves many iterations and in each round a different subset of
samples is chosen as a test set and training set [134]. Models are therefore tested
using a full training set by means of repeated resampling in a systematic man-
ner. Maximising, in that way, the number of data points used for testing helps
to protect against overfitting of the data. There are different cross-validation
techniques which will depend mainly on the method of sample subset selection
for each iteration [134]. The choice of cross-validation method is dictated by the
data: the number of samples in the training and test sets, the inherent correlation
in the data and ordering of the samples and the total number of variables or the
presence of replicate samples. Usually the method of choice is the one generating
the lowest predicted residual sum of squares (PRESS). In our laboratory, data are
subjected to leave-one-out cross-validation (LOOCV) [135, 136], where part of
the samples are used as a training set and the remaining samples as the test set,
ensuring that the number of samples in the test set is proportional to the total
number of samples from each class and that at least one sample from each class
is present in the test set. The selection of the optimum number of components
is performed using the lowest prediction error in cross-validation carried out on
the samples in the training set, i.e. the optimal prediction of the training set
using test set (samples excluded in the calibration step) or the highest F-1 score
selection method for the two-class models. This method finds balance between
false positives (class 1 predicted but actually class 0) and false negatives (class
0 predicted but actually class 1), as simply counting the number of correctly
predicted samples would be unfair when the number of samples between classes
is not equal. This double cross-validation is repeated 2000 times with randomly
chosen samples in the training and test set to prevent bias due to the choice of
training or test set. The size of both training and test set affects the classification
result. With small sample size only the major differences between groups will
be detected, whereas larger sample size allows for more robust model and more
representative results.
OPLS cross validation provides a scores plot, which shows whether there is any
difference between the two classes of samples and in this case dots cluster away
from each other indicating that there are features in the dataset, that allowed
discrimination between the two classes. The backscaled loadings plots present
the OPLS model that was ’back-scaled’ by plotting the variables with the colour
scale representing their respective correlation weights. This results in a loadings
44
Figure 2.15: Representative cross-validated metabolomic analysis by 1H
HR-MAS NMR. In scores plot blue and red dots represent scores from two different
treatments. Plots discussed in the text.
coefficient plot [113]. The main advantage of the plot is that it shows the variables
with the discriminatory importance directly on the spectrum. The variables that
are important for discrimination between classes are mapped in red and orange,
whereas variables with negative correlation are mapped in blue. The next panel
in the plot in Figure 2.15 indicates that only 2 components were sufficient to
discriminate between the two classes of samples with low PRESS per sample
(the following panel). Histograms of the number of times that a particular Q2
(goodness of fit) value was obtained in each of the rounds of resampling is shown
on the next plot. The Q2 value was calculated as Q2 = 1 - (PRESS/TSS) where
PRESS is the sum of squared differences between the known and predicted classes,
and TSS is the sum of squared differences between the known classes and their
average ( = the total variance). A Q2 of 1 represents the perfect score, whereas a
score below 0 indicates no discriminatory power of the model and it is generally
considered to be good when its value is higher than 0.5 [107, 137]. Finally, this
procedure is repeated and the results are compared to a reference values obtained
by computing Q2 for models where the classes were assigned randomly, i.e. the
cross-validation procedure was repeated again after randomising the Y-table (the
classifiers) [107, 137]. It allows to measure the performance and stability of the
models and is referred to as permutation tests. By comparing obtained Q2 of the
model (Figure 2.16 on the next page, a) with the Q2 of the randomised model
(Figure 2.16 on the following page, b) one can see if the model performs well. The




Figure 2.16: Visual evaluation of the permutation test for the significance
testing. a) Q2 distribution for the D-LAK threshold model and b) Q2 distribution for
the random class assignments, c)The red-shaded area of overlap between two
histograms.
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which Q2 value corresponds to a good discrimination between groups [107].
2.3.4 Summary
This chapter provides an overview of tools and methods used in metabolomics.
It specifically explains the applications of NMR and solid-state NMR in the con-
text of metabolomics and presents the steps involved in the pre-processing and
processing of the data. The chapter also provides an overview of the multivariate
data analysis methods used in the field and explains the rationale behind apply-
ing each of them.
Some of the key issues that researchers in the field of metabolomics are faced
with are also covered. Metabolomic data is inherently complex and biological
contextualisation difficult and requiring knowledge of metabolic networks and
tools. This is compounded by the fact that there is no single analytical method
that can detect all the metabolites within the system due to chemical heterogene-
ity and there are no standardised methods to process and interpret the data.
Some of those issues will be solved to an extent by technological advances and
development of new methodologies, while efforts in development and curation
of community databases will help metabolite identification. The final steps of
analysis, biological interpretation, have considerable potential for improvement




Metabolomic investigation of a relationship
between Pseudomonal growth behaviour and
cystic fibrosis patient lung function
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Work described in this chapter has been published as:
Kozlowska, J., Rivett, D.W., Vermeer, L.S., Carroll, M.P., Bruce,
K.D., Mason, A.J. & Rogers, G.B., A relationship between Pseudomonal
growth behaviour and cystic fibrosis patient lung function identified in a metabolomic
investigation. Metabolomics 2013 (9) 1262-1273
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3.1 Introduction
Cystic fibrosis (CF) is the most common autosomal recessive inherited disorder
in the Western world [138] and in UK almost 10,000 people are affected with
more than two million people being carriers of the faulty cystic fibrosis trans-
membrane conductance regulator (CFTR) gene [139]. CF is caused by loss-of-
function mutations of the CFTR gene, that results in production of abnormally
viscous secretions by epithelial cells lining the surfaces of lungs, pancreas, liver,
reproductive track and intestine of patients. Almost 2000 gene mutations have
been described in CFTR, which can be grouped according to their disruptive
mechanism on CFTR function, and association with residual function and dis-
ease severity [140]. While CF is a multi system disease, the primary cause of
death in patients with CF is respiratory failure [139]. CF is a progressive con-
dition and over time infection becomes established and chronic by adulthood.
Chronic lung infections in CF patients are typically dominated by high levels
of Pseudomonas aeruginosa (P. aeruginosa) and its presence is associated with
reduced life expectancy [141]. P. aeruginosa was cultured in specimens from 61
% of all patients, ranging from 21 % of those less than 1 year of age to more than
80 % of those aged 26 years or older [142]. P. aeruginosa is an opportunistic
pathogen and its virulence stems from a multitude of factors; it is able to form
biofilms, secrete toxins and is intrinsically resistant to various antibiotics as well
as host defences [141]. Periodic exacerbations (episodes of sub-acute worsening)
of P. aeruginosa respiratory infection in patients with CF have traditionally been
treated with antipseudomonal antibiotics. Despite frequent intravenous therapy,
patients continue to have a decline in pulmonary function of approximately 2 %
per year, and eventually 90 % of such patients die of lung disease [142]. There is
still no cure for CF, however, more than 50 % of the CF population in the UK
will now live beyond the age of 41 thanks to many treatments, including antibi-
otics, physiotherapy, exercise and nutrition, available to manage the condition.
This is a significant improvement since 1999, when only half of sufferers would
live beyond 30 years [139].
Undoubtedly, improved use of antibiotics is responsible for a substantial por-
tion of the increased survival that has occurred in patients with CF and antibi-
otic therapy remains essential component in the management of CF lung disease.
Three distinct antibiotic strategies are used depending on the stage of the infec-
tion. First, early aggressive antibiotic therapy against Pseudomonal infection has
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been advocated to delay onset of chronic P. aeruginosa colonisation [143, 144].
Once colonisation with pathogens such as Staphylococcus aureus (S. aureus) and
P. aeruginosa is established chronic maintenance antibiotics are prescribed to
minimise decline in lung function and reduce the frequency and severity of ex-
acerbations of pulmonary symptoms. During exacerbation intensive antibiotic
regimens are frequently administered to relieve symptoms and restore pulmonary
function to baseline values [143, 145]. The choice of appropriate antimicrobial
therapy should be based on review of recent cultures of airway secretions, but a
combination of an aminoglycoside and beta-lactam is recommended to provide
synergy and slow emergence of resistance [146]. Antimicrobial resistance is a
major problem in CF patients and increasing numbers of patients with chronic
P. aeruginosa infection develop multiresistant strains resistant to all drugs in
at least major classes of antipseudomonal antibiotics: beta-lactams, aminoglyco-
sides, and quinolones [145].
3.1.1 Metabolomics for diagnostics of CF
It has long been known that bacteria can influence their environment by secret-
ing a large number of metabolites. P. aeruginosa growth influences metabolite
production, consumption, and biotransformation and therefore has the potential
to play a selective role in microbiota composition in the mucus in the CF lung
influencing the course of the disease and severity of the symptoms. Therefore es-
tablishing the impact of P. aeruginosa growth on airway secretion composition is
fundamental to understanding the behaviour of this pathogen in vivo, its impact
on the host and relationship with other colonising species.
While high-throughput sequencing and microarrays have proven successful to
interrogate 16S rRNA gene sequences in defining the components of the micro-
bial community in the CF lung [147], a metabolomics approach was proposed to
determine the functional impact of isolates on the CF lung. The CF biofilm is
not a sum of its bacterial components, but a complex polymicrobial community
and the snapshot of the dynamic state of the CF lung can be obtained using
metabolomics [52]. Such variation in composition also poses technical problems
to current diagnostics which are culture-based and often unable to isolate all po-
tentially clinically significant bacterial species present in a sample. In this study
a systems biology approach will be applied utilising the research platform based
on NMR metabolomics. It was hypothesised that the phenotypes of clinical iso-
lates would be reflected in the differences in the metabolite levels in spent media
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and that those changes might correlate with patient outcome. Since the bacterial
species in CF vary markedly between patients, being able to relate the microbiota
composition, particularly the dominant P. aeruginosa strain characteristics, to
the lung function in a quick and high-throughput manner would be highly benefi-
cial. It would allow better diagnosis, treatment and, in the future could possibly
inform new strategies to tailor the composition of bacterial community in order
to promote or silence certain bacterial behaviour in vivo and predict the effects
of new therapeutic interventions. Identification of the key biochemical signatures
of P. aeruginosa at different time points of the infection and at varying viru-
lence of the pathogen would allow more effective treatment and prophylaxis; the
limitations of currently used diagnostic methods are well documented [148]. Of
particular importance is prevention of phenotypic diversification of the pathogen
and formation of biofilm by aggressive antibiotic prophylaxis [149].
3.1.2 Development of CF airway composition
The observation that the variation amongst species colonising CF airways is much
lower than in the airways of a healthy individual [147, 150] and also the presence of
a consistent microbiome pattern of the core species [151] suggests involvement of
a selective mechanism in the infection. This is supported by the relative stability
of the overall composition in the adult patient lung during antibiotic treatment
and exacerbations [152], which suggest that the colonising species have success-
fully adapted to the environment and that they are able to selectively compete
or cooperate with other species.
Van der Gast et al. identified clinical factors that can influence the composi-
tion of CF lung, which are CFTR genotype and recent antibiotic treatment [151].
Interestingly, factors such as patient age, gender or FEV1 showed no significant
correlation with the composition of CF lung microbiota [151], however, the study
ignores the input from the dominant strain P. aeruginosa. Nevertheless, this
finding emphasised the need for a new method of assessing CF patients outcome,
as forced expiratory volume in 1 s (FEV1) is currently used as the single main es-
timator of mortality and is also used as a main classifier for lung transplantation
[153], despite the fact that it does not correlate with the lung composition and
dynamics. Interestingly, preliminary data analysis of the samples showed strong
negative correlation between mean FEV1 and spent culture pH (R = -0.76, p
= 0.002) (Figure 3.1 on the next page). No significant correlation was found
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Figure 3.1: The relationship between mean FEV1 and spent culture pH
shown for each of the isolates (R = -0.76, p = 0.002). Analysis performed by Dr
Damian Rivett.
however between lung function and sputum pH (R = 0.50, p = 0.067) or between
sputum pH and spent culture pH (R = -0.37, p = 0.188). Tables 3.2 on page 56
and 3.3 on page 57 list further significant correlations. Therefore a further objec-
tive was to investigate if culture pH also correlates with the nutritional changes.
Secretory products of pathogens are known to contribute to the survival strat-
egy. Alkaline protease secreted by P. aeruginosa is involved in the activation of
the epithelial sodium channel (ENaC), leading to further impairment of mu-
cociliary clearance [154]. Another pathogen, Burkholderia cenocepacia (B. ceno-
cepacia), secretes lipase, which promotes its epithelial invasion, whereas alginate
production by P. aeruginosa mucoid phenotype enhances persistence of B. ceno-
cepacia [155]. Many bacterial pathogens are also known to secrete toxins tar-
geting their competitors residing in the same niche. Here, the differences in the
metabolic composition of the secretions will be investigated. Colonising bacteria
can influence the emergent properties of the community and this in turn can be
a modulating factor [24]. Since P. aeruginosa is the dominant isolate, its growth
will be the major factor affecting availability of certain carbon and nitrogen
sources and also production of other metabolites. Furthermore, P. aeruginosa
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isolates from different CF patients have been reported to show a broad range
of phenotypes and growth characteristics in vivo, such as planktonic growth or
biofilm formation [149] presumably providing basis for the selection strategy.
It has been postulated that the lower airways in chronically infected indi-
viduals represent a complex ecosystem where infections are driven by communi-
ties themselves by constant interplay between the host immune responses and a
pathogen as well as between bacterial species [148]. Kelpac-Ceraj et al. suggested
that looking at the composition of this ecosystem would allow better prediction
of disease progression than investigating specific pathogens [150]. In order to
identify the key selective drivers in this process the secretion characteristics of
the whole community was examined using an untargetted -omics approach, as it
requires determination of changes in the levels of a large number of metabolites.
1H NMR spectroscopy has been used previously to characterise Pseudomonal
growth (PAO1 type strain) in a standard laboratory medium [156]. Here, the
study is to be repeated with Pseudomonal CF isolates from patients cultured in
a synthetic airway model medium. The challenge for the method will be the fact
that this study investigates differences at the species level and the composition
of bacterial communities in CF individuals shows relatively low variation, there-
fore the nutritional characteristics of their secretions might exhibit only subtle
changes that only a sensitive method can detect. It was hypothesised that NMR
metabolomics of isolates from sputum samples alone from cystic fibrosis patients
will allow discovery of metabolic classifiers that would enable assessment of the
severity and course of the infection. The study investigated metabolic differences
between different Pseudomonal isolates, while aiming to more closely replicate
the physiochemical composition of CF airway secretions in a controlled manner
and cultured clinical isolates in a defined synthetic CF medium (SCFM).
3.2 Materials and methods
Here, P. aeruginosa strains isolated from sputum samples collected from 13 adult
CF patients were subjected to 1H NMR metabolomics analysis. For patients 12
and 13 two dominant morphotypes were selected. Table 3.1 on the following




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 3.2: Relationships between the sample characteristics and strain
cluster membership. Assessment of significance was performed using a one-way
ANOVA unless stated (#) whereby a Kruskal-Wallis test was used. Asterisk denotes
significant (p <0.05). R2 indicates the amount of variance in the characteristics












Species richness# 0.284 0.159
Culture pH 0.004∗ 0.751








Table 3.3: Summary of the significant (p <0.05) pairwise Spearman‘s
correlation coefficients observed between the sample characteristics. All




Mucoid: Species richness 0.652
Mucoid: Firmicutes 0.782
Mucoid: Proteobacteria -0.556
Sex: Species richness -0.559
BMI: Diabetes -0.630
BMI: Firmicutes 0.691
Mean FEV1: Culture pH -0.736
CFPE: Culture pH 0.573
Species richness: Firmicutes 0.843
Species richness: Fusobacteria 0.660
Species richness: Proteobacteria -0.955









3.2.1 Bacterial growth conditions
Bacterial quantification and genotyping in samples has been performed by Dr
Geraint B. Rogers. P. aeruginosa density in samples at harvesting was deter-
mined by quantitative (Q) PCR enumeration of oprL gene copies in total DNA
extracts, using a protocol described previously [157]. Random Amplified Poly-
morphic DNA (RAPD) assays were performed for each P. aeruginosa isolate
as described previously [158]. A defined synthetic CF medium (SCFM) closely
replicating the physiochemical composition of CF airway secretions was used as
described previously [159–162]. The SCFM contained: 10 g/L BSA, 10 g/L
porcine gastric mucin, 1.4 g/L herring sperm DNA, 10 mM MOPS, 5 g/L egg
yolk emulsion, 3.6 µM FeSO4, 51.8 mM NaCl, 2.28 mM NH4Cl, 2.128 mM L-
lysine HCl, 14.9 mM KCl, 1.78 mM L-alanine, 1.754 mM CaCl2, 1.661 mM L-
proline, 1.609 mM L-leucine, 1.549 mM L-glutamate HCl, 1.446 mM L-serine, 1.3
mM NaH2PO4, 1.25 mM Na2HPO4, 1.203 mM L-glycine, 1.12 mM L-isoleucine,
1.117 mM L-valine, 1.072 mM L-threonine, 0.827 mM L-aspartate, 0.802 mM L-
tyrosine, 0.676 mM L-ornithine HCl, 0.633 mM L-methionine, 0.606 mM MgCl2,
0.53 mM L-phenylalanine, 0.519 mM L-histidine HCl, 0.348 mM KNO3, 0.306
mM L-arginine HCl, 0.16 mM L-cysteine HCl, 0.119 mM diethylene triamine
pentaacetic acid, 0.013 mM L-tryptophan. The pH of the medium was adjusted
to 6.8. The medium was filter sterilised using a 0.45 µm-pore-size syringe filter
with the exception of porcin gastric mucin, which was sterilised separately by
heating at 70 ◦C for 24h in 95 % ethyl alcohol as described previously [163]. Fig-
ure 3.3 on page 63 shows representative 1H NMR spectra of selected constituents.
Incubation was performed in 9 ml volumes of SCFM in 15 ml Falcon tubes
(BD Biosciences, Oxford, UK) with tight lids, for 72 hours at 37 ◦C , with in-
version every 12 hours. Following incubation, bacterial cells were pelleted by
centrifugation at 12,000 x g, 10 min at 4 ◦C , with the supernatant transferred to
fresh NMR tubes with 10 % v/v D2O added to provide a deuterium lock signal.
3.2.2 NMR
1H NMR spectra were recorded on a Bruker Avance 400 MHz spectrometer
equipped with a 5 mm QNP probe (Bruker UK Limited, Coventry, UK) with
sample isolates tested in triplicate and kept at room temperature. A zgesgp
pulse sequence (Bruker) with excitation sculpting using gradients was used [164].
The 1H 90 degree pulse was 9.75 µs. For each spectrum, 65,536 data points were
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acquired with 16 scans. To help in the assignment of the metabolite resonances,
J-resolved 2D correlation with presaturation during relaxation delay using gradi-
ents (JRES, Bruker) spectra were recorded for some of the samples, using default
pulse sequences as provided by Bruker. The spectral width was 20 ppm. Free
induction decays were multiplied with an exponential function corresponding to
a line broadening of 0.3 Hz. The spectra were Fourier transformed and calibrated
with 2,2,3,3,-D4-3-(Trimethylsilyl) propionic acid sodium salt (TSP-2,2,3,3-D4)
with reference signal at 0 ppm. Phase correction was performed manually and
automatic baseline correction was applied.
3.2.3 Multivariate analysis
A detailed explanation of the pre-processing and processing methods and param-
eters is discussed in Chapter 2 on page 18 and the software manual can be found
in Appendix A on page 177.
Regions above 9.074 ppm and below 0.116 ppm were excluded because of
excessive noise content and few signals. The water peak, ethanol and TMSP
reference signal were also excluded. The spectra were bucketed using a 0.02 ppm
bin size with additional, manual bucketing applied to adjust for peak shifting as
described below, leaving 336 data points per spectrum. Spectra were normalised
using probabilistic quotient normalisation (PQN) [124]. PCA was used to iden-
tify clustering patterns from the major variations between the 49 NMR spectra.
For this analysis, spectra were Pareto scaled after normalisation. In order to find
metabolomic classifiers for each cluster membership and provide a robust sta-
tistical analysis of the models, each possible PCA cluster was analysed against
SCFM cluster using orthogonal PLSDA (OPLSDA) in a series of binary com-
parisons subjected to cross-validation procedure. Here, spectra were autoscaled.
Both normalisation and autoscaling were included in the cross-validation. In the
process 75 % of the samples were used as a training set and the remaining 25
% as a test set, ensuring that the number of samples in the test set was propor-
tional to the total number of samples from each class. To choose the number
of components for the model, a leave-one-out cross-validation was carried out on
the samples in the training set, and the F1-score used to choose the number of
components, with the additional constraint to use a maximum of 8 components.
This was repeated 2,000 times with randomly chosen samples in the training and
test set to prevent bias due to the choice of training or test set. This leads to
4 × 2000 models. The same procedure was repeated with randomised predictor
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variables (Y table) to provide a reference Q2 value. Resonances identified as sig-
nificant from backscaled loadings were verified against the peak intensity of the
original spectra after PQN normalisation. Peaks providing the basis for discrimi-
nation between the classes were assigned by comparing chemical shift values and
multiplicities from J-resolved NMR spectra to values from the Biological Mag-
netic Resonance Data Bank (BMRB) [92] and The Human Metabolome Database
(HMDB) [91], by analysis of published P. aeruginosa metabolic data [165, 166]
and NMR spectra generated from individual medium components (Figure 3.3 on
page 63).
3.2.4 Relationships between PCA and clinical character-
istics
This statistical analysis was performed by Dr Damian Rivett using R (v.2.13.0,
www.r-project.org). One-way factorial ANOVA were performed to test for
significant relationships between the P. aeruginosa strain cluster membership and
sample characteristics, with a significance threshold of p < 0.05. Homogeneity of
variance and normality of errors were assessed using the Fligner-Killeen and the
ShapiroWilk tests respectively prior to the ANOVA. If a factor failed either test
a nonparametric Kruskal-Wallis rank sum test was performed. Factors that were
found to be significant using ANOVA were further studied using Tukey‘s honest
significant difference (HSD) as a post hoc test. Correlations between the sample
characteristics were performed using Spearman‘s rho correlations.
3.3 Results
3.3.1 1H NMR spectroscopy of Pseudomonas CF isolates
cultured in an airway model medium
1H NMR spectroscopy has been used previously to investigate the growth of
P. aeruginosa type strain PAO1 in Luria-Bertani broth, a standard laboratory
medium [156]. In that study NMR was used to demonstrate metabolic differences
between planktonic and biofilm modes of growth as reflected by the composition
of the spent medium. This study was a step further and investigated metabolic
differences between different Pseudomonal isolates, while aiming to more closely
replicate the physiochemical composition of CF airway secretions in a controlled
manner and cultured clinical isolates in SCFM.
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Figure 3.2: Representative 1H NMR spectra generated from non
inoculated SCFM, PAO1 inoculated SCFM, and representative members
of each of the four putative clinical isolate clusters. Shaded regions indicate
large regions of the 1H NMR spectra excluded on the basis of solvent or buffer
peaks-water around 4.8 ppm and MOPS peaks around 2.2, 3.0-3.3 and 3.9 ppm.
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Representative 1D 1H NMR spectra are shown for each of the isolate clusters
identified by PCA described below, revealing the effect of culturing either P.
aeruginosa PAO1 or CF clinical isolates (Figure 3.2 on the previous page). Isolate
6 was excluded from analysis due to insufficient growth in SCFM medium.
Methodological problems
1H NMR spectra generated for each isolate and for the sterile medium showed
high degree of reproducibility within replicates. This study successfully identified
metabolic changes and related them to univariate measures of patient outcomes,
however adherence to the SCFM growth protocol was problematic for the NMR
study and subsequent multivariate analysis. Since liquid-state NMR was used,
large complexes, viscous or solid constituents in the sample will give rise to broad
peaks, which obscure the signal from metabolites in the NMR spectrum. This
problem is discussed in Chapter 2 in Section 2.2.2 on page 24 and one of the
solutions for the future study is to use cpmg pulse sequence [78]. SCFM con-
tains a number of components, such as mucin and BSA, which resulted in peak
broadening and loss of resolution due to high viscosity (Figure 3.3 on the next
page). In addition, a number of the strains analysed were highly mucoid and
capable of producing large amounts of exopolysaccharide (EPS), which leads to
the same problem. Finally, although less noticeable in the SCFM spectrum, reso-
nances attributable to the, presumably, non-metabolised MOPS buffer dominate
the spectra derived from spent media (Figure 3.4 on page 64).
These components of the sample led to a number of very broad resonances,
particularly between 3.5 and 4.5 ppm, and substantial, pH dependent shifting of
both broad and sharper resonances between 3.00 and 3.30 ppm and around 2.10
ppm, (Figure 3.2 on the previous page) as expected from the pH dependence
of buffer resonance chemical shifts (Figure 3.5 on page 65). Noticeable peak
shifts were most likely due to pH- and ionic strength-induced alteration to the
ionisation equilibrium for the function groups of the MOPS buffer. To remove
the influence of MOPS buffer from the analysis, the following regions were ex-
cluded from further analysis in addition to the water and ethanol peaks (5.024.65
ppm; 3.703.76 and 1.221.15 ppm): 4.023.87 ppm; 3.502.87 and 2.271.96 ppm.
Large scale shifting of buffer resonances resulted in ineffective peak alignment
using correlation optimised warping (COW) (Figure 3.6 on page 66). Although
peak realignment could conceivably be achieved through pH adjustment of spent
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Figure 3.4: Chemical structure of MOPS buffer (A), simulated 1D 1H
NMR spectrum of MOPS buffer (B) and fragment of NMR spectrum
showing the problem of obscuring broad MOPS buffer peak (C).
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Figure 3.5: 1H NMR spectra generated for MOPS buffer in 10% D2O at
various pH.
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Figure 3.6: Correction of peak shifting using Correlation Optimised
Warping (COW). Correction works well for the region containing between 4.20 and
3.60 ppm-MOPS buffer (A), however alignment of the multiple peaks between 2.30
and 2.00 ppm is unsuccessful-MOPS buffer (B).
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media as is done for e.g. urine samples [167], manual peak bucketing was able
to eliminate the observed peak shifts. The exclusion of large regions, consider-
able spectral overlap and the appearance of broad resonances following bacterial
growth also precluded the use of statistical correlation spectroscopy (STOCSY)
or other two-dimensional techniques to aid assignment for many resonances. For
this reason our present efforts were largely restricted to using the 1H NMR tech-
nique and multivariate analysis to divide the isolates into groups with similar
growth strategies.
3.3.2 PCA identifies putative clusters
The clustering patterns between spectra obtained for the clinical isolates (n =
41) and SCFM medium (n = 8) were identified using PCA. The representative
2D scores plots of component 1 (PC1) versus component 2 (PC2), which explain
67.7 % of the variation in the spectra, reveal four putative separate clusters rep-
resenting the different biochemical composition of the samples as detected by the
NMR spectra (Figure 3.7 on the following page). In the PCA scores plot, each
data point corresponds to one 1D 1H NMR spectrum, and the reproducibility of
the method was confirmed by the close arrangement of data points corresponding
to replicates from each isolate (Figure 3.7 on the next page). NMR spectra of
the CF clinical isolates fell into two, readily identifiable, main clusters (I and II)
that were separated by PC1, which accounted for 56.3 % of the variation in the
spectra. Cluster II is possibly subdivided into two or three further putative clus-
ters (IIa-c) separated by PC2, with groups of isolates in separate quadrants of
the PCA scores plot. The spectra from isolates in the three or four clusters were
each well separated from those of the sterile synthetic media with the exception
of isolate 1 which caused almost no change in the 1H NMR spectra of the spent
media. Cluster I was mostly separated from SCFM by PC2. Three of the four
isolates found in Cluster I (1, 10, 12b) are notable in that they lead to a very
acidic pH in the spent media (Table 3.1 on page 55). This might cause the cluster
members to be distinguished purely on the basis of pH dropping below pH 6.0
which causes MOPS resonances to shift even beyond the ranges excluded above
(Figure 3.5 on page 65) and could possibly influence the clustering of the isolates.
A broad resonance at 4.04 ppm does appear for these isolates which can be as-
signed to the MOPS resonance expected in this region, however additional MOPS
resonances expected between 3.50 and 3.87 ppm could not be discerned above
the contribution from metabolite resonances. Cluster II was further separated
from SCFM by PC1, but also along PC2 where isolates were further separated
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Figure 3.7: Scores scatter plot resulting from applying PCA to the 1H
NMR data by component 1 (PC1) and component 2 (PC2). The percentage of
variance in the data explained by each component is indicated on the relevant axis.
Strain identification numbers are shown. Ellipses are drawn to show putative clusters
of spectra. SCFM-synthetic cystic fibrosis media.
into upper and lower quadrants. Initially a three cluster model was considered
with Cluster IIa in the lower quadrant and Cluster IIb in the upper quadrant.
The existence of a fourth putative Cluster IIc, with isolates located intermediate
to Clusters IIa and IIb, was considered and tested by OPLS-DA below. Key
resonances whose variation contributes to PC1 and PC2 are shown in the corre-
sponding PC backscaled loadings plots (Figure 3.8 on page 70 - Figure 3.12 on
page 74) and Table 3.4 on the following page presents Q2 values of the models
resulting from each binary comparison.
3.3.3 OPLS-DA supports clusters identification
Orthogonal projection to latent structures discriminant analysis (OPLS-DA) was
then used to compare 1H NMR spectral data generated from sterile synthetic me-
dia with each of the four putative strain clusters and to test whether Cluster II
could indeed be considered as three separate clusters. Cross-validation was per-
formed on all models and the output plots are presented: Figure 3.8 on page 70
- Figure 3.12 on page 74. The resulting 2D scores plots show good separation
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Table 3.4: Predictive Q2 values for all models. Cluster IIa and IIb contain
isolates 4, 7, 11, 13, 14 and 2, 5, 9, 12, 13b, respectively, in the 3 cluster model and
lose isolates 2, 4, 5, 14 to Cluster IIc in the four cluster model. Q2 values for models
run with permutated class assignments are given in parentheses.
Test 3 cluster model 4 cluster model
SCFM versus cluster I 0.92 (-0.63) 0.92 (-0.63)
SCFM versus cluster IIa 0.99 (-0.44) 0.99 (-0.47)
SCFM versus cluster IIb 0.99 (-0.46) 0.99 (-0.48)
SCFM versus cluster IIc - 0.99 (-0.40)
Cluster IIa versus cluster IIb 0.71 (-0.46) 0.91 (-0.50)
Cluster IIa versus cluster IIc - 0.84 (-0.47)
Cluster IIb versus cluster IIc - 0.92 (-0.44)
between the three or four putative clusters and SCFM with Q2 values > 0.90, in-
dicating a highly reliable model as compared with an ideal score of 1 (Table 3.4).
Initially, the PCA scores plot identified two separate isolate scores clusters (Clus-
ter I and Cluster II) with Cluster I, comprising isolates 1, 3, 10 and 12b. Using
OPLS-DA, putative Clusters IIa and IIb, containing isolates 4, 7, 11, 13, 14 and
2, 5, 9, 12, 13b respectively, could be separated (Figure 3.11 on page 73) with Q2
of 0.69. However, when a further putative cluster (IIc) was considered, compris-
ing isolates 2, 4, 5 and 14 (PCA scores for these isolates show an intermediate
distribution between the upper and lower quadrants due to PC2), the apparent
separation as monitored by scores plots (Figure 3.9 on page 71 and Figure 3.10
on page 72) and Q2 (Table 3.4) indicated that a four cluster model may be useful
when greater numbers of patient isolates are available.
3.3.4 Relationships between strain cluster membership
and sample characteristics
To determine whether differences in the nutritional modifications to airway secre-
tion composition that result from the growth of P. aeruginosa may have clinical
impacts, membership of CF sputum isolate clusters, as defined based on PCA
and OPLS-DA, for both three and four cluster models, was compared with a
number of potentially key strain or sputum sample characteristics. These fac-
tors were isolate auxotrophy, mucoidy, pigmentation, spent culture pH, sputum
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Figure 3.8: LOOCV output files for the comparisons of SCFM and
putative Clusters I (A) and IIa (B). From top left to bottom right: scores plots
showing good separation between classes; back-scaled loadings plots showing 1H
resonance frequencies that discriminate between the two classes under comparison;
histograms showing number of principal components used to separate the classes;
prediction residual error sum of squares (PRESS) indicating low within-sample
variation; Q2 value histogram comparing random class assignment (grey) and the
actual class assignment (blue); comparison of model predicted for the sample
classification as compared to the actual class.
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Figure 3.9: LOOCV output files for the comparisons of SCFM and
putative Clusters IIb (A) and IIc (B). From top left to bottom right: scores
plots showing good separation between classes; back-scaled loadings plots showing 1H
resonance frequencies that discriminate between the two classes under comparison;
histograms showing number of principal components used to separate the classes;
prediction residual error sum of squares (PRESS) indicating low within-sample
variation; Q2 value histogram comparing random class assignment (grey) and the
actual class assignment (blue); comparison of model predicted for the sample
classification as compared to the actual class.
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Figure 3.10: LOOCV output files for the comparisons of Cluster IIc and
either putative Clusters IIa (A) or IIb (B) in a putative four cluster
model. Scores for Cluster IIc shown in red (A) and then blue (B). From top left to
bottom right: scores plots showing good separation between classes; back-scaled
loadings plots showing 1H resonance frequencies that discriminate between the two
classes under comparison; histograms showing number of principal components used
to separate the classes; prediction residual error sum of squares (PRESS) indicating
low within-sample variation; Q2 value histogram comparing random class assignment
(grey) and the actual class assignment (blue); comparison of model predicted for the
sample classification as compared to the actual class.
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Figure 3.11: LOOCV output files for the comparisons of Cluster IIa
(blue) and Cluster IIb (red) in a 3 (A) or 4 (B). From top left to bottom
right: scores plots showing good separation between classes; back-scaled loadings plots
showing 1H resonance frequencies that discriminate between the two classes under
comparison; histograms showing number of principal components used to separate the
classes; prediction residual error sum of squares (PRESS) indicating low
within-sample variation; Q2 value histogram comparing random class assignment
(grey) and the actual class assignment (blue); comparison of model predicted for the
sample classification as compared to the actual class.
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Figure 3.12: Leave-one-out cross-validation (LOOCV) output files for the
comparisons of Cluster I (blue) and Cluster IIb (red) in a 3 (A) or 4 (B)
class model. From top left to bottom right: scores plots showing good separation
between classes; back-scaled loadings plots showing 1H resonance frequencies that
discriminate between the two classes under comparison; histograms showing number
of principal components used to separate the classes; prediction residual error sum of
squares (PRESS) indicating low within-sample variation; Q2 value histogram
comparing random class assignment (grey) and the actual class assignment (blue);
comparison of model predicted for the sample classification as compared to the actual
class.
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pH, species richness and relative phyla abundance as defined by 16S rRNA gene
clone sequencing analysis, P. aeruginosa density as determined by quantitative
PCR, patient age, sex, genotype, BMI, diabetic status, FEV1, and the number of
respiratory exacerbations over the preceding 12 months. This analysis has been
performed by Dr Damian Rivett and the details can be found in the methods
section. Highly significant relationships were identified between cluster member-
ship and lung function (FEV1) (F(3,10) = 5.64, p = 0.0159) and between cluster
membership and spent culture pH (F(3,10) = 8.63, p = 0.004,) (Figure 3.13 on
the following page). These significant relationships were tested using Tukey‘s
honest significant difference (HSD) to assess for significant differences between
clusters. In the three cluster model, this analysis found significant differences
between Clusters I and IIb (padj = 0.020) and between Clusters IIa and IIb (padj
= 0.030) for lung function (FEV1) with patients in Cluster IIb having relatively
poor lung function (Figure 3.13 on the next page, a). In the four cluster model,
Cluster I was shown to be significantly different from both clusters IIb (padj =
0.005) and IIc (padj = 0.010) (Figure 3.12 on the preceding page). A possible rela-
tionship was also observed between sputum pH and cluster membership (F(3,10)
= 3.06, p = 0.078, pH ranged from 5.9 to 7.8). Significant differences in spent
culture pH were observed between Cluster I and both Clusters IIa and IIb in the
three cluster model (Figure 3.13 on the next page, b). Therefore, although Clus-
ter I and Cluster II are clearly separated in the PCA analysis (by PC1), the only
significant differences that were found both in FEV1 and spent culture pH were
between Cluster I and Cluster IIb with a significant difference in FEV1 also seen
between Clusters IIa and IIb. These clusters are separated in the PCA analysis
by PC2 and hence identification of resonances contributing to PC2, rather than
PC1, or OPLS-DA analyses between these clusters should identify metabolomic
changes that cause the variance in FEV1 or spent culture pH.
3.3.5 OPLS-DA identifies characteristic metabolite con-
sumption and production
The OPLS-DA comparisons of Cluster IIb with Cluster I (Figure 3.12 on the
preceding page) and Cluster IIa (Figure 3.11 on page 73) again support the clus-
tering determined above and allow identification of resonances from metabolites
that may be implicated in FEV1 and/or spent culture pH. Plotting normalised
spectra from each of the four clusters, coloured according to cluster, highlights
resonances whose intensity is consistently altered between clusters (Figure 3.15
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AB
Figure 3.13: Box plots comparing FEV1 (A) and spent culture pH (B) for
each of the clusters in the three cluster model; * indicates p < 0.05.
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AB
Figure 3.14: Box plots comparing FEV1 (A) and spent culture pH (B) for
each of the clusters in the four cluster model; * indicates p < 0.05.
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on the following page). Comparing the backscaled loadings plots for the com-
parisons between Cluster IIb and Cluster I and between Cluster IIb and Cluster
IIa identifies metabolites whose differing intensities correlate with the significant
differences identified above for lung function FEV1 and/or spent culture pH. No-
tably, levels of lysine or ornithine appear higher in the spent media of isolates in
Cluster I or IIa when compared with those from Cluster IIb, where lung function
was poorest, as evidenced by their characteristic resonances at 3.765 ppm (Fig-
ure 3.15 on the next page, A) and 1.465 ppm (Figure 3.15 on the following page,
B). A resonance characteristic of leucine at 1.728 ppm (Figure 3.15 on the next
page, B) is also elevated in spectra of spent media of isolates in both Clusters I
and IIa while a broad resonance that appears at 6.80 ppm (Figure 3.15 on the
following page, C), in many spectra from Cluster IIb isolates, is largely absent
from either Clusters I or IIa. Spectra from isolates in Cluster IIc are intermedi-
ate between spectra from isolates in either Cluster IIa or IIb for these features.
An additional broad resonance at 5.77 ppm is notable (Figure 3.15 on the next
page, C) but its intensity does not correlate with FEV1 and is one of the main
resonances that contributes to the separation of the isolates by PC1 in the PCA
analysis.
3.4 Discussion
Untargeted metabolic profiling was applied to the spent media (metabolic foot-
printing) to compare 15 Pseudomonal isolates from 13 CF patients and their
nutritional adaptations to chronic CF lung infections. The metabolite composi-
tion of the spent culture media was compared between isolates, patients and with
the patient lung function and various sample characteristics. The influence of the
nutritional sources on bacterial community composition has been discussed previ-
ously [168, 169] and high cell number of P. aeruginosa colonising CF lung affects
the host by selectively allowing co-infection and subsequent co-colonisation by
other bacterial species.
Bacteria influence the environment within the host by large- and fine-scale
modifications in the utilisation of compounds such as carbon and nitrogen sources
and the production of major metabolites. It was hypothesised that probing those
modifications will provide an indication of the degree to which P. aeruginosa iso-
late growth might have a differential impact on CF airway secretions and to try
to identify a composition favoured during e.g. exacerbations and used them for
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Figure 3.15: Normalised 1H spectra (with excluded regions but otherwise
untreated) of spent media coloured according to cluster membership.
(Cluster I-blue, Cluster IIa-red, Cluster IIb-green, Cluster IIc-yellow). Spectral
regions between 3.5 and 3.85 ppm (A), 5.6 and 6.9 ppm (B) and 1.4 and 1.8 ppm (C)
are shown.
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early diagnosis. Insights into nutritional composition and its role in promot-
ing or silencing communication between different species colonising CF lung and
identifying the consequences of any alterations will be helpful in treatment and
management of the condition.
The aim was to obtain a dynamic snapshot of major compositional changes
taking a systems biology approach and the method of choice was 1H NMR spec-
troscopy. It allows to monitor all the metabolites simultaneously with high re-
producibility, therefore allowing to see the between sample variation in chemical
composition.
In the experiment a defined synthetic growth medium (SCFM) was used in
order to replicate more closely the composition of CF lower airway secretions. It
was demonstrated in previous studies to be a suitable medium for in vitro model
of CF lower airway conditions [160, 162]. Adherence to the well validated SCFM
growth procedures presented some challenges for the NMR and in the future the
constituents would have to be replaced with deuterated forms or by less viscous
buffers in order to avoid pH-dependant peak shifts and peak broadening. Also,
HR-MAS NMR could be considered in order to eliminate the broad resonances.
The exometabolome (spent culture media) was analysed as this provides a
direct measure of the interaction of bacteria with the environment and addressed
the main question: ”To what degree the impact of P. aeruginosa growth dif-
fered between clinical isolates under conditions approximating those encountered
in vivo”. Metabolic profiling showed substantial differences between different
CF isolates, which were categorised into four separate clusters (Figure 3.7 on
page 68), representing four end-stage phenotypes. The clustering was driven
mainly by changes in levels of amino acids, which may be an evidence of metabolic
adaptation to the host environment. Strains could have evolved more efficient en-
ergy strategies in the low oxygen tensions in mucopurulent CF sputum. Studies
shown that amino acid levels influence the antibiotic susceptibility of P. aerugi-
nosa [170] and their growth strategies [171, 172].
Cluster membership was found to correlate with spent culture pH (Table 3.2
on page 56), despite careful exclusion of pH shifting resonances from the ana-
lysis and successful spectral alignment. However, visual inspection of the spectra
from each cluster (Figure 3.2 on page 61) shows clear variation in levels of me-
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dia constituents and metabolites produced/consumed between isolates and not
pH-induced peak-shifts. No correlation between P. aeruginosa cell count and
cluster membership was found (Table 3.2 on page 56), indicating that isolates do
not cluster according to cell numbers, but are indeed separated by divergence in
growth strategies. The cause of the change in pH of the medium could be due to
change in levels of non-pH neutral components. It could also be due to proton
extrusion into the medium, which is an important component of the adaptation
to growth at low pH. Nevertheless, the impact of P. aeruginosa growth on pH
could have major clinical implications since it has been shown to influence both
bacterial community composition [173, 174] and behaviour [175]. Innate defence
processes such as ciliary function [176] and mucus viscosity [177] have also been
shown to be affected by alterations in airway secretion pH.
A highly significant relationship was also found between the cluster member-
ship of CF isolates and the lung function of the patient from which they were
obtained (as measured by FEV1) (Table 3.2 on page 56). This demonstrates the
strong relationship between the nutritional modification of the environment by
P. aeruginosa growth and patient lung function and suggests that further re-
search to deepen our understanding of bacterial community composition in the
CF airways is needed.
The CF lung is a very heterogeneous environment with a broad range of
species [147] with nutritional requirements being the main selective pressure in
the colonisation process. Interestingly, bacterial species commonly found in oral
cavity are not reported in CF lower airway secretions and this is thought to be
due to changes in the nutritional availability which in CF lung is modified by
dominant bacterial species [178, 179]. Such interactions, however, are still poorly
understood in the CF lower airways.
3.5 Conclusion
1H NMR was applied to see the effect of P. aeruginosa growth in a model CF
medium on different isolates. NMR divided isolates into 4 clusters, based mainly
on divergence in metabolite production, which suggests that P. aeruginosa iso-
lates are able to adopt different growth strategies in response to changing envi-
ronment. Highly significant relationships between P. aeruginosa isolate, patient
lung function (FEV1) and spent culture pH suggests future application in pre-
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dicting patient lung function via characterisation of P. aeruginosa growth.
This study is an example of how NMR metabolomics offers a way of imple-
menting personalised healthcare protocols. It measures the metabolite levels in
an organism and models the changes in its levels in biological fluids and tissues
and links those variables to health and/or diseased status. The altered levels
of certain metabolites can be then used as predictors of susceptibility to dis-
ease or likely effectiveness of the treatment. Such systems (of the whole human
organism) measurements and modelling approaches unravel human complexity
and meet the medical requirements of today’s market; the methodologies are ro-
bust, cost efficient and high-throughput. Nevertheless, this study highlights the
importance of experimental planning and shows the main limitations of liquid
state NMR methodology. The SCFM growth medium contains a number of large
and viscous components which could not be eliminated and resulted in the pres-
ence of broad, peak-obscuring metabolic changes. The most difficult problem to
overcome was pH-sensitive peaks from non-metabolised MOPS buffer. In this
study peak alignment and exclusion successfully mitigated this effect, however,




Application of NMR metabolomics in
investigation of the effects of gastrointestinal
microbiota divergence in genetically identical
mice
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4.1 Introduction
The microbial diversity in a human ecosystem is high and estimated to be occu-
pied by more than 10,000 microbial species [3]. Human distal gut represents the
highest density natural bacterial ecosystem known and contains more bacterial
cells than all of other microbial communities within human ecosystem combined
[180]. The human colon ecosystem alone has been estimated to contain more
than 400 bacterial species the vast majority of which belong to two phyla of
bacteria-the Bacteroidetes (48 %) and the Firmicutes (51 %) [180, 181]. These
complex microbial communities are believed to contribute to health maintenance
and, when in imbalance, to the development of diseases. Despite being an integral
part of human biology, the development and evolution of intestinal microbiota
and how its composition relates to human physiology is still considered poorly
understood [160, 181, 182]. The gut microbiota has been linked to immunity [183]
and nutrient intake, as well as cardiovascular health [184], obesity [29, 30, 185], di-
abetes [186], metabolic abnormalities [187], inflammatory bowel conditions [188],
hepatic function [189] nervous system development [190], carcinogenesis [191]
and recently allergy [32, 33]. Microbiome sequencing studies showed that the
microbiota composition correlates with characteristic changes and health and
disease risk [192, 193]. However, a new consensus emerged which suggests that
bacterial community composition changes should be accompanied by studies of
community function and understanding at the molecular level [194]. This can
be accomplished by investigating host metabolism, modulation of host signalling
pathways and synthesis of metabolites inferred from metabolomic studies. Only
such a detailed understanding of host-microbiota interactions would reveal how
microbiome relates to disease [194]. Metabolites are effector molecules and simul-
taneous analysis of a large number of metabolites in a host gut will highlight the
differences in function of gut microbial communities and will allow to link them
with disease characteristics which can perhaps be modulated by perturbations
from small molecule drugs or pre- and probiotics [195]. Moreover, the phenotype
of colonising bacteria can influence the emergent properties of the community
and this in turn can be a factor modulating e.g. nutritional extraction or sus-
ceptibility to certain diseases in some hosts [26, 28]. Therefore divergence in the
microbiota and metabolome of genetically-identical mice could have a significant
impact on research and possibly confound the experimental findings of such stud-
ies.
85
Consequently researchers are becoming increasingly aware of the way gut mi-
crobial communities might influence host physiology, yet its impact on research
using genetically-identical animals is not known. Using genetically homogeneous
mice theoretically enables reproducible studies in animals. The genetic back-
ground of mice is stable and so is the reproducibility of that background in
different laboratories and through time [196]. The objective of this study was to
compare the microbiomes and the metabolomes of mice caged in four separate
rooms and look for possible links between microbiota composition and various
conditions.
In this chapter, 1H NMR metabolomics has been applied to investigate the
faecal metabolome of genetically-identical mice, housed in four separate units.
Faecal samples from 20 mice housed in four separate barrier rooms, within the
same facility, who were fed the same chow were used in this study. Samples
consisted of individual faecal pellets taken from individual mice. After collection,
pellets were placed into separate collection tubes and frozen prior to analysis.
4.1.1 Gastrointestinal microbiota composition in host
From the view point of a damage-response framework [12], a host is born sterile
and the acquisition of the gut microbial flora can be considered an infection,
which is later considered commensal through colonisation that does not lead to
host damage due to the infection. Microbes living in the gut environment have to
pass a strict selection by surviving the action of digestive enzymes, the presence
of cell-surface molecular paraphernalia, attack by bacteriophages and the immune
system of the host. The network of adaptive stress responses when entering a
new host resulting in adaptive mutations and the ability to grow rapidly enable
some microbes to survive such constant interplay of the resident gut microbial
communities and the host microbiome [197, 198]. Mice provide an experimentally
tractable model to investigate how resident microbial communities impact small
molecule metabolites present in host biofluids and how this divergence can impact
research using animal models.
4.1.2 Gastrointestinal microbiota composition discrimi-
nation in mice
16S rRNA genetic analysis, performed by Dr Geraint B. Rogers, identified bacte-
rial species in the faecal samples obtained for this study and revealed the faecal
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Figure 4.1: Variation in microbiota phyla based on the bacterial identities
derived from 16S ribosomal RNA gene sequencing Provided by Dr Geraint B.
Rogers.
microbiota to be dominated by the phyla Bacteroidetes and Firmicutes (62.4 ±
22.4 (SD) % and 34.7 ± 23.9 %, respectively) (Figure 4.1) with marked variation
between mice. A range of diversity and richness measures were used to assess
changes in microbiota composition, including taxa richness, Chao1, Shannon in-
dex, Simpson index 1-D [199] and the results are summarised in Table 4.1 on the
following page. All the measures were significantly lower for mice from room 4
as compared with mice from other room groups.
Analysis of the predominant genera, shown in Table 4.2 on page 89, identified
the twenty genera with the highest mean relative abundance. They were similar
to genera reported elsewhere [200]. Most samples were dominated by Prevotella,
(39.0 ± 20.2 % of sequences). Controlled ANOVA tests identified significant
differences between room groups (Table B.1 on page 186). Hierarchical clus-
ter analysis divided the samples into three clusters based on predominant genera
(Figure 4.2 on page 90). Again, marked differences between room groups, but also
within the groups were detected. Cluster I comprised samples from all animals
from room 3 and additional animals from rooms 1 and 2, cluster II comprised all
animals from room 4 and cluster III included all of the remaining animals from
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Table 4.1: Bacterial alpha diversity assessed using the Chao1 richness estimate,
OTU richness, and Shannon Index, with Kruskall-Wallis test of K samples with a
controlled multiple pair-wise comparison. Significant differences in measures are
indicated using standard notation; samples that share a letter are not significantly
different, while samples that do not share a letter are significantly different. Room 4
is significantly different than rooms 1, 2 and 3 for all measures (p <0.001). Provided
by Dr Geraint B. Rogers.
Chao1
Sample Mean Std. deviation significance
Room 1 257.84 27.03 B
Room 2 282.94 58.70 B
Room 3 311.44 88.59 B
Room 4 168.43 18.52 A
OTU richness
Sample Mean Std. deviation significance
Room 1 354.80 17.00 B
Room 2 421.40 151.13 B
Room 3 706.40 342.38 B
Room 4 208.00 23.67 A
Shannon index
Sample Mean Std. deviation significance
Room 1 7.74 2.23 B
Room 2 10.23 1.71 B
Room 3 9.10 1.22 B
Room 4 4.45 0.38 A
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Table 4.2: The 20 genera identified with the highest mean abundance in
the faecal samples collected from 20 genetically-identical mice hosted in four
different rooms. Provided by Dr Geraint B. Rogers.






















Figure 4.2: A hierarchical cluster diagram showing relative percentage of
the associated genera in each sample. The main differences were observed
between Prevotella, Caprococcus, Bacteroides and Parabacteroides. Room group 1
and room group 2 exhibit some co-clustering indicating differences within the groups.
Provided by Dr Geraint B. Rogers.
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rooms 1 and 2. Notable is the absence, or very low abundance, in room group 4
of a number of genera including Sutterella, Sphingobacterium, Novispirillum and
Porphyromonas. Taken together, the bacterial microbiota showed marked diver-
gence that was, in most cases, linked to room occupancy with the microbiota
composition allowing classification of the samples into three clusters.
This is interesting since all mice received the same standard diet, mouse chow,
which is composed of carbohydrates readily fermented in the colon to short
chain fatty acids (SCFA), primarily acetate, butyrate, lactate and propionate
[201, 202]. SCFA levels have been demonstrated to be important in determin-
ing the species composition of colonic microbiota, prevention of the growth of
pathogens [174, 203] and modulate nutrition, adipose tissue deposition, immu-
nity and cancer amongst other conditions [202, 204].
It was therefore investigated whether differences in microbiota composition in
genetically-identical mice with identical diet could lead to distinct metabolomic
characteristics and what is the overall relationship between gut microbiota and
metabolome of the host. The complexity of the microbial communities, however,
hampers identification of the functional connections. Studies using both mice
and humans aim to show what effect the gut microbiota has on the host meta-
bolome [198, 205–208]. Thorough understanding of the mechanisms involved in
the interactions between the microbiota and its host and between metabolism of
the gut microbiota and metabolic outcomes of the host are necessary to develop
new treatments for metabolic diseases.
4.2 Materials and methods
4.2.1 NMR
Samples consisted of individual faecal pellets taken from individual mice. Af-
ter collection, pellets were placed into separate collection tubes and frozen prior
to analysis. For the NMR study, pellets of mouse faeces were resuspended by
vortexing in 500 µlof phosphate buffer saline. The sample was then centrifuged
at 13,000 ×g for 10 min and the supernatant transferred to a fresh tube. Cen-
trifugation was repeated and the resulting supernatant lyophilised overnight and
resuspended in 500 µlof D2O. Samples were prepared in triplicate and
1H NMR
spectra were acquired on 400 MHz on a Bruker Avance spectrometer (Bruker,
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Coventry, UK) equipped with a 5 mm QNP probe using a zgesgp pulse sequence
incorporating water suppression via excitation sculpting with gradients. The
1H 90 degree pulse was 9.75 µs. The spectral width was 20 ppm. Free induc-
tion decays were multiplied with an exponential function corresponding to a line
broadening of 0.3 Hz. The spectra were Fourier transformed and calibrated to
a 2,2,3,3,-D4-3-(Trimethylsilyl) propionic acid (TSP) reference signal at 0 ppm.
Phase correction was performed manually and automatic baseline correction was
applied. To help in the assignment of the metabolite resonances, J-resolved 2D
correlation was performed with pre-saturation during the relaxation delay using
gradients (J-Res, Bruker).
4.2.2 Multivariate analysis
Pre-processing and orthogonal projection to latent structures discriminant ana-
lysis (OPLS-DA) were carried out with software that was developed in our lab-
oratory for a previous study [209] using the Python programming language with
numpy and scipy for calculations, and matplotlib for visualisation. The nonlinear
iterative partial least-squares (NIPALS) algorithm [108] was used for OPLS-DA
analysis. Regions above 8.5 ppm and below 0.45 ppm were excluded from the
analysis because of noise content. The water peak and TSP reference signal were
also excluded. Spectra were bucketed using 0.005 ppm bin size leaving 1588 data
points per spectrum. These spectra were normalised [124] and auto-scaled (vari-
ance of every data point normalised to 1). Cross-validation was performed where
75 % of the samples were used as a training set and the remaining 25 % as a
test set, ensuring that the number of samples in the test set was proportional to
the total number of samples from each class, and that at least one sample from
each class was present in the test set. To choose the number of components for
the model, a leave-one-out cross-validation was carried out on the samples in the
training set, and the F1 score selection method was used to choose the number of
components, with the additional constraint to use a maximum of 8 components.
A double cross-validation was repeated 2000 times (or 100 times) with randomly
chosen samples in the training and test set to prevent bias due to the choice of
training or test set. This led to 4 × 2000 models (or 100 models). Finally, this
procedure was repeated with randomly generated class assignments to provide
a reference Q2 value. Peaks provide the basis for discrimination between the
classes were assigned by comparing chemical shift values and multiplicities from
J-resolved NMR spectra to values from the Biological Magnetic Resonance Data






















































































































































































































































































































































































































4.3 Results and Discussion
Analysis of the composition of the gut microbial communities, associated with
health and disease, and the gene content has been done extensively using se-
quencing [210–212]. The experimental evidence, however, shows that functional
similarities are found between divergent communities and, conversely, distinct
functional attributes can result from microbiota of similar composition [195, 213].
This highlights the importance of investigating the function of gut communities
and not only the composition as only then we will be able to understand host-
microbial interactions in depth and identify the compounds that mediate the
resulting function.
Metabolomics allows simultaneous measurement of a large number of metabo-
lites in a sample and the resulting data provide a fingerprint of the function of a
given microbiota. Comparing NMR profiles of samples allows to cluster them ac-
cording to the levels of metabolites in them. Such grouping of samples/microbial
communities based on changes in metabolome allows to link them to changes in
function over time or in response to a specific treatment or a condition [214].
1H NMR spectroscopy was performed on buffered saline extracts from faecal
samples numbered blindly from 1 to 20. It was hypothesised that there would
be differences when comparing the metabolome of faeces from mice whose faecal
microbiota were distinct. Initial examination of 1D 1H NMR spectra from dif-
ferent clusters showed marked differences between metabolite levels (Figure 4.3
on the preceding page). PCA of spectra allowed comparison of all of the spec-
tra simultaneously. The top panel in Figure 4.4 on the next page shows all the
samples prepared in triplicate and recorded. Close clustering of the replicates
indicates good reproducibility of the experiment and robustness of the method.
The bottom panel shows the same samples coloured according to the cluster
membership from the hierarchical cluster analysis of gut microbiomes: Cluster I,
Cluster II and Cluster III. The samples are not grouped perfectly by cluster mem-
bership based on microbiota, which suggests that there are other discriminating
factors such as contributions from the room group membership. To see which
metabolites separate clusters from each other, further analysis involved a series of
pairwise orthogonal partial least squares discriminant analysis (OPLS-DA) tests.
Each comparison analysed spectra according to classes suggested by clustering
according to the microbiota composition (Figure 4.2 on page 90) determined by
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Figure 4.4: Scores plots from unsupervised PCA analysis (spectra normalised
using auto-scaling as used in OPLS-DA analysis). Samples are colour coded according
to randomly assigned sample number (top) or cluster (bottom) from the hierarchical
cluster analysis of gut microbiomes with black, blue and red representing, respectively,
Cluster I, II, and III.
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16S sequencing.
Figure 4.5 on the next page presents scores plots which show a separation
between clusters in the left panel: Cluster I vs Cluster II, Cluster I vs Cluster
III, and Cluster II vs Cluster III. Cluster I and Cluster III show some degree
of overlap, meaning that the metabolic differences between these two clusters
were not as great as between other comparisons. This can be also seen from the
Q2, which for this comparison was 0.52 (Table 4.4 on page 104). Such a score
indicates an effective separation of class members, however, it is lower than the
other two comparisons and far from the ideal score of 1. The right side of the
panel shows identified key drivers of the differences in the metabolomic data from
the back-scaled loadings plots and assigned resonances with high variance and
high weight, indicated by greater intensity and yellow/red color respectively (Fig-
ure 4.5 on the next page-right panels). Table 4.3 on page 98 lists all the peaks seen
in the spectra along with tentative chemical shift assignments. Resonances were
assigned based on multiplicities derived from JRES, the size of J-coupling and
1H chemical shifts with reference to the E. coli metabolome database [58]. The
analysis indicate that samples in Cluster II had higher levels of valine, alanine,
isoleucine, phenylalanine and tyrosine as compared to faecal samples in Cluster
I, samples in Cluster II had higher levels of butyrate, lactate and acetate as com-
pared to Cluster I, whereas Cluster III had higher levels of acetate, butyrate,
propionic acid and lower levels of valine and alanine as compared to samples in
Cluster II. Notably, samples in Clusters I and II were distinguished by the greater
abundance of a number of amino acids in the faecal metabolomes in Cluster II
whereas the faecal metabolomes of mice from Cluster III were distinguished from
those in Cluster I and II on the basis of short chain fatty acids which were more
abundant for those in Cluster III.
4.3.1 PCA vs OPLS-DA
OPLS-DA was also carried out for comparisons dividing samples according to
room occupancy or dominant phyla and the results are presented in Figure
4.6. Q2 values obtained for each test were compared with a reference Q2 value,
obtained after repeating cross-validation with randomly generated class assign-
ments and are presented in Table 4.4 on page 104. As shown, Q2 values for the
metabolomic data pairwise analysis performed when separated according to these




Figure 4.5: OPLS-DA scores plots (left panels) and back-scaled loadings
plots (right panels) with resonances with high variance and high weight highlighted
in red for comparisons between the faecal metabolomes as clustered according to
microbiome community. From the top: Cluster I vs Cluster II (A), Cluster I vs
Cluster III (B), Cluster II vs Cluster III (C). Distinguishing metabolites that could be
unambiguously assigned are annotated in each back-scaled loadings plot and the
cluster with increased metabolite yield is indicated with an arrow.
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Table 4.3: Tentative chemical shift assignment in 1H NMR spectra of faecal samples.
assignment ppm multiplicity J coupling peak
acetate 1.92 s
butyrate 0.89 t 7.49 Hz
2.16 t 7.49 Hz
1.57 q 7.50 Hz
proprionic 1.06 t 7.82 Hz
2.17 q
lactate 1.34 d 7.06 Hz








1.24 m very small
1.45 m very small
alanine 1.49 d 7.37 Hz
3.79 q
fatty acids 0.729 broad s




2.3 q or d
2.291 s
succinate (?) 2.41 s
3.248 ?
glycine (?) 3.551 s




1.5 m very small
glycolic acid (?) 3.945 s




tyrosine 6.9 d 8.2 Hz
7.2 d 8.2 Hz











IFigure 4.6: Leave-one-out cross-validation (LOOCV) output files for the
comparisons between room groups (A-F): room 1 vs room 2 (A), room 1
vs room 3 (B), room 1 vs room 4 (C), room 2 vs room 3 (D), room 2 vs
room 4 (E), room 3 vs room 4 (F) and samples with high vs low
percentage of Bacteroidetes (G), Firmicutes (H), Proteobacteria (I). From
top left to bottom right: scores plots showing separation between classes; back-scaled
loadings plots showing 1H resonance frequencies that discriminate between the two
classes under comparison; histograms showing number of principal components used
to separate the classes; prediction residual error sum of squares (PRESS) indicating
low within-sample variation; Q2 value histogram; comparison of model predicted for
the sample classification as compared to the actual class. A double cross-validation
was repeated 2000 times for comparisons A-F and 100 times for comparisons G-I.
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Table 4.4: Predictive Q2 values for all models. Q2 values for models run with
randomised class assignments are given in parentheses.
Model Q2
Cluster I vs Cluster II 0.88 (-0.15)
Cluster I vs Cluster III 0.52 (-0.15)
Cluster II vs Cluster III 0.81 (-0.18)
Room 1 vs Room 2 0.93 (-0.14)
Room 1 vs Room 3 0.90 (-0.15)
Room 1 vs Room 4 0.85 (-0.15)
Room 2 vs Room 3 0.67 (-0.09)
Room 2 vs Room 4 0.80 (-0.12)
Room 3 vs Room 4 0.86 (-0.15)
High Bacteroidetes vs low Bacteroidetes 0.41 (-0.15)
High Firmicutes vs low Firmicutes 0.41 (-0.17)
High Proteobacteria vs low Proteobacteria 0.66 (-0.18)
clear metabolomic differences were observed between samples based on clusters
defined by the composition of the bacteria present. Diet can influence microbial
composition [215], however, in this study all mice received the same standard
diet. One study [216] points out that the microbiome composition is unstable
and can exhibit detectable changes within 24 h of changing the diet. Here and
in other studies the selective mechanisms for divergence in bacterial composition
remain largely unclear [195, 217] but could be driven by competition, inhibition
and niche specialisation of bacteria or a combination of all these factors [214].
The relative contribution of Bacteroidetes, Firmicutes and Proteobacteria to
each of the samples tested was also assessed using OPLS-DA. Here, Q2 scores
were lower (Table 4.4), which indicates poor models, i.e. the discriminating
factor between the metabolite composition of samples was not (solely) the con-
tribution from different phyla. OPLS-DA indicated significant differences in the
metabolome of faeces from mice housed in different room groups with Q2 scores
all > 0.67, which indicates that housing alone may contribute to divergent gut
metabolomes.
The best separation and the highest Q2 was obtained for comparison between
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rooms 1 and 2 and rooms 1 and 3, whereas the most overlap and the lowest Q2
was obtained when comparing high and low Bacteroidetes content and low and
high Firmicutes content. Nevertheless, the models separated the spectra and the
backscaled loadings revealed similar patterns for comparisons between rooms 1
and 2, rooms 1 and 3, rooms 1 and 4, and also between high and low Bacteroidetes
and Firmicutes content content. A similar pattern of discriminatory metabolite
changes could be seen when comparing Cluster I and Cluster III (Figure 4.5 on
page 97, B) and also Cluster II and Cluster III (Figure 4.5 on page 97, C). Other
comparisons presented different pattern of altered metabolite levels again show-
ing that the room membership is an additional factor in clustering seen in PCA
(Figure 4.4 on page 95).
PCA of metabolomes extracted from faeces of mice hosted in different rooms
found additional factors other than microbiota composition that drive the clus-
tering pattern. Separation seen in PC1, which represents the main source of
metabolome variation in the data set, in this case is not linked to OPLS-DA
analysis, i.e. the discriminatory features in OPLS-DA are not the same as the
features giving separation in PCA. This reveals that the room membership is
an important factor differentiating between metabolome of mice hosted in dif-
ferent rooms. In the previous chapter, a study of P. aeruginosa strains isolated
from sputum samples from cystic fibrosis patients, univariate patient data has
been related to multivariate NMR data to show the functional effects of bacte-
rial colonisation in a host. Here, two sets of multivariate data are presented-a
hierarchical cluster analysis showing relative percentage of the associated genera
in each sample and OPLS-DA showing differences in the metabolite composition
between the samples. This allowed investigation of differences in host metabo-
lome and align it with microbiota variation at the genus level.
4.4 Conclusion
Mouse models are commonly used in biomedical research and in order to avoid
potentially confounding differences in genetic backgrounds, mice are taken from
inbred populations to ensure homogeneity. When purchased for research, individ-
ual mice are considered identical and are expected to provide a uniform platform
for study. The potential of the gut microbiota to influence the host in relation
to health and a wide range of clinical syndromes is being increasingly recognised.
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The variation in gastrointestinal microbiota composition is likely to be more sig-
nificant when mice are moved between facilities, experience changes in diet, and
are exposed to other animals or in experimental facilities, that are not highly
controlled. Therefore, the divergence of mice gut microbiota identified in our
metabolomic study, that was due to mice being housed in separate controlled
units require further consideration and efforts are needed to ensure that mice
used in research are indeed equivalent.
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5
Combined systems approaches to understand
pathogen-antibiotic interactions
107
Work described in this chapter has been published as:
Kozlowska, J., Vermeer, L.S., Rogers, G.B., Rehnnuma, N., Amos,
S-B.T.A., Koller, G., McArthur, M., Bruce, K.D. & Mason, A.J. Com-
bined systems approaches reveal highly plastic responses to antimicrobial peptide




Antimicrobial agents have been used for more than 70 years in the treatment of
infectious diseases [218] and resistance development is a natural process. Most
pharmaceutical antibiotics are derived from naturally occurring bacterial defences
manufactured by fungi, bacteria, and algae against other fungi, bacteria, and al-
gae. Natural antibiotics and the bacteria they are targeting have co-evolved over
millions of years. During these battles bacteria have developed counter-measures
in the form of genes necessary to produce and resist enemy antibiotics. Such
arms races allowed bacteria to accumulate genes for bacterial resistance. How-
ever, the incorporation of antibiotics into animal feeds and the uncontrolled use
of antibiotics in the clinical setting is likely to have led to loss of the balance
and development of antimicrobial resistance [219–221]. Manufactured antibiotics
have not been able to counteract bacterial adaptive responses and evolving new
defences [220]. This has become an important concern in multiple healthcare
contexts and is compounded by the scarcity of new therapeutic agents. The
world is faced with drug-resistant bacterial infections, which cannot be treated
by any of the current antibacterial options hence there is an urgent need for
novel agents [222]. According to the Centers for Disease Control and Preven-
tion (CDC) rates of infection due to both Gram-positive and Gram-negative
pathogens are increasing [223]. Infectious diseases are known as one of the most
life-threatening disabilities worldwide. Approximately 13 m deaths related to in-
fectious diseases are reported each year [218]. Indeed, currently more people die
in US hospitals due to meticillin-resistant Staphylococcus aureus (MRSA) infec-
tions than of HIV/AIDS and tuberculosis combined [224]. This is compounded
by the emergence of panresistant Gram-negative bacteria such as Acinetobacter
species, multidrug-resistant (MDR) P. aeruginosa, carbapenem resistant Kleb-
siella species as well as E. coli in most geographical areas [225]. According to
the European Centre for Disease Prevention and Control (ECDC) infections due
to these drug-resistant bacteria in the EU result in extra healthcare cost each
year of at least e 1500 m. Of particular concern is the increased percentage of
Klebsiella pneumoniae (K. pneumoniae) resistant to carbapenems, current last-
line antibiotics against these bacteria. In contrast, the percentage of (MRSA)
isolates appears stable, and seems to be decreasing in some countries. However,
MRSA remains a public health priority, as the percentage of MRSA continues to
be high in several countries, especially in southern Europe.
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It is therefore crucial to establish antibacterial strategies that will not only
be able to treat drug resistant infections but, more importantly, foresee how re-
sistance evolves. There is significant uncertainty, however, that such need will be
met in the foreseeable future as, from 13 pharmaceutical leaders in the market
of anti-infective drug discovery and development today, only a few big pharma-
ceutical companies (GlaxoSmithKline, AstraZeneca and Merck & Co) are still
actively researching antibiotics. In the last 50 years, bacteria have developed re-
sistance to every antibiotic within only few years of its release [226]. Since 2000,
five new antibiotics have been launched, however, all of them were limited to
treatment of Gram-positive infections [227]. It is therefore noteworthy that the
overall number of compounds in development to treat Gram-negative infections,
in particular, is very low. This reflects the challenge of developing treatments
against Gram-negative bacteria, because of the presence of an outer membrane
permeability barrier, multiple eﬄux pumps, and antibiotic- and target-modifying
enzymes [228, 229]. There is ongoing effort to highlight the potentially disastrous
outcomes of such situation, including the well-publicised annual report of the
Chief Medical Officer of the United Kingdom in March 2013, which addressed
the threat of antimicrobial resistance and called for antimicrobial resistance to
be put on the national risk register [230].
Mechanisms of antimicrobial resistance
Interactions between bacteria and their environment, and host in the case of
pathogens or commensals, provide a selection pressure for bacterial adaptation
that supports increased survival [231]. The network of interconnected and tightly
controlled stress responses not only protects bacteria, but also affects their an-
timicrobial susceptibility via modifications to the cell at a cellular, metabolic and
genetic level. The common characteristic of many stress responses is activation
and upregulation of error-prone DNA polymerases and simultaneous downregula-
tion of enzymes responsible for DNA damage repair and movement of transposons
(mobile genetic elements) leading to point mutations and recombination [231].
The SOS response to antibiotic treatment has been demonstrated in numer-
ous studies to induce toxin production [232–235], propagation of virulence factors
and antibiotic resistance genes. In Gram-negative bacteria, resistance determi-
nants are carried in the mobile gene casettes (integrons), which are controlled
by the SOS response and LexA-RecA regulon in E. coli and Vibrio cholerae (V.
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cholerae) [236]. Moreover, the SOS response stimulates high mutation rates,
which might relieve the stress but also facilitate acquisition of antibiotic resis-
tance genes.
Exposure to different classes of antibiotics can induce resistance development
via different mechanisms. Penicillin and other β-lactam antibiotics induce the
SOS response by interfering with cell wall synthesis [237], therefore cells be-
come temporarily resistant by inhibiting cell division. Resistance upon exposure
to β-lactam antibiotics can be also a result of a lack of autolytic enzymes, se-
cretion of β-lactamase, activation of eﬄux pumps and also modifications to its
target-penicillin binding proteins (PBPs) due to accumulation of (p)ppGpp and
subsequent induction of the stringent stress response [238, 239]. Antibiotics of
the quinolone class have been demonstrated to be mutagenic [240]. Their primary
target is topsoisomerase IV and gyrase and mutations to the genes encoding these
enzymes could be responsible for the rise of antimicrobial resistance, therefore
exposure to them could induce resistance as demonstrated by Cirz et al. [241].
Furthemore, Beaber et al. [242] showed that V. cholerae exposed to quinolone,
acquired resistance to antibiotics not by mutagenesis, but via movement of in-
tegrating conjugative elements (ICEs). ICEs are one of the three main types of
selftransmissable mobile genetic elements and key mediators of horizontal gene
flow in bacteria. Similarly to plasmids, they transfer during the process of con-
jugation, however, they are able to integrate into the host chromosome, replicate
and excise to transfer again, which is typical of bacteriophages [243]. Sublethal
doses of streptomycin, on the other hand, produce mutations in bacteria via an
SOS-independent fashion, mainly by interfering with ribosomal translation [244].
Aminoglycoside resistance in strains of P. aeruginosa is a result of exposure to
the treatment and ribosome disruption, which activates the MexXY-Opr mul-
tidrug eﬄux system [245]. In a recent study by Dalebroux [246] it was shown
that Salmonella typhimurium (S. typhimurium) becomes resistant to polymixin
B and the mammalian antimicrobial peptide C18G after exposure by making
modifications to the component of LPS, Lipid A, and also glycerophospholipids
(GPLs) in the inner leaflet of the OM. It has also been shown that exposure of E.
coli to sublethal doses of a range of antibiotics regardless of their mechanism of
action resulted in multidrug resistance [247] and one of the proposed mechanisms
was increased mutation rate due to raised levels of ROS [248].
However, antimicrobial exposure is not the only way in which bacteria can
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acquire antimicrobial resistance. Research shows that bacterial natural envi-
ronment and the stress responses that are triggered in response to environmental
changes are sufficient to diminish innate antimicrobial susceptibility and generate
resistant mutants even without exposure to antimicrobials due to e.g. oxidative
stress [245, 249], nitrosative stress, nutrient limitation, membrane damage, heat
and ribosomal stress [245] or selective pressure exerted by the host [46]. This
can be an indirect effect, merely due to growth inhibition or bacteria entering a
dormant state [237, 250], or a direct result of inducing a myriad of bacterial stress
responses. They may result in changes promoting antibacterial resistance such as
activation of eﬄux pumps [245], remodelling of antimicrobial targets [238, 251],
induction of resistant growth modes such as biofilms [252] and generation of mu-
tations leading to increased resistance [35].
The ability to suppress bacterial stress responses, mainly the SOS response,
has become of interest and seems a likely goal for treatment of some of the bac-
terial infections. There is also evidence that diversifying antibiotic prescription
patterns can help increase bacterial susceptibility to certain antimicrobials [253].
5.1.2 Antimicrobial peptides and innate immunity
Faced with multidrug antimicrobial resistance researchers turned towards agents
with broad-spectrum activity and mechanisms of action with proposed lower
propensity for resistance development: antimicrobial peptides (AMPs). The rea-
son to study AMPs is twofold. First, both bacteria and AMPs are ancient; they
have evolved together and studying bacterial responses to a wide range of AMPs
can provide insight into the inherent ability of bacteria to respond to challenges
and the adaptive mechanisms available to overcome them. The second reason is
that AMPs have prospects to be developed into anti-infective therapeutic agents
as antimicrobials, adjuvants for synergistic effect or as immunomodulatory and/or
endotoxin-neutralising compounds [254–258].
AMPs are polypeptide antimicrobial substances with fewer than 100 amino
acid residues, that are secreted from various cells and tissues of many inverte-
brates, plants or animals but also archaea, eubacteria, protista. They have shown
direct activity against Gram-negative and Gram-positive bacteria, fungi, viruses
and protozoa [25, 259].
AMPs represent a large and diverse group of molecules that can be classified
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according to their amino acid composition or structure. It is the class of cationic
antimicrobial peptides that offers potential in treatment of microbial infections,
but also as antivirals, immunomodulators and antitumoral drugs [260]. The dis-
advantage of anionic antimicrobial peptides is that they often require cationic
moieties such as synergistic cationic antimicrobial peptides or cations such as
zinc (Zn+2) to act as cationic linkage between the anionic antimicrobial peptide
and the anionic microbial cell membrane [261]. As of October 2013 over 2000
different antimicrobial peptides and synthetically created peptides are known and
their number is constantly increasing [262]. Several databases exist that catalogue
antimicrobial peptides on the basis of the source organism, biological activities
and specific peptide features. Currently the largest database is maintained by
the Wang group http://aps.unmc.edu/AP/main.php [262].
There is little structure and sequence homology between peptides recovered
from different species, even those that are closely related [254]. Despite such
variability, there are a few common features including: small size (12-50 amino
acids long), hydrophobicity and nominal cationic charge ranging from +2 to +9
[263]. Some antimicrobial peptides are secreted constitutively, while others are
secreted in response to invading microbes and the presence of bacterial signalling
molecules e.g. LPS and lipoteichoic acid (LTA) and bacteria [25].
Despite being exposed to AMPs for millennia, bacteria have not yet devel-
oped full resistance to broad spectrum AMPs. Nevertheless, AMPs can still
represent a trigger for resistance development via alteration of cell surface charge
and electrostatic repulsion of AMPs, activation of eﬄux pumps to extrude AMPs,
production of proteases to cleave AMPs or trapping proteins [264, 265]. More-
over, unlike antibiotic resistance genes which are located on laterally transferable
elements such as plasmids or transposons, most genes involved in resistance to
AMPs are on the chromosome, close to housekeeping genes, and are considered
as the integral part of the genome of some bacteria [266]. Knowledge of the
molecular basis of bacterial AMPs resistance may therefore provide new targets
for antimicrobial therapeutics.
AMPs are currently considered to act mainly at the level of cytoplasmic mem-
brane and outer membrane as pore-forming molecules, but have also been re-
ported to disrupt nucleic acids, affect protein synthesis, inhibit enzymes and
sequester nutrients essential for the bacteria [25]. A number of leading review
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articles [267–270] suggest that they may also have other immunomodulatory ac-
tivities important for the anti-infective host defence. Immunomodulatory prop-
erties of AMPs reported in recent studies include the modulation of the levels of
proinflammatory cytokines and chemokines by altering gene expression of host
cells, activation of host immune cells (monocytes, macrophages, neutrophils) and
ROS and RNS, stimulation of angiogenesis and wound healing and recruitment of
leukocytes to the site of infection. These activities are not directly antimicrobial,
nevertheless, they result in protection of the host against infection and allow
selective control of the infection and immune responses [258, 271, 272]. They
play important roles in preventing infection, but also in the clearance of infection
and are thus often referred to as host defence peptides in contrast with peptides
acting directly on bacteria and having a microbicidal effect.
Structural classes of AMPs and determinants of antimicrobial activity
The multidimensional properties of AMPs described above and a broad-spectrum
antimicrobial activity are possible due to tremendous structural, and thus func-
tional, diversity of those molecules. At least four structural groups have been
proposed for AMPs according to their conformations: amphipathic α-helices,
β-sheet structures stabilised by disulfide bridges, extended structures with one
or more amino acids being predominant and loop peptides with only one disul-
fide bridge. Despite the differences at the primary and secondary structural
level, most cationic antimicrobial peptides are amphipathic, i.e. they have a
hydrophobic region, but also a positively charged hydrophilic structural domain
and therefore can exist at the interference between polar and non-polar environ-
ments. The positive charge allows peptides to interact with negatively charged
targets including DNA, RNA etc. and also bacterial membranes, as the initial in-
teractions are electrostatically driven due to the negatively charged membranes,
whereas amphipathicity facilitates binding and insertion of the peptide into the
hydrophobic core of the lipid membranes [273].
Several studies have demonstrated the importance of an α-helical structural
domain, showing that the increase in the amount of α-helical structure is related
to enhanced antimicrobial activity [274, 275] or broadening of the spectrum of
activity [276]. In contrast, more disordered peptides that have the ability to
disorder the lipids in their vicinity perform better than peptides that remain
structured (manuscript in preparation). This was also observed in a molecular
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dynamics simulation study where α-helical conformation was not required for
pore formation and peptides were not highly structured. Indeed, experimental
studies involving stabilised α-helical peptides have shown reduced antimicrobial
activity [277] and that partial unfolding might facilitate pore formation [278].
Consequently, despite being very intensively studied experimentally, relatively
little is known regarding the mechanism of pore formation or the structure of
the pore itself. It is commonly accepted that many antimicrobial peptides form
toroidal pores and this molecular dynamics simulation study demonstrated that a
threshold concentration is required to create enough stress in the membrane and
that pore formation is facilitated by aggregation of the peptide on the membrane
[278].
Other features known to be important determinants of antimicrobial activity
are amphipathicity, hydrophobicity and charge [279]. The parameters are inter-
correlated and modification to one can be compensated by changes in others,
hence the optimal antimicrobial efficiency is a result of balanced coordination of
all those factors [280, 281].
The lipid composition of the cell membrane of multicellular animals plays an
important role in the selectivity of AMPs for their target. First the negative
charge on the bacterial surface allows preferential binding of polycationic antimi-
crobial agents such as AMPs. In the mammalian cell the bilayer is asymmetric-the
outer leaflet is composed of mainly phosphatidylcholine (PC) and sphingomyelin
(SM) with zwitterionic head groups and the cytoplasmic surface is composed of
the negatively charged lipids such as phosphatidylserine (PS), phosphatidylinosi-
tol (PI) and zwitterionic phosphatidylethanolamine (PE). The cholesterol present
in mammalian membranes reduces the activity of AMPs, by stabilising the lipid
bilayer and interacting with the peptide [254, 282]. Although the asymmetry
of the E. coli inner membrane is unknown it is principally composed of zwitte-
rionic PE (80%) and at least 15% of negatively charged phospholipids such as
phosphatidylglycerol (PG) or cardiolipin (CL) allowing formation of strong elec-
trostatic interactions with polycationic antimicrobial agents [254, 283].
Modes of action of AMPs
Despite the vast number of known AMPs, their exact mode of action remains
unclear or controversial in many cases. One of the reasons for this is that con-
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centrations of AMPs used in some studies exceed the concentration needed to
see a bacterial response. AMPs, as any other antibiotic, require a minimum
concentration to have a growth inhibiting effect against a given bacterial strain,
which is often expressed in terms of minimum inhibitory concentration (MIC).
The concentrations above the MIC usually have an immediate macroscopic effect
such as loss of viability or membrane lysis. It is not clear, however, what are the
molecular mechanisms that induce inhibition when crossing the threshold divid-
ing proliferating bacterial populations from nonproliferating ones. Possibilities
include enzyme inhibition leading to disruption of bacterial metabolism or AMPs
acting in a cooperative manner due to the increased concentration [278, 284].
A study by Huang el al. [284] exposed alterations in the behaviour of AMPs
when certain molecular threshold concentrations were reached including confor-
mational changes and differences in the association state as well as changes in the
membrane topology such as poration. Such events associated with reaching the
threshold concentration are potentially bactericidal, however, so far they were
observed only in model lipid bilayers, with some AMPs reaching full membrane
saturation, and not in in vivo studies. Those considerations apply to the AMPs
with a membrane disruptive mechanism of action. For non-disruptive AMPs,
where the primary aim is cytoplasmic invasion, parameters such as the partition
constant, aqueous phase and membrane-bound peptide concentration do not cor-
relate directly with the disruptive action of the peptide in the cytoplasm [285].
Since AMPs are cationic, they likely cause partial or complete neutralisation
of the bacterial membrane upon binding and indeed a number of AMPs dis-
play membrane charge neutralising properties with other concomitant threshold
effects [285–287] implying that membrane charge neutralisation and membrane
saturation could constitute the main killing strategy for some AMPs. Another
problem is that quantitative structure-activity relationship (QSAR) studies look
at isolated processes in much simplified systems and the findings may not be
reflected in in vivo studies [288]. Modifications to an AMP to promote one activ-
ity may inhibit another. This emphasises the need for a novel high-throughput
method that would allow to probe the activity of AMPs in the whole bacterial cell.
Until recently, the existing dogma was that most cationic AMPs kill through
membrane disruption or pore formation [289]. The initial interaction between
peptide and the OM is thought to occur due to electrostatic attraction between
cationic peptides and either negatively charged LPS in Gram-negative bacteria
or LTA in Gram-positive bacteria (Figure 5.1 on page 118). Lipopolysacchar-
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ride (LPS), also known as endotoxin, is the main constituent of the OM found
in Gram-negative bacteria. It is a highly conserved, amphiphilic lipid that con-
sists of three regions: O-polysaccharide (the O- or somatic-antigen), the core
polysaccharide known as 2-keto-3-deoxyoctonic acid (KDO) and lipid A. Lipid A
is anchored in the OM [290]. AMPs distort the integrity of the OM by breaking
the non-covalent associations between LPS and divalent cations such as calcium
(Ca2+) and magnesium (Mg2+), facilitating insertion of the peptide into the mem-
brane by a process known as self-promoted uptake [279].
Different killing mechanisms have been proposed that can occur at the mem-
brane including: fatal depolarisation of the membrane, pore formation by various
models and subsequent cellular leakage, formation of transient channels, micel-
larisation of the membrane or activation of deadly processes such as production
of hydrolases that degrade the cell wall, thereby distorting lipid distribution be-
tween leaflets of the lipid bilayer [279]. Experimentally, it has not been possible to
directly determine the number of peptides within the pore. The commonly cited
number of 4-7 peptides [291, 292] has been indirectly inferred from a combination
of neutron scattering data and oriented circular dichroism (OCD) measurements.
There is considerable evidence, however, that some peptides target intracellular
components upon entry to the interior of the cell rather than the membrane itself
[289]. Having tools that enable to study how AMPs achieve their killing effect
and in what conditions is of particular importance as this can potentially lead
to better understanding of the pathologies and inform the development of AMP-
based therapeutic agents.
In this study structurally and physically related AMPs were applied: maga-
inin 2, pleurocidin and buforin II. Also, based on understanding of these three
naturally occurring peptides a range of D-peptides have been designed comprising
D-amino acids only in an attempt to circumvent the effect of proteases secreted
by target pathogens [293], and incorporate structural features, including high
cationicity and propensity for adopting α-helix rich conformation [294–296] and
proline kink. Incorporation of proline on the hydrophilic face of the amphipathic
α-helical AMPs increases the conformational flexibility and has been linked to
improvement of antibacterial activity and reduction of the hemolytic effect [297–
299]. Each of those peptides have been described to operate by different killing
mechanism while the opportunity was taken to understand the mechanism of ac-
tion of D-LAK120-AP13 for the first time. As described in the previous chapter,
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Figure 5.1: The structure of the cell wall of Gram-positive and
Gram-negative bacteria. Modified from Fierke Research Group
(http: // www. umich. edu/ ~ caflab/ lpxc2. htm ).
bacteria are able to harness a vast range of stress responses in order to overcome
or adapt to the threat posed by AMPs and choosing peptides with various mech-
anisms of action was an attempt to probe the variety of these responses.
Considering their bactericidal strategies, peptides can be generally categorised
as membrane disruptive and membrane non-disruptive, with the former being the
dominant mechanism [25]. Magainin 2 [300], a cationic α-helical antimicrobial
peptide (Figure 5.2 on the next page, a) isolated from the skin of African Clawed
frog Xenopus laevis, is considered to have a membrane disrupting activity towards
both Gram-positive and Gram-negative bacteria. It is thought to bind preferen-
tially to negatively charged phospholipids present in bacterial membranes with
the formation of a dynamic peptide-lipid pore and subsequent cell permeabili-
sation by a mechanism known as the toroidal pore model where the lipid bends
back on itself. The detailed molecular mechanism of this model has been de-
scribed [291]. Apart from the toroidal pore model there are at least three other
proposed models by which peptides are able to aggregate and/or re-orient in the
membrane and disrupt its integrity: the barrel-stave [259], the aggregate [301]
and the carpet model [302].
Membrane non-disruptive peptides have alternative mechanisms of action that
involve the interaction of the peptide with the membrane which does not nec-
essarily result in membrane disruption; their main targets are polyions such as
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a b
Figure 5.2: Structures of SDS-bound magainin and pleurocidin solved in our
laboratory showing side chain orientation and backbone topology. Images created with
MOLMOL software and rendered with POVRay. The typical conformers from the
ensembles closest to the average structure are shown. PDB entries for magainin
2-2LSA and pleurocidin-2LS9.
DNA or RNA. Once they penetrate the bacteria, they can potentially kill by
interfering with bacterial metabolic processes [259, 289, 303]. An example of a
well studied membrane non-disruptive peptide is buforin II, a 21-amino acid long
cationic peptide derived from the Asian toad Bufo gargarizans, which is known
to form an extended helical structure [304]. It was shown to have the ability
to translocate through bacterial membranes and bind to DNA in a cooperative
manner with high affinity forming peptide-DNA complex [64, 304]. The proline
kink in buforin II is known to be crucial for enabling translocation into the E.
coli cytosol [305]. However Buforin II has only barely detectable antibacterial
activity against planktonic E. coli cultures [64].
Pleurocidin is a naturally occurring peptide showing antimicrobial activity
against Gram-negative as well as Gram-positive bacteria. It was isolated from
the skin and intestine of the winter flounder Pleuronectes americanus [306]. This
25-mer peptide has an amphipathic helical structure very similar to that of ma-
gainin 2 [306] (Table 5.1 on the following page). The study by Yoshida et al.
[307] showed that pleurocidin, similarly to magainin, was able to translocate
across the model membrane and to cause dye-leakage, however, when lower lev-
els of peptide were used (at MIC50) a pleurocidin analogue was demonstrated
to act on RNA and protein synthesis by inhibiting histidine incorporation with-
out concomitant membrane permeabilisation [308] suggesting that the peptide
has multiple modes of activity. Pleurocidin was also shown to associate strongly
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Table 5.1: Comparison of physical and biological features of peptides used
in this study. Hydrophobicity (H) and mean hydrophobic moment (µH) are shown
according to the Eisenberg scale [1] and were calculated using the HydroMCalc Java
applet made available by Alex Tossi [2]. Proline residues are underlined. Peptides in
italics are D-amino acids. *Mean hydrophobic moment assuming formation of ideal
α-helix.








































Buforin II TRSSRAGLQFPVGRVHRLLRK 7 -0.37 0.30 >26.30 >26.30
Magainin 2 GIGKFLHSAKKFGKAFVGEIMNS 4 -0.03 0.28 6.86±1.58 10.60±2.21
D-LAK120-AP13 KKLALALAKKWLPLAKKLALALAKK 9 -0.10 0.21 1.08±0.62 1.22±0.19
Pleurocidin GWGSFFKKAAHVGKHVGKAALTHYL 5 -0.02 0.22 0.66±0.22 1.65±0.87
with anionic lipid head groups, where it forms ion channels in planar lipid bi-
layers most probably by formation of toroidal pore [273]. Proton decoupled 15N
solid state NMR spectroscopy showed that at neutral pH pleurocidin is oriented
parallel to the membrane surface, whereas 2H solid state NMR revealed that it
disrupts membranes containing anionic lipids (phosphatidylglycerol (PG)) more
effectively than zwitterionic (phosphatidylethanolamine (PE)) [309]. Moreover,
intrinsic fluorescence measurements showed that pleurocidin insertion into lipid
membranes occurs exclusively in the presence of anionic lipids as does strong
dye leakage and increased peptide translocation across the membrane [307, 309].
In the presence of sodium dodecyl sulfate (SDS) micelles the peptide adapts α-
helical conformation (Figure 5.2 on the previous page, b).
A number of AMPs while having membrane disruptive activity, have been
shown to operate through intracellular modes of killing, such as binding nucleic
acids [304, 310] or inhibiting nucleic acid or protein synthesis [308, 311, 312] and
the exact modes of action of AMPs remains an area of controversy [256, 313].
120
This again highlights the need for a new method which would allow to investigate
the mechanisms of action of AMPs using a holistic approach.
5.1.3 Systems biology: omics metodologies
The understanding of how AMPs function is therefore far from complete. At-
tempts to optimise AMP potency in the laboratory, that focus on only one pos-
sible bactericidal mechanism, ignore the possibilities offered by taking a holistic
approach that can reveal the true source(s) of bactericidal potency along with a
better understanding of bacterial counter-measures. The purpose of combining
metabolomics and transcriptomics is to obtain a more comprehensive insight on
system level adjustments in bacteria under stress from AMPs. The full power of
-omics based research tools has yet to be brought to bear in antibiotic research
[314] and the detailed mechanistic analysis of host-pathogen systems, encom-
passing all aspects of such a complex interaction is still in its infancy. Examples
of previous studies include those that focus on Gram-positive bacteria (Bacil-
lus subtilis [315], Staphylococcus aureus [316], Streptococcus pneumoniae [317])
which have demonstrated the existence of complex regulatory patterns in which
several signal transduction pathways were induced. In our laboratory the focus is
on trying to understand the relative difference in antibacterial potency of struc-
turally related AMPs to Gram-negative bacteria such as Escherichia coli and
Pseudomonas aeruginosa [64, 318–320]. Since these peptides act at widely dif-
fering effective concentrations it was hypothesised that studying their effects at
sub-lethal concentrations would provide a detailed overview of the mechanisms of
action of each AMP. Therefore, a method has been devised that could efficiently
identify conditions where bacteria responded to AMP challenge without intro-
ducing possible, non-specific complications that might result from large scale cell
death. 1H high resolution magic angle spinning (HR-MAS) NMR was used to
identify the lowest AMP concentration that elicited a response from metabolically
active, challenged bacteria. A robust, cross-validated, multivariate analysis iden-
tified metabolites whose levels were altered in response to AMP challenge. These
were used to classify the AMP according to the elicited response whilst providing
a first indication of whether E. coli responded in a generic or specific manner
to AMP challenge. Having identified sub-lethal conditions where a response was
confirmed, electron microscopy and transcript profile analyses enabled a detailed
description of the E. coli response to AMP challenge.
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5.2 Materials and methods
5.2.1 Materials
Peptides (Table 5.1 on page 120) pleurocidin, magainin II, buforin 2 were pur-
chased from Pepceuticals Ltd (Nottingham, UK) as desalted grade and further
HPLC purified using water/acetonitrile gradients using a Waters SymmetryPrep
C8, 7 m, 19300 mm column. D-LAK120-AP13 was synthesised by V. Abbate
(King’s College London). Escherichia coli (E. coli) NCTC 9001 was a gift from
K. D. Bruce (King’s College London). All other reagents were analytical grade
or better.
5.2.2 Bacterial culture and challenge
Cultures of Escherichia coli NCTC 9001, a strain isolated from a patient with
cystitis, were grown overnight in Mueller-Hinton broth (MH) at 37 ◦C . Once the
OD620 reached≈1.0, 1 ml aliquots of bacterial suspension were transferred into 1.5
ml microcentrifuge tubes and aqueous solutions of peptides - magainin 2, buforin
II, pleurocidin and D-LAK120-AP13 were added at the following concentrations:
250 µg/ml, 125 µg/ml, 62.5 µg/ml, 15.6 µg/ml, 3.9 µg/ml and incubated for
30 min at 37 ◦C . In order to be able to monitor the microbial recovery and
growth, 10 µl of each suspension was sampled in 190 µl fresh medium onto a 96-
well microplate. The OD620 was measured at time 0 and after 4 h of incubation
at 37 ◦C . The microcentrifuge tubes were centrifuged at 5000 × g for 5 min
and the bacterial pellets were snap frozen in liquid nitrogen, lyophilised and
kept at -20 ◦C until further use. Pellets from triplicate tubes were combined for
subsequent HR-MAS analysis. Each challenge was independently repeated nine
times.
5.2.3 HR-MAS NMR
High-resolution magic angle spinning (HR-MAS) experiments were performed on
a Bruker Avance 400 MHz spectrometer equipped with a 4 mm 1H/13C HR-MAS
probe. The lyophilised cell pellets were thawed at room temperature, trans-
ferred to an NMR rotor inserts and rehydrated with 30 µl of D2O 2 hours before
the acquisition. 1D spectra were recorded at a constant temperature of 310 K
with magic angle spinning applied at 5 kHz. 1D 1H spectra were recorded using
a standard cpmgpr1d spin echo pulse (cpmgpr; Bruker) with water presatura-
tion during recycle delay of 1 second and a total of 128 scans were acquired.
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The spectral width was 16.02 ppm and 1H 90 pulse length was 7.81 µsec. The
free induction decay was multiplied with an exponential function correspond-
ing to a line broadening of 0.3 Hz. Phase correction was performed manually
and automatic baseline correction was applied. A total of 120 samples were
analysed with between 6 and 13 samples per treated condition and 17 control
samples (no AMP treatment). A number of 2D experiments were run to fa-
cilitate identification of the compounds: homonuclear J-resolved 2D correlation
with presaturation during relaxation delay using gradients (J-Res; jresgpprqf),
1H/13C correlation via direct inept transfer, phase sensitive using states, with
decoupling during acquisition (HSQC 13C; AA-hsqcwg-13C), 2D homonuclear
shift correlation with presaturation during relaxation delay (COSY; cosyprqf)
all acquired using standard Bruker pulse sequences. Spectra were Fourier trans-
formed, manually phase and automatically baseline corrected and calibrated with
2,2,3,3-D4-3-(Trimethylsilyl) propionic acid sodium salt (TMSP-2,2,3,3-D4) with
the reference signal at 0 ppm.
5.2.4 Assignment
Resonances were assigned based on J-coupling partners revealed by COSY, mul-
tiplicities derived from JRES, statistical correlation spectroscopy (STOCSY) [94]
and both 1H and 13C chemical shifts with reference to the E. coli metabolome
database [58].
5.2.5 Multivariate data analysis
Spectra were analysed by PCA and OPLS-DA. Details of the method can be
found in Chapter 2.3 on page 35 and the software manual can be found in Ap-
pendix A on page 177. First, the spectra were aligned to the reference peak and
spectral regions such as water and reference peak (4.8 ppm and 0 ppm, respec-
tively) and regions of no interest and/or no spectral information were removed.
Spectra were then normalised using probabilistic quotient normalisation (PQN)
[124] and autoscaled but not bucketed. Cross-validation was performed where 66
% of the samples were used as a training set and the remaining 33 % as a test set,
ensuring that the number of samples in the test set was proportional to the total
number of samples from each class, and that at least one sample from each class
was present in the test set. To choose the number of components for the model, a
leave-one-out cross-validation was carried out on the samples in the training set,
and the F1-score used to choose the number of components, with the additional
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constraint to use a maximum of 10 components. This double cross-validation was
repeated 2000 times with randomly chosen samples in the training and test set
to prevent bias due to the choice of training or test set. This leads to 3 × 2000
models, each of these models leads to a point on the scores plot, but loadings and
weights are presented as averages over all these models. The chosen number of
components minus one was then used as an OPLS filter and a PLS-DA analysis
with two components was carried out on the filtered data to yield one predictive
and one orthogonal component. Finally, this procedure was repeated with ran-
domly generated class assignments to provide a reference value for Q2. In each
case, genuine or permutated class assignments, the Q2 value quoted is the mean
of all models. Back-scaled loadings plots [113] were used to identify resonances
with high variance and high weight, therefore the discriminating resonances, and
verified against the peak intensity of the original spectra after PQN normali-
sation. Freely available MultiExperiment Viewer (MeV) which is a part of the
TM4 Microarray Software Suite [133] was used for hierarchical cluster (HCL)
analysis and generation of heatmaps. The euclidian distance algorithm was used
to compute the differences between two gene expression levels (metabolite level
changes) and the average linkage method was used to define the distances.
5.2.6 Scanning and transmission electron microscopy
Both SEM and TEM were used to examine the structural changes in bacteria
induced by AMPs. Samples for the imaging were prepared in parallel with the
samples used for HR-MAS NMR and hence represent bacteria in stationary phase.
SEM sample preparation was performed by the author, whereas TEM samples
were prepared by Centre for Ultrastructural Imaging (CUI) at King’s College
London. For SEM, the pellet obtained after centrifugation was fixed in 25 µl
of 2.5 % (v/v) glutaraldehyde in 0.2 M sodium cacodylate buffer and kept at
4 ◦C until further use. In 24-well tissue culture plates 20 µl aliquots of vortexed
bacterial pellet was smeared on 12 mm round poly-L-lysine (BD Biosciences,
Bedford) cover slips with adjacent chambers filled with sufficient amount of 0.2
M sodium cacodylate to prevent drying of the slides and kept in a hydration
chamber for 2 h. Cover slips were then washed with 0.2 M sodium cacodylate
buffer followed by rinsing with 30 %, 70 %, 100 %, 100 %, and 100 % ethanol
and incubating for 10 min between each wash. Hexamethyldisilazane (HMDS)
was used for drying of the specimen by washing cover slips in 50/50 100 %
ethanol/HMDS for 10 min followed by the final wash in HMDS for 10 min.
The coverslips with dehydrated cells were mounted on the specimen stubs and
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sputter coated with gold. Micrographs were acquired with FEI Quanta 200F
FEG scanning electron microscope. Bacterial pellets for TEM processing were
prepared as described above. Cells were pelleted by centrifugation and the pellet
was post fixed in 1 % osmium tetroxide in 0.1 M phosphate buffer for 60 min
an RT. The pellet was dehydrated by exposure to a graded series of ethanol (10
%, 70 % for 10 min each) followed by four washes in 100 % ethanol for 15 min
each. Next, the pellet was subjected to two washes in propylene oxide, 10 min
each. Tubes containing pellets were constantly rotated during the washes and
the following procedures and the washes were performed in the fume hood. The
supernatant was removed and the pellet placed into a mixture of 50 % resin
and propylene oxide for 90 min and transferred to 100 % resin overnight before
polymerisation at 60 ◦C for 24 hours. The resin blocks were sectioned with Leica
Ultra-cut ultramicrotome to semi-thick sections (0.75 µM- 2 µM) and stained
with toluidine blue and used to determine the areas for thin sectioning (90 nm).
The sections were then placed onto 150 mesh copper grids coated with pioloform
support film. Grids were then stained with uranyl acetate and lead citrate before
viewing on Hitachi H7600 transmission electron microscope. For both techniques,
around 15 images were taken for each treatment. The following magnifications
were used and images were selected that are representative of the effect observed:
700 ×, 5000 ×, 12000 ×, 25000 ×, 70000 ×.
5.2.7 GeneChips
GeneChip experiments were performed using the Affymetrix R© (Santa Clara, CA)
E. coli Genome 2.0 Array with effective, response inducing, sub-MIC AMP con-
centrations determined from the HR-MAS metabolomic study; pleurocidin 62.5
µg/ml, buforin II 250 µg/ml, magainin 2 125 µg/ml and D-LAK120-AP13 15.6
µg/ml. Each array includes approximately 10,000 probe sets for all 20,366 genes
present in four strains of E. coli over the entire open reading frame (ORF);
K12 (MG1655 laboratory strain), CFT073 (uropathogenic), 0157:H7-EDL953
(enteropathogenic) and O157:H7-Sakai (enteropathogenic). RNA was extracted
using RiboPure and enriched using MICROBExpress Bacterial mRNA Enrich-
ment Kit after the DNA digestion step (Life Technologies, Paisley, UK). At each
step the quality of RNA was assessed using Pico100 (Picodrop Ltd, Hinxton,
UK). cDNA was synthesised from mRNA and purified using Qiagen MinElute
PCR (Qiagen, Manchester, UK). cDNA was then fragmented and labeled using
terminal transferase and biotinylated Affymerix R© GeneChip labelling reagent
according to the manufacturer’s instructions. Fragmentation and labeling were
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Figure 5.3: Flow diagram of steps in target preparation for Affymetrix R©
GeneChip system.
assessed with the 2100 Bioanalyzer (Agilent Technologies, Wokingham, UK) to
obtain the size distribution and yield. cDNA was kept at -80 ◦C until microarray
hybridisation. Target hybridisation, scanning and Affymetrix R© data analysis
and formatting was performed by the Genomic Centre at King’s College London.
Hybridisation of the target to the GeneChip was prepared according the stan-
dard Prokaryotic Target Hybridisation protocol according to the manufacturer’s
instructions. The efficiency of the hybridisation step was assessed by examining
hybridisation of Poly-A controls provided for the Affymetrix R© GeneChip. Ar-
rays were scanned on an Affymetrix R© GCS3000 microarray system and image
acquisition, quantification and data analysis were performed using Affymetrix R©
Command and Expression Console Software. Data were normalised using the Ro-
bust Multi-array Average (RMA) algorithm built into Expression Console. Pre-
selection of gene lists for each treatment was performed using Qlucore Omics Ex-
plorer (Qlucore AB, Lund, Sweden). First, ANOVA across all samples identified
the twenty most differentially expressed genes according to each replicated treat-
ment. These were then assessed by principal component analysis to confirm that
independently replicated experiments produced consistent results. Signal intensi-
ties for gene expression were then averaged across technical duplicates/triplicates
and log transformed. For the gene annotation enrichment analysis, differentially
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expressed genes in treatment versus control samples were selected by a paired, ho-
moscedastic t-test with a significance cutoff of p < 0.05 and lists for the four AMP
treatments were then compared using Venny [321]. Microarray data are available
in the ArrayExpress database (www.ebi.ac.uk/arrayexpress) under accession
number E-MTAB-1703. To better understand the differences between the effects
of the four treatments, significance thresholds that identified the approximate
top 200 - 250 differentially expressed genes were selected; p ≤ 0.0184 for buforin
II and D-LAK120-AP13, p ≤ 0.0425 for pleurocidin and p ≤ 0.078 for magainin
2. These lists were analysed using the GOEAST Gene Ontology Enrichment
Analysis Software Toolkit where the Benjamini-Hochberg option was selected al-
lowing an FDR up to 15 % [322]. Discriminating metabolite changes, identified
from HR-MAS NMR, were then mapped onto the KEGG pathway using Bio-
Cyc Omics Data Analysis (http://ecocyc.org/PToolsWebsiteHowto.shtml#
omicsDataAnalysis) and genes related to given metabolic pathway checked
against consistently differentially expressed genes, whether or not they had passed
the significance test described above.
5.2.8 Multiparameter viability assays
In order to assess the functionality and cellular integrity of bacteria the follow-
ing viability assays have been used: membrane potential assay, esterase activity
assay and BacLight Live-Dead stain for microscopy [323].
As previously, E. coli NCTC 9001 were grown from glycerol stocks in Muller-
Hinton broth overnight at 37 ◦C without shaking until an OD620 of 1.0 was
reached. 1 ml aliquots of culture were challenged for 30 min with four pep-
tides at and below the threshold concentrations established with NMR. Cells
were then harvested by centrifugation at 5,000 × g for 5 min and washed in 50
mM phosphate buffer (pH 7.0). For BacLight Live/Dead stain cells were diluted
to 4 × 108 CFU/ml, whereas for the remaining assays cells were diluted to 2 ×
108 CFU/ml. All experiments were performed at room temperature. Negative
controls were obtained either by treatment with 70 % isopropanol for 10 min and
removed by centrifugation at 5,000 × g for 5 min and re-suspension in PBS, or by
heat killing at 85 ◦C for 10 min on a heat block. Assays were performed in black,
flat bottom, 96-well plates and read on a Synergy HT multi-mode microplate
reader (BioTek, Winooski, VT).
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Membrane potential
25 mg of dye DiBAC4 (Anaspec, Fremont, CA) was reconstituted in 2.42 ml
ethanol to obtain a 20 mM stock solution which was stored at -20 ◦C . The stock
was diluted further with water to working concentration of 12.5 µM immediately
before use. 20 µlof 12.5 µM dye was added to a 96-well plate, covered by 180
µlbacterial suspension in PBS and mixed. The plate was incubated in the dark for
5 minutes and fluorescence emission was measured (excitation 485 nm, emission
535 nm). Since membrane damage leads to higher fluorescence intensity, values
were background corrected and expressed as a reciprocal before being normalised
with untreated cells defined as being 100 % and isopropanol treated cells defined
as 0 %.
Esterase activity
5 mg of esterase substrate 5,6-carboxyfluorescein diacetate (CFDA) was dissolved
in 1.086 ml dimethyl sulfoxide (DMSO) to obtain 10 mM stock kept at -20 ◦C
. Stock was diluted 40 × in water immediately before use to obtain working
concentration of 250 µM, which was pre-aliquoted to a 96-well plate. 180 µlof
bacterial suspension in PBS was added to the plate and mixed with the detection
solution. The plate was incubated in the dark for 30 minutes with occasional
shaking and fluorescence emission measured (excitation 485 nm, emission 535
nm).
LIVE/DEAD BacLight
This assay was performed by the author and the images were taken and processed
by Dr Garrit Koller. LIVE/DEAD BacLight kit (Life Technologies, Paisley, UK)
was used to measure membrane integrity. Harvested cells were reconstituted
with saline and 3 µlof the dye mixture (1.5 µlof SYTO9 (3.34 mM) and 1.5 µlof
propidium iodine (20 mM)) was added to each 1 ml of bacterial suspension and
mixed. Tubes were incubated for 15 minutes in the dark with occasional shaking
and fixed with 20 % paraformaldehyde (PFA) and kept at 4 ◦C . Specimens
were viewed on an Olympus BX60 microscope fitted with an Andor Ultrahigh-
resolution CCD setup. A × 20 oil immersion lens was used to obtain a 200 µm




Parent strain BW25113 and Keio knockout strains [324] for ∆yejF, ∆yjjB, ∆yohN,
∆yrdB, ∆metB, ∆cyoA, ∆cyoC, ∆cyoD, ∆speB, and ∆argR were obtained from
the Coli Genetic Stock Center (Yale University, New Haven, CT). The activities
of the peptides were assessed in planktonic suspension in polypropylene 96 well
plates (Greiner Bio-one, Frickhausen, Germany) according to a modified broth di-
lution assay [325]. Bacteria were grown without shaking in 50 ml Mueller-Hinton
(MH) broth at 37 ◦C . Peptides (pleurocidin, magainin 2 and LL-37) were tested
in duplicates with two rows allocated for each peptide. In each of columns 2 - 11,
50 µlof MH broth was added under sterile conditions. In the first column of each
row, 50 µlof 256 µg/ml stock peptide solutions, prepared in distilled water, were
added and then the broth from the second column was pipetted into the first col-
umn and thoroughly mixed before being deposited again in the second column.
This process was repeated throughout the tray providing a twofold dilution of
peptide with each row. Bacteria with an OD620 of 0.001 were then added to each
well in volumes of 50 µlgiving a further twofold dilution and a final volume of 100
µlper well. The final column was used either as sterility control (100 µlbroth) or
negative control (no peptide). Plates were incubated overnight at 37 ◦C and the
OD620 read. Growth curves prepared from duplicates were fitted to determine the
peptide concentration required to inhibit growth by 50 % (MIC50). The MIC50
quoted for each peptide (Table 5.1 on page 120) is an average value from at least
two independent repeats.
5.3 Results
5.3.1 1H HR-MAS NMR metabolomics reveals threshold
AMP concentration
1H HR-MAS NMR metabolomics allowed successful differentiation between bac-
terial responses to a challenge with four distinct AMPs (Table 5.1 on page 120).
All of the cationic amphipathic AMPs chosen for this study were of similar length
and were all C-terminally amidated with nominal charge ranging from +4 to +9.
Unlike in conventional microdilution assays [325] that were used in MIC testing
(MIC50 for all peptides given in Table 5.1 on page 120), for the AMP challenge
experiments higher bacterial cell densities (8 × 108 CFU/ml) were required at
the stationary phase. At the higher bacterial titre, the relative potency of AMPs
was similar, however, the effect of the four AMPs was somewhat different from
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Figure 5.4: AMP challenge of E. coli NCTC 9001: overnight cultures were
challenged with increasing amounts of each of four AMPs for 30 minutes and the
recovery of aliquots added to fresh media was measured after 4 hours incubation at
37 ◦C (A). ∗ indicates the peptide concentration causing a significant (p <0.1)
reduction in OD620 relative to the lowest peptide concentration used. Membrane
potential of challenged bacteria as measured by the voltage sensitive dye DiBAC4 and
expressed as a percentage of untreated cell (B). Esterase activity determined by
cleavage of 5,6-carboxyfluorescein diacetate expressed as a percentage of the maximum
observed activity (C). Peptide concentrations are given in µg/ml.
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the minimum inhibitory concentrations (MICs), with D-LAK120-AP13 having a
substantially greater effect on bacterial numbers as detected in the challenge and
recovery assay (Figure 5.4 on the preceding page (A)). Magainin 2 and Buforin II
had insufficient inhibitory effect for a MIC to be determined at the higher titre.
Nevertheless, the amount of peptide causing a significant reduction in bacterial
re-growth was established with D-LAK120-AP13 effective at 15.6 µg/ml, pleu-
rocidin at 62.5 µg/ml and magainin 2 at 125 µg/ml required for a significant
effect. Buforin II had no observable effect on bacterial re-growth at any of the
peptide concentrations tested (Figure 5.4 on the previous page (A)). Addition-
ally, a multi-parameter assay was taken to assess the effect of peptide challenge
on membrane potential (Figure 5.4 on the preceding page (B)), esterase activity
(Figure 5.4 on the previous page (C)) and membrane integrity in the challenged
stationary phase bacteria. The results suggested that only the concentrations of
pleurocidin and D-LAK120-AP13 above the threshold were lethal. A dose depen-
dent response to each of the four AMPs was observed, however even at higher
peptide concentrations, the membrane potential was not completely lost while
the esterase activity was higher than in the untreated cells, which is a typical
response in E. coli to exposure to sublethal stress [323].
Both 1D and 2D NMR spectra acquired for the metabolomics study were
of good quality and major metabolites were assigned as seen from assigned
COSY 5.5 on the following page and HSQC 5.6 on page 133.
One dimensional 1H NMR spectra were obtained for all samples. PCA identi-
fied outlier spectra resulting from either poor baseline or signal to noise, whereas
either PLS regression analysis or a series of OPLS-DA tests were used to interro-
gate the spectra. The lowest concentration of each AMP that caused a significant
change in the spectra relative to spectra from untreated cells was determined us-
ing PLS-DA in a step-wise manner. The resulting Q2 values are presented in
Table 5.2 on page 138. An arbitrary value ≥ 0.6 was taken to select a reliable
model where the AMP challenge has a significant effect. This value was also
compared with the reference Q2 that was obtained with randomly assigned class
identifiers in order to show a model with no effect. 2D scores plots that resulted
from each of the cross validated OPLS-DA analyses are shown in Appendix B on
page 185 (Figure B.9 on page 195, B.10 on page 196, B.11 on page 196). Scores
plots for the threshold concentrations of AMP and for the highest AMP concen-
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Figure 5.5: Representative 2D COSY spectrum of E. coli NCTC 9001
challenged with pleurocidin at the threshold concentration and the assigned metabolic
compounds.
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Figure 5.6: Representative 2D 1H - 13C HSQC spectrum of E. coli NCTC
9001 challenged with pleurocidin at the threshold concentration and the assigned
metabolic compounds.
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tration of buforin II are presented in Figure 5.11 on page 140. A clear separation
of the OPLS-DA scores that was obtained at the indicated AMP concentration
and was accepted as an indication of a threshold concentration of AMP needed
for a response detectable in the bacterial metabolomes. This threshold concen-
tration varied considerably for the four AMPs and was directly related to the
apparent antibacterial efficacy as detected by MIC50. The growth curves (Fig-
ure 5.4 on page 130 (A)) indicated that bacterial growth remained greater than
50 % of maximum after challenge with AMPs at the threshold concentration,
while esterase activity was increased relative to untreated cells (Figure 5.4 on
page 130 (C)) and membrane potential was not completely lost (Figure 5.4 on
page 130 (B)). Taken together the threshold value corresponded to a sub-lethal
AMP concentration, therefore the NMR metabolomic technique identified condi-
tions where metabolically active E. coli were responding to the AMP challenge
without simply reporting on bacterial cell death. Comparing the backscaled
loadings for each binary comparison between untreated bacteria and those chal-
lenged with each AMP using OPLS-DA, identified metabolites whose differing
intensities correlated with the effect of each AMP. A hierarchical cluster ana-
lysis was used to reveal variation in metabolite levels when comparing bacteria
challenged at threshold concentrations (Figure 5.7 on the next page) and com-
paring above and below threshold concentrations (Figure 5.8 on page 136). Both
common and AMP specific changes in E. coli metabolite levels were observed
in response to challenge with the four AMPs. Notably, the hierarchical analysis
grouped the peptides according to their potency as seen in both dendrograms.
Assigned metabolites were used as an input to a network pathway analysis, which
was conducted using MetaboAnalyst [101, 326]. The magnitude and direction of
changes in metabolite levels were not taken into account. Metabolic pathways
were identified according to p-values obtained from pathway enrichment analysis
and pathway impact from pathway topology (Figure 5.22 on page 153). Changes
in alanine, aspartate and glutamate metabolism had the greatest impact and were
a common feature of challenge with all four peptides with changes in pyruvate,
butanoate and arginine/proline metabolism highlighted according to the distinct
challenges.
The dynamic response of E. coli NCTC9001 to challenge with pleurocidin or
magainin 2 was assessed over a period of 2 hours at the following intervals: 5
minutes, 15 minutes, 60 minutes and 120 minutes. The OPLS-DA scores plots
(Figure 5.9 on page 137) indicate that a response to AMP challenge at the level of
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Figure 5.7: Hierarchical clustered heatmap comparing loadings obtained from
cross-validated OPLS-DA comparing untreated bacteria with AMP at the threshold
concentrations indicated above.
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Figure 5.8: Hierarchical clustered heatmap comparing loadings obtained from
cross-validated OPLS-DA comparing untreated bacteria with AMP at the above and
below threshold concentrations.
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Figure 5.9: Comparison of OPLS-DA scores plot from 2000
cross-validated models for bacteria treated with 125 µg/ml magainin 2
(A) or 62.5 µg/ml pleurocidin (B), against untreated control at t = 5, t =
15, t = 60, and t = 120 minutes.
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Table 5.2: Predictive Q2 values for OPLS-DA models. Q2 values for cross
validation performed with permutated classes are provided in parentheses.
[AMP] (µg/ml) Q2
Pleurocidin Magainin 2 Buforin II D-LAK120-AP13
3.9 0.32 (-0.29) n.d n.d. 0.37 (-0.30)
15.6 0.53 (-0.31) 0.29 (-0.36) n.d. 0.59 (-0.28)
62.5 0.81 (-0.41) 0.20 (-0.31) n.d. 0.81 (-0.31)
125 0.80 (-0.29) 0.68 (-0.34) n.d. 0.83 (-0.26)
250 n.d. n.d. -0.30 (-0.39) n.d.
Figure 5.10: Hierarchical cluster analyses of metabolic responses to
pleurocidin (left) and magainin 2 (right) challenge recorded for five
different incubation periods. The responses are broadly similar over time but, in






Figure 5.11: Metabolomic analysis by 1H HR-MAS NMR of lyophilised,
stationary phase E. coli cell pellets. OPLS-DA scores plots are shown for
challenge at the following threshold concentrations; pleurocidin at 62.5 µg/ml (A),
magainin 2 at 125 µg/ml (B), D-LAK120-AP13 at 15.6 µg/ml (C) and buforin II at
250 µg/ml (D).
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the metabolome can be detected throughout the period tested. However, when
the backscaled loadings were compared in a hierarchical cluster analysis (Fig-
ure 5.10 on page 138), modest but notable differences in the affected metabolites
were discerned. This suggested that the bacterial response detected beyond an
hour after challenge is characteristically distinct from that probed within the first
30 minutes. These conditions - 30 minutes incubation at the determined thresh-
old concentration - were therefore used for subsequent electron microscopic and
transcript profiling analyses of samples prepared in parallel to those used above.
5.3.2 Scanning and transmission electron microscopy iden-
tifies differences in the response to each AMP
Changes in E. coli internal or external morphology in response to challenge
with AMP were monitored respectively using transmission and scanning electron
microscopy (TEM/SEM) at either one or four times the sub-inhibitory AMP
threshold concentration known to induce a metabolomic response (Figure 5.14
on page 144 to 5.19 on page 149 and B.1 on page 187 to B.8 on page 194). The
bacterial response to each AMP challenge varied considerably and was in quali-
tative agreement with the metabolomic study; buforin II had no noticeable effect
when compared with untreated bacterial cell controls (Figure 5.16 on page 146
and 5.17 on page 147 D/E), with each of the three other AMPs inducing sub-
stantial changes to external and/or internal morphologies. For magainin 2, a
regular, almost circular nucleoid condensation was observed in some, but not all,
cells (Figure 5.3.2 A, B.7 on page 193) while some impairment of cell division
was evident with extended rods observed (Figure 5.15 on page 145 A). Pleuro-
cidin also induced nucleoid condensation but this was much more widespread;
observed throughout the bacterial cell population (Figure B.4 on page 190/ B.5
on page 191). This was accompanied by some possible protein aggregation and
the production of large amounts of a fibrous material (Figure 5.14 on page 144 B).
In addition to the production of the fibrous material, SEM identified moderate
vesicle production, a known envelope stress response in Gram-negative bacteria
[327]. Finally, D-LAK120-AP13 induced dramatic changes in both the internal
(Figure 5.14 on page 144 C) and external E. coli morphologies (Figure 5.16 on
page 146 C). Extensive release of outer membrane vesicles was evident which was
coincident with a loss of the normal rod shape, consistent with bacteria budding
prematurely (Figure 5.16 on page 146 C). Inside bacterial cells, extensive nucleoid
condensation and protein aggregation was observed throughout the bacterial cell
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Figure 5.12: Transmission electron micrographs at × 25,000 magnification
of AMP challenged E.coli NCTC 9001. Bacteria were challenged for 30
minutes with AMPs above the threshold concentration that elicits a bacterial response




Figure 5.13: Transmission electron micrographs at × 25,000 magnification
of AMP challenged E.coli NCTC 9001. Bacteria were challenged for 30
minutes with AMPs above the threshold concentration that elicits a bacterial response
as determined by the 1H NMR metabolomics study; 62.5 µg/ml D-LAK120-AP13
(C), 250 µg/ml buforin II (D).
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EFigure 5.14: Transmission electron micrographs at × 25,000 magnification
of untreated E. coli NCTC 9001.
population (Figure 5.14 C; Figure B.2 on page 188, B.3 on page 189). Taken
together, although there were some qualitative similarities in the response of E.
coli cells to each of the three more potent AMPs, markedly distinct responses to
each peptide were observed overall. Transmission electron micrographs obtained
at higher magnification and with AMP added at a concentration above the de-
tected threshold value indicated that, for all four peptides, the bacterial envelope
remained intact and no release of cell contents was apparent (Figure 5.19 on
page 149).
5.3.3 Global transcriptome response
The response of E. coli to challenge with the four AMPs was then probed at
the level of the transcriptome. Transcript profile changes in the NCTC 9001
strain, a clinical isolate from a patient with cystitis, were monitored using the
E. coli Genome 2.0 Array where four strains including laboratory, uropathogenic
and enteropathogenic strains are featured. Due to the high degree of similar-
ity between strains, in the majority of cases, a single probe set represents the
equivalent ortholog in all four strains. All genes that are subsequently described
in detail are found in both laboratory (K12 substr. MG1655) and uropathoge-
nic (CFT073) strains with the majority also found in the two enteropathogenic
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Figure 5.15: Scanning electron micrographs at × 25,000 magnification of
AMP challenged E. coli NCTC 9001. Bacteria were challenged for 30 minutes
with AMPs above the threshold concentration that elicits a bacterial response as




Figure 5.16: Scanning electron micrographs at × 25,000 magnification of
AMP challenged E. coli NCTC 9001. Bacteria were challenged for 30 minutes
with AMPs above the threshold concentration that elicits a bacterial response as
determined by the 1H NMR metabolomic study; 62.5 µg/ml D-LAK120-AP13 (C),
untreated E. coli NCTC 9001 (D).
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EFigure 5.17: Scanning electron micrographs at × 25,000 magnification of
AMP challenged E. coli NCTC 9001. Bacteria were challenged for 30 minutes
with AMPs above the threshold concentration that elicits a bacterial response as
determined by the 1H NMR metabolomic study; 250 µg/ml buforin II (E).
strains. PCA of the twenty most differentially expressed genes across all groups
showed the three independent replicates of each condition clustered together indi-
cating the AMP challenge and transcript profiling assay were reproducible (Fig-
ure 5.20 on page 150). Further analysis, where either an arbitrary significance
level (p ≤ 0.05) for differential gene expression or manual manipulation of signifi-
cance levels leading to an optimal separation by principal components, generated
lists of differentially expressed genes related to each treatment. E. coli genomes
commonly encode between approximately 4,200 and 5,500 protein coding genes
[328, 329]. Of the approximately 10,000 probe positions, between 139 and 632
differentially expressed unique genes (p ≤ 0.05) were detected for each treatment
following challenge with AMP at the threshold concentration eliciting a bacterial
response. This corresponds to 2.5 - 15.0 % of the available genome. Magainin 2
induced differential expression of only 139 genes which contrasted with the much
greater number of genes whose expression was altered in response to challenge
with either buforin II or D-LAK120-AP13; 625 and 632 respectively. Pleurocidin
induced differential expression of 298 genes. The distribution of differentially
expressed genes according to each AMP treatment is represented in a Venn dia-
gram and reveals that the vast majority (76.3 %) are specific to each of the four
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Figure 5.18: Transmission electron micrographs of AMP challenged E.
coli NCTC 9001. Bacteria were challenged for 30 minutes with AMPs above the
threshold concentration that elicits a bacterial response as determined by the 1H NMR
metabolomic study; 250 µg/ml buforin II (A),125 µg/ml pleurocidin (B).
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CD
Figure 5.19: Transmission electron micrographs of AMP challenged E.
coli NCTC 9001. Bacteria were challenged for 30 minutes with AMPs above the
threshold concentration that elicits a bacterial response as determined by the 1H NMR
metabolomic study; 250 µg/ml magainin 2 (C) and 62.5 µg/ml D-LAK120-AP13
(D).
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Figure 5.20: Output from Qlucore Omics Explorer showing three
dimensional Principal Component Analysis of 20 most differentially
expressed genes across all 14 GeneChips for E. coli NCTC 9001 as detected
by the GeneChip E. coli Genome 2.0 Array. Bacteria were challenged for 30 minutes
with AMPs at the threshold concentration that elicits a bacterial response as
determined by the 1H NMR metabolomic study; 250 µg/ml buforin II, 62.5 µg/ml
pleurocidin (B), 125 µg/ml magainin 2 (C) and 15.6 µg/ml D-LAK120-AP13 (D).
The axes (1, 2, 3) relate to principal component 1 (PC1) , PC2 and PC3 respectively
and indicate how much variance is explained by each of these first three principal
components. The plot indicates the reproducibility of the transcript profiling
experiment by showing that variance in the 20 most different differentially expressed
genes is closely related to the AMP challenge applied.
AMP challenges (Figure 5.21 on the following page). Only 32 differentially ex-
pressed genes, 2.4 % of the total, were common to at least three treatments while
there was only one, yjjB, which was common to all four treatments. Qualita-
tively therefore, transcriptomic data supported the electron microscopy findings
as, while common responses can be identified, the dominant impression was of a
largely specific response to each AMP challenge.
Discriminating metabolite changes with the most impact (Figure 5.22 on
page 153) were mapped onto their respective Kyoto Encyclopaedia of Genes
and Genomes (KEGG) pathways. This allowed identification of differentially
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Figure 5.21: Transcript profiles and role of individual genes in response to
AMP challenge. Four way Venn diagram showing the distribution of differentially
expressed genes detected by the GeneChip E. coli Genome 2.0 Array (p ≤ 0.05)
following challenge of stationary phase E. coli NCTC 9001 with each of four AMPs at
subinhibitory concentrations known to elicit a bacterial response; pleurocidin at 62.5
µg/ml, magainin 2 at 125 µg/ml, D-LAK120-AP13 at 15.6 µg/ml and buforin II at





Figure 5.22: Network pathway analysis by MetaboAnalyst software showing
matched pathways according to p-values from pathway enrichment analysis and
pathway impact values from pathway topology analysis based on the identified NMR
resonances distinguishing control from the treatment with 62.5 µg/ml pleurocidin (A),
125 µg/ml magainin 2 (B), 15.6 µg/ml D-LAK120-AP13 (C), 250 µg/ml Buforin II
(D).
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expressed genes that potentially participate in mediating the response to AMP
challenge. Changes in alanine, aspartate and glutamate metabolism were com-
mon to all four peptides and changes in expression of gltX, dapA and metB, coding
for respectively glutamyl-tRNA synthetase, dihydropicolinate synthase and cys-
tathionine gamma-synthase, were observed in the gene lists though these did not
always satisfy the significance thresholds used above. Knockout mutants of dapA
and gltX are not available from the Keio collection but ∆metB and five other
knockout mutants (∆cyoA, ∆cyoC, ∆cyoD, ∆speB, and ∆argR coding respec-
tively for cytochrome o uniquinol oxidase subunits II, III and IV, agmatinase
and arginine repressor), linked to changes in arginine/proline metabolism, were
tested for altered sensitivity to AMP challenge though none was found.
Up-regulated in response to challenge by all four AMPs, yjjB, encodes a 157
amino acid, conserved, inner membrane protein predicted to have four trans-
membrane helices but with no known function. Of the five genes whose expres-
sion was generically affected by the three AMPs of natural origin, three were up-
regulated in response to AMP challenge; manA codes for mannose-6-phosphate
isomerise, cysE codes for a serine acetyltransferase and yohN codes for a 112
amino acid integral membrane protein annotated and established as a periplas-
mic modulator of nickel and cobalt eﬄux and renamed rcnB [329]. In contrast,
yejF, part of an ABC transporter identified as a possible nickel, and probable
microcin C transporter [330], and yrdB, which codes for a highly anionic, glu-
tamine rich, 85 amino acid hypothetical protein from the DUF1488 superfamily,
are down-regulated. Comparison of the growth of parent strain BW25113 and
four knockout mutants (∆yejF, ∆yjjB, ∆yohN and ∆yrdB) obtained from the
Keio collection [324] confirmed yohN confers sensitivity to Co2+ and possibly
Ni2+ (Figure 5.23 on the following page). The growth of these strains was also
tested in the presence of AMPs (Figure 5.24 on page 157). While the MIC for
pleurocidin was not affected by the presence of any of the four deletions, a modest
but significant (p < 0.05) increase in sensitivity was observed for all four deletion
strains when challenged by magainin 2. When the experiment was repeated with
LL-37, an AMP of human origin, three of the deletions rendered the bacteria more
sensitive while deletion of yrdB had no effect. Table 5.3 on page 156 lists genes re-
lated to metal binding that were differentially expressed, such as genes involved in
nickel ion binding nikA and nikB, components of nickel ABC transporter, which
were upregulated when challenged with pleurocidin and magainin 2, but downreg-
ulated in response to the D-peptide and buforin II. A member of two-component
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Figure 5.23: Sensitivity of Wild type and four mutants from the Keio
collection to different cations: (A) MgCl2, (B) NiCl2, (C) CoCl2. (∗∗) p ≤ 0.05
relative to BW. ∆yohN confers sensitivity to Co2+ and possibly Ni2+.
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regulatory system which mediates copper tolerance, cusR was upregulated across
all challenges. Other genes involved in metal binding, which are considered iron
uptake virulence factors found were: fepC, encoding iron-enterobactin transporter
ATP-binding protein and iucD of the aerobactin operon which were substantially
downregulated in response to all four peptides, fepG encoding iron-enterobactin
transporter permease, which was upregulated for D-peptide and magainin 2, but
downregulated for pleurocidin and buforin II. Also, both genes encoding highly
conserved proteins IscU and IscA that are members of an operon iscSUA, which
provides scaffold protein for assembly and transfer of iron-sulfur clusters were
strongly repressed across all challenges. This is also evident from ontology search
of biological processes (Figure B.12 on page 197) where iron-sulfur cluster assem-
bly and metalo-sulfur cluster assembly can be found for bacteria challenged with
pleurocidin.
Table 5.3: Differentially expressed genes related to metals and metal
binding up- or downregulated in response to challenge with AMPs at
sub-inhibitory concentration. In bold p ≤ 0.05.
Fold change
Gene symbol Gene title Pleurocidin Buforin DLAK Magainin
nikA nickel-binding, heme-binding periplasmic protein 2.45 0.51 0.56 1.34
nikB nickel transporter permease 0.51 0.78 0.61 1.89
iscA iron-sulfur cluster assembly protein 0.52 0.40 0.56 0.93
iscU iron-sulfur cluster assembly scaffold protein 0.54 0.41 0.57 0.86
fepC iron-enterobactin transporter ATP-binding protein 1.08 1.06 1.19 0.45
fepE ferric enterobactin transport protein 0.21 0.18 0.26 0.51
fepG iron-enterobactin transporter permease 0.84 0.95 1.35 1.21
feoA Ferrous iron transport protein 0.78 0.43 0.43 0.32
fdoH Formate dehydrogenase-O iron-sulfur subunit 0.31 0.63 0.57 0.45
iucD IucD protein 0.50 0.53 0.63 0.79
The ontological profile related to each challenge offers another view of how
closely related the response to each AMP is to each other. Here, instead of com-
paring individual genes on the basis of their identity, the comparison is based
on the cellular component, biological process or molecular function and is less
affected by redundancy or more subtle changes in response and consequently
better reflects the fundamentals of the bacterial response. Ontological analysis,
which employed a Benjamini-Hochberg method to control false discovery rate
(FDR) and displays statistically overrepresented, differentially expressed genes
in a graphical format according to their relationships in a hierarchical tree, was
carried out on gene lists comprising the 200 - 250 most differentially expressed
156
Figure 5.24: Role of individual genes in response to AMP challenge. Effect
on sensitivity of E. coli BW25113 to magainin 2, pleurocidin and LL-37 of mutations
in four of six genes commonly regulated in response to AMPs of natural origin.
genes for each of the individual AMP treatments (Figure B.13 on page 198, B.14
on page 199, B.15 on page 200 and B.16 on page 201) and for comparisons of up
to three AMP treatments (Figure 5.25 on the following page, 5.26 on page 159
and B.12 on page 197). The three AMPs derived from natural sources are sus-
pected of acting on different cellular components. Indeed, comparing gene ontol-
ogy (GO) term enrichment for cellular components (Figure 5.25 on the next page)
showed a very different profile for each of magainin 2, buforin II and pleurocidin.
Magainin 2 appears confined to affecting membrane components (Figure 5.25 on
the following page; B.13 on page 198) and had little effect on molecular functions
or biological processes. Buforin II, in contrast, did not impact on any membrane
components, instead focussing on components in the cell or cell part (Figure 5.25
on the following page; Figure B.14 on page 199 A) where 41 % of the differentially
expressed genes related to binding are found in the analysis of molecular function
(Figure B.14 on page 199 B). Pleurocidin elicited responses both in membrane
components and in the cell itself (Figure 5.25 on the next page; Figure B.15
on page 200) with biological processes, in particular polysaccharide and macro-
molecule metabolism and transport, impacted. This was reinforced by the finding
that some 35 genes related to transporter activity were differentially expressed
(Figure B.16 on page 201). These observations reinforce the view that AMPs
impact on bacterial cells in distinct and AMP-specific ways. When the top 250
genes differentially expressed in response to challenge with D-LAK120-AP13 were
analysed, very few enriched pathways were found when biological processes were
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Figure 5.25: Multi GOEAST comparison of gene ontology (GO) terms
relating to cellular component for differential gene responses in stationary
phase E. coli NCTC 9001. Challenge was induced with sub-inhibitory
concentrations of pleurocidin (red: p1), magainin 2 (blue: p2) and buforin II (green:
p3). Red arrows represent relationships between two enriched GO terms, black arrows
between enriched and un-enriched terms and black dashed arrows represent
relationships between two un-enriched GO terms. Raw p values for GO terms have
been adjusted using the Benjamini-Hochberg method allowing FDR < 15 %.
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Figure 5.26: Multi GOEAST comparison of molecular function in
differentially expressed genes of E. coli NCTC 9001 in response to challenge
with pleurocidin (red), magainin 2, (blue) and buforin II (green) as detected by the
GeneChip R© E. coli Genome 2.0 Array. Bacteria were challenged for 30 minutes with
AMPs at the threshold concentration that elicits a bacterial response as determined by
the 1H NMR metabolomic study; 250 µg/ml buforin II, 62.5 µg/ml pleurocidin and
125 µg/ml magainin 2.
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considered, with no enriched cellular components or molecular function identified.
This indicates a non-specific response for this designed peptide notwithstanding
its shared responses with buforin II observed above.
Other virulence related genes whose expression was altered in response to the
challenge are listed in Table 5.4 on the following page.
5.4 Discussion
5.4.1 Evaluation of combined -omics approach
In summary, combining the methods applied in this study, the metabolomic, elec-
tron microscopy and transcript profiling analyses, created a platform that allowed
identification of an array of both generic and specific responses to a challenge with
AMPs. The peptides chosen to be tested in this study share many physicochem-
ical features - all four peptides used were cationic, of similar lengths, and will
adopt conformations with secondary amphipathicity. Their presumed target is
the E. coli inner membrane, but they differ in their modes of action. The study
indicates that the whole cell is much more than the simple sum of its parts and
the interactions between different parts resulted in many new physiological func-
tions which cannot be observed with individual components. Together with the
strengths and weaknesses of the analytical methods that were identified in this
study, it underscores the value of a combined approach. The electron micrographs
showed distinct changes to internal structure and morphology of bacterial cell ef-
fected by each challenge at sub-inhibitory concentrations. It indicates that AMPs
induce very different responses in bacteria, however, a complementary method
was needed in order to investigate the details of the molecular mechanisms in-
volved and investigate how each AMP operates. Transcript profiling provided a
wealth of information on the bacterial response and gene ontology categorisation
of the differentially expressed genes suggested processes, functions and cellular
components and the individual gene products implicated. These findings suggest
that in order to illuminate further how bacteria attempt to fight off challenges
posed by AMPs a wide range of experiments. The results also suggest that tran-
script profiling may also be more sensitive than the other approaches used since it
alone was able to identify a significant response to buforin II which, despite hav-
ing the highest AMP concentration used (250 µg/ml) did not have a discernible
effect on either the internal or external cellular morphology nor was a response de-
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Table 5.4: Differentially expressed genes related to various virulence
factors up- or downregulated in response to challenge with AMPs at
sub-inhibitory concentration. In bold p ≤ 0.05.
Fold change
Cell division Pleurocidin Buforin DLAK Magainin
mltE 1.29 0.94 0.77 1.24
sulA 0.75 0.65 0.50 0.64
ftsA 1.49 1.91 1.88 1.81
sdiA 0.86 0.60 0.51 0.47
xerC 1.08 1.06 1.19 0.45
ftsX 0.88 1.53 1.24 0.82
fimbrie/motility
yqiH 2.07 1.68 1.38 0.84
ycbS 1.12 1.02 1.16 1.25
cheA 0.52 0.57 0.76 0.84
fliP 1.36 1.07 1.14 1.58
yhcD 0.88 0.84 0.93 0.83
fimC 0.93 0.24 0.23 0.83
flk 1.09 0.66 0.58 1.20
papK 2 0.80 0.37 0.35 0.72
fimI 1.07 0.58 0.62 0.93
csgA 0.93 1.20 0.95 1.44
focA 1.20 1.91 1.38 1.08
ydeR 0.74 0.66 0.87 0.98
ydeS 0.62 0.51 0.77 1.09
papE 2 0.79 0.24 0.20 0.68
yfcV 0.83 0.52 0.52 1.06
yadL 0.82 1.02 2.13 0.91
yadM 0.93 1.04 0.80 1.04
DNA damage/nucleoid condensation
recB 0.72 0.82 0.67 0.86
recG 0.48 0.52 0.52 0.73
dinG 0.68 0.65 0.63 0.68
ligA 0.93 1.04 0.94 1.47
recN 0.62 0.38 0.41 0.36
recE 0.81 0.82 0.88 0.88
xerC 1.08 1.06 1.19 0.45
yrdD 1.11 0.63 0.57 0.57
yjhR 1.03 0.47 0.54 1.03
Z1843 1.02 1.48 2.62 1.28
dinI 0.65 0.31 0.26 0.75
cell wall/outer membrane synthesis
mltE 1.29 0.94 0.77 1.24
rhsD 0.85 1.27 0.93 0.92
wcaA 0.72 0.58 0.61 0.83
yfbH 0.49 0.65 0.75 0.79
ECs3935 0.75 0.94 1.04 0.68
cpsB 0.71 0.73 0.71 1.09
galF 1.51 1.02 0.95 0.90
wcaJ 0.63 0.55 0.89 1.26
imp 0.81 0.81 0.98 0.73
rfaF 0.84 0.68 0.73 0.79
rspA 1.05 1.25 0.98 1.62
mraY 1.28 2.10 1.90 1.47
murG 1.68 2.67 2.50 1.27
murC 1.83 2.31 2.51 1.34
murD 1.07 1.23 1.27 1.26
lolB 1.00 0.92 1.07 1.04
pal 1.47 1.28 1.59 1.08
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tected by 1H HR-MAS NMR. The transcript profiling method remains expensive
however and the consumable costs per sample make its use in a high throughput
manner unattractive. The NMR metabolomic technique has the advantage of
having low per sample consumable costs, which enables a much greater range
of test conditions to be assessed. In this study it was possible to test a range
of peptides at increasing peptide concentrations, which would not be possible
using only transcriptomics. NMR metabolomics is also highly reproducible and
able to provide quantitative information. In view of this metabolomics could be
considered as a standalone method for interrogating bacterial responses to chal-
lenge. In the present study, however, while both generic and specific changes in
metabolites were identified in response to AMP challenge, information provided
by transcript profiling or micrographs may seem more discriminating and infor-
mative. The reason for that is that many bacterial metabolic pathways overlap
and the same metabolic pathways may underpin several stress responses. This
suggests that a study considering a larger number of AMPs, both distinct and
closely related is needed. This would allow greater weight to be afforded to cer-
tain key metabolites, known to be altered in response to a given class of AMP
with known influence on bacterial stress responses.
5.4.2 Life and death at the membrane?
The aim of this study was to investigate, whether by looking at the bacterial
stress responses to a challenge with carefully selected AMPs at sub-lethal con-
centration, a detailed systems wide view of the mechanism of action of those
AMPs can be obtained. Upon challenge, multiple interactions occur within the
cell and within the host simultaneously and sequentially in various cellular de-
partments and many AMPs that share a range of structural and physical features
that have been linked to antibacterial activity vary dramatically in their potency
towards the same bacterial target. Pleurocidin, despite having similar secondary
structure, charge and hydrophobicity to magainin 2 (Table 5.1 on page 120)
is ten times more active against Gram-negative bacteria [64]. Since their am-
phiphilicity is very similar, the difference in bactericidal activity is presumably
due to the presence of some structural elements such as flexibility around glycine
residues or high concentration of positively charged residues within the folded
structure, which would modulate biophysical properties of the peptide. The high
resolution structures of both magainin 2 and pleurocidin in the anionic detergent
SDS (PDB entries 2LSA and 2LS9 respectively) have been recently solved in our
laboratory and similar regions of flexibility have been found around the glycine
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residues in the middle section of the sequence (Gly 13/18 magainin 2; Gly 13/17
pleurocidin). Only in the membranes that most closely mimic the inner mem-
brane of Gram-negative bacteria are any differences between the two peptides
observed; here pleurocidin adopts a notably more disordered conformation un-
der these conditions [64]. The more disordered conformation of pleurocidin in
the E. coli target membrane is possibly related to pore formation [331] or the
proposed intracellular targeting strategy [308] which, in both cases, would serve
to boost its potency. This demonstrates the limitations of such artificial model
classification into very few conformational and functional paradigms. Such a
classification system does not account for all the killing mechanisms that pep-
tides exhibit and all the interactions that a peptide molecule can effect on the
bacterial cell. The structural or even functional categorisation as membrane
disruptive or membrane non-disruptive peptides is a weak indicator of peptide
activity or spectrum. This is supported by a recent molecular dynamics study of
AMPs interacting with phospholipid membrane [285], which revealed that con-
comitant, non-specific peptide interactions with other peptides or molecules take
place as well as formation of secondary structures other than simple α-helix or
β-sheet. This could be an explanation for the varying antimicrobial activity and
even different killing mechanisms of peptides with similar secondary structures
and biophysical properties. Such nonspecific, indefinite behaviour hinders bac-
terial resistance development to AMPs [332]. It is also possible that, depending
on pathogen and/or the physiological settings such as the growth phase of bac-
teria, the localisation of the infection or presence of other AMPs and immune
mechanisms of the host organism, AMPs can act on bacteria using more than
one mechanism [279]. There is therefore need for a technique which allows to
consider all mechanisms simultaneously and look at all primary and secondary
effects that the peptides have on bacterial physiology and morphology without
prior knowledge of their killing mechanisms. The interactions are still not well
understood due to their complex and dynamic nature, but also because of the
lack of suitable tools.
Previous -omics based studies comparing AMP action in Gram-positive bac-
terial species found that there was very little overlap in response between Strep-
tococcus pneumoniae that had been challenged with each of three rather different
antimicrobial peptides [317], while two earlier studies [315, 316], which focussed
on peptides with the plasma membrane as a presumed common target, found
rather more overlap. Here, a more holistic approach was applied to try to dis-
163
criminate between the different modes of actions of magainin 2 and pleurocidin
and place their differing membrane activities in a wider context, enabling a more
sophisticated understanding of their respective mechanisms of action while ex-
plaining the greater potency of pleurocidin. This combined approach was readily
capable of distinguishing pleurocidin and magainin 2 on the basis of the bacterial
responses observed in their metabolomic and transcript profiles and the results
were further complemented by electron micrographs. Despite the shared proper-
ties and presumed initial target being the bacterial inner membrane, transcript
profiling identified only 19 genes whose differential expression was common to
both AMP challenges, with differential expression of some 399 genes being a
specific response to either pleurocidin or magainin 2. The results show that the
E. coli response to AMP challenge is plastic and sufficiently sensitive to detect
differing bactericidal strategies of each peptide. The changes in the internal
morphology of E. coli seen in electron micrographs suggest that each of AMPs
was able to enter Gram-negative bacteria, even at sub-inhibitory concentrations.
Pleurocidin had a more profound effect, which would support the greater potency
of this peptide. The results presented suggest that a systems approach is needed
and simply studying membrane interactions is not sufficient, particularly when
trying to increase potency of peptides.
Buforin II is known to operate by different mechanism than pleurocidin and
magainin 2 and is also much less potent. It was therefore hypothesised that the
bacterial response to this peptide would highlight responses to pleurocidin that
are related to an intracellular targeting strategy. Neither the NMR metabolomic
nor electron micrograph studies though identified a strong response to even very
elevated concentrations of this peptide; consistent with our previous work which
identified only a very weak effect against planktonic cultures of either E. coli or
P. aeruginosa [64]. Nevertheless, a large number of significantly differentially ex-
pressed genes in response to buforin II challenge were detected by transcript pro-
filing. While around 64 differentially expressed genes were detected in common to
challenge with buforin II and pleurocidin, 33 differentially expressed genes were
common to buforin II and magainin 2 with a further 534 differentially expressed
genes identified that were not affected by either magainin 2 or pleurocidin. Only
six differentially expressed genes were identified as a common response to these
three AMPs, which further emphasises the plasticity of the E. coli response and
indicates that bacteria have a large repertoire of responses to challenges, which
is a necessary adaptive mechanism in order to survive within the host.
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Considering the ontology of the differentially expressed genes can suggest how
each individual AMP operates and which stress responses in a bacterium were
activated. Here, the ontological profiles have been used to compare the relative
importance of the properties of each AMP, which reveals and supports the view
that these three peptides adopt distinct bactericidal strategies. The ontological
profiles reveal very different changes in transcript profiles following sub-lethal
challenge with the three different AMPs. Obtained GO terms are in full agree-
ment with existing paradigms for the mode of action of each AMP. This supports
the view that such a combined approach can be applied to faithfully reveal the
mechanism of action of peptides and not simply detect the events associated with
bacterial cell death. In particular, the identification of eight GO terms linked to
membranes supports the established view that magainin 2 largely acts on the
plasma membrane of Gram-negative bacteria. In contrast, within the top 200
differentially expressed genes, no membrane GO terms were linked to the action
of buforin II which is considered to seek intracellular targets, while the effect on
binding and a host of biosynthetic pathways is acute. For pleurocidin, where
multiple bactericidal mechanisms have been proposed, there is substantial over-
lap between the cellular component GO terms with those affected by magainin 2.
This indicates that the bacterial membrane is indeed a common target. However,
in contrast with magainin 2, pleurocidin impacts on a large number of intracel-
lular biological processes, in particular macromolecule metabolic and transport
processes. This strongly indicates that a multifaceted antibacterial strategy un-
derpins the high antibacterial potency of this AMP.
5.4.3 Can understanding the bacterial response be ex-
ploited to improve AMP potency?
Since the bacterial response to AMP challenge is highly plastic, it is unlikely
that simply deleting one gene implicated in the stress response is going to have
a great impact on sensitivity. To test this hypothesis, a number of mutants were
studied and identified by mapping metabolite changes with the greatest pathway
impact onto their respective pathways. No differences in bacterial susceptibility
was detected and further work will be required to more effectively disrupt such
pathways in order to identify any relationship with sensitivity to AMPs.
Six gene products were identified that were significantly affected by the chal-
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lenge of each of the three AMPs derived from natural sources. Of these six genes,
two were down-regulated; yrdB an anionic 85 amino acid hypothetical protein
and yejF. The yejF gene codes for the ATPase in the ABC transporter YejABEF
which, when mutated, confers resistance to microcin C [330]. The speculated role
of YejABEF as a nickel transporter has been questioned as it is phylogenetically
distant from other oligopeptide transporters [330]. However, since yejF is down-
regulated in the present study in response to all three peptides obtained from
natural sources and its deletion renders E. coli more sensitive to both magainin
2 and LL-37, this behaviour does support the earlier finding that the activity of
this protein can have a considerable effect on peptide antibiotic potency. Indeed,
while mutations in yejABEF confer resistance to microcin C in E. coli, deletion
of yejF in Salmonella enterica increased sensitivity to AMPs, including both hu-
man beta defensins 1 and 2 (hBD-1 and hBD-2) [333].
Four genes were found to be up-regulated: cysE and manA, which are less
attractive as an antibiotic target, since they are widely distributed amongst taxa,
including animals and yohN and yjjB, which are mainly distributed in Enterobac-
teriaceae and although their functions are not well understood, they might be
more attractive targets for further investigation and possible targets for adju-
vants that could boost the potency of the host innate immune response. Here,
deletion of these genes caused a significant, but modest increase in sensitivity to
magainin 2 and LL-37 while the potency of pleurocidin was unaffected.
Iron plays an essential role for bacterial growth and metabolism and iron
restriction is a central aspect of host defence against many bacteria. A host
can limit availability of free iron by ion-binding proteins-ferritin, lactoferrin and
transferrin. The importance of metals in virulence has been demonstrated in
studies by Weinberg [334] and Holbein [335], which demonstrated that increased
availability of iron promotes infection, whereas other studies showed that iron
deficiency increased host resistance to infection [336] and that mutants for iron
uptake lose their virulence. Moreover, bacteria require manganase (Mn) and zinc
(Zn) and transporters for these metal ions have been associated with virulence
[337, 338]. Here, those four mutants have been tested against different divalent
cations, but only ∆yohN was found to confer sensitivity to Co2+ and possibly
Ni2+.
These results show that the combined systems approach is indeed capable
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of identifying genes that regulate resistance/sensitivity in E. coli and stress re-
sponse pathways induced but that the large number of potentially differentially
expressed genes in bacterial repertoire will mitigate the effect that silencing one
gene product may have. This also emphasises the need to understand bacterial
stress networks in detail.
Finally, one of the peptides used in the study, D-LAK120-AP13, was com-
posed of D-amino acids only and it was of interest to contrast its effect on bacteria
with the expected results for the three peptides representing naturally occurring
AMPs. The peptide was designed in an attempt to circumvent the effect of
proteases secreted by target pathogens, and incorporate structural features, in-
cluding high cationicity and propensity for adopting α-helix rich conformation
[296], therefore being able to insert into and disorder the E. coli inner membrane.
The peptide also has a proline kink, which gives conformational flexibility [295]
that facilitates penetration into bacteria [304, 305]. The peptide had a highly
robust and potent effect against E. coli, which was evident from a significant
metabolomic response even at very low peptide concentrations. Circumstantial
evidence for the ability to penetrate within bacterial cells was shown by transmis-
sion electron microscopy, with the most profound changes due to challenge with
any of the four AMPs observed, and also transcript profiling. Further underlining
the plasticity of the E. coli response, transcript profiling identifies a further 390
differentially expressed genes that were uniquely affected by D-LAK120-AP13.
Interestingly, there was a considerable degree of overlap with the response to
buforin II with 192 differentially expressed genes in common. These two pep-
tides have a greater nominal cationic charge in solution at neutral pH than either
pleurocidin or magainin 2 and both incorporate a proline induced kink in the
secondary amphipathic conformation. Taken together, the data support highly
effective entry of D-LAK120-AP13 into Gram-negative bacterial cells and it is
this that may underpin its high antibacterial potency.
Considering bacterial stress responses, in the present study differentially ex-
pressed genes (p ≤ 0.05) have only been found in response to AMP challenge that
relate to DNA damage and EvgS regulator. The response regulator EvgS was
overexpressed in response to pleurocidin, but not to other peptides. Genes related
to the DNA damage stress response were up- or downregulated in response to
pleurocidin, magainin 2, DLAK120-AP13 but not buforin II, which is in agree-
ment with electron micrographs where buforin II showed no effect with other
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peptides having an effect relative to their potency. Moreover, each AMP resulted
in differential expression of a different set of genes, which would explain different
patterns and degrees of nucleoid condensation depending on the challenge seen
in transmission electron micrographs. Also, sulA, a component of the SOS stress
response, encoding cell division inhibitor protein, was downregulated in response
to D-LAK120-AP13, which could explain round shaped cells, rather than rod
shaped, which indicates excessive division rate. This mechanism prevents the
premature segregation of damaged DNA to daughter cells during cell division.
EvgA and EvgS are components of a two-component system that controls ex-
pression of multiple genes conferring antibiotic resistance in E. coli [339], known
to modulate multidrug resistance of E. coli by increasing eﬄux of drugs [340].
It was also demonstrated to activate genes related to acid resistance, osmotic
adaptation, and drug resistance, such as emrK [341], which was also found to be
highly upregulated in response to challenge with pleurocidin. Interestingly, mdlB,
another gene related to multidrug resistance was substantially downregulated in
response to all challenges, pleurocidin in particular (fold change = 0.263). This
could have clinical significance, whereby multidrug (and drug-specific) exporters
could be considered a target in formulating strategies to treat drug-resistance to
agents with mechanism of action similar to pleurocidin.
The reason why genes related to other stress responses were not detected as
being differentially expressed (p ≤ 0.05) could be that our ANOVA test was too
stringent or that the sub-inhibitory concentration did not induce a sufficient re-
sponse. However, a number of genes have been identified related to virulence
factors, which could be a suitable target for antimicrobial agents. Vast amount
of genes differentially expressed across all challenges were linked to metals. This,
suggests that this could also play an important role in bacterial response to an-
timicrobial threat and warrants further research.
With four distinct but physicochemically related AMPs now tested by a com-
bined systems biology approach, a total of at least 1342 differentially expressed
genes (p ≤ 0.05) have been identified as being potential tools that can be manip-
ulated by the bacteria to overcome AMP challenge. This is equivalent to between
24 and 32 % of the total E. coli genome and suggests, with more structurally
diverse AMPs yet to be tested, that bacteria have a wide variety of means of over-
coming AMP challenges. Understanding these responses enables both the mode
of action of AMPs to be elucidated as well as suggesting strategies to overcome
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these defences. This novel approach may find generic applicability in the study
of antibiotic-bacteria arms races.
5.5 Conclusion
AMPs have tremendous structural diversity and an impressive array of clinically
meaningful activities. This has provided a huge impetus to the development
of new synthetic peptides. Even so, despite nearly two decades of serious de-
sign efforts, there has been limited success in the clinic. This is partially due
to lack of suitable tools and the increasing antimicrobial resistance to existing
antibiotic warrants studies of AMPs, pathogens triggers and the various host
immune responses. Rational development of prevention and control measures
against infectious diseases requires an understanding of the mechanisms of such
interactions. The work flow proposed in this study utilising NMR metabolomics
coupled with electron microscopy and transcriptomics allowed accurate predic-
tion of the killing strategy of each AMP provided novel prospective for previous
functional and biophysical studies and shows that NMR metabolomics could be
used to study host-bacterial interactions as either a standalone method or in com-
bination with transcriptomics. Although some common features of the bacterial
response to AMP challenge could be identified, the metabolomes, morphological
changes and the vast majority of the changes in gene expression were specific to
each AMP. The study shows that the antibacterial mode of action of AMPs can
be accurately predicted by comparing ontological profiles generated by transcrip-
tomic analyses. The response of E. coli to AMP challenge is highly plastic, with
the bacteria capable of deploying a multifaceted response adapted to each AMP,




Conclusion and future work
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6.1 Summary
In this thesis the applicability of NMR metabolomics to study host-bacterial in-
teractions was investigated. Each of the three results chapters tackle a different
instance where an improved understanding of the interactions between bacteria
and host will result in beneficial impact on host health and disease. Having ar-
gued that a systems biology view of such interactions is necessary, its importance
is demonstrated using three scenarios where NMR metabolomics is applied to
help study complex responses.
First, in Chapter 3 NMR metabolomics was used to investigate the lung af-
fected by Cystic Fibrosis by analysing changes in spent media composition after
growth of dominant P. aeruginosa strains isolated from CF patients. The ap-
proach showed that subtle differences in airway secretions could be expected due
to growth of different isolates of the P. aeruginosa isolates. 1H NMR metabo-
lomics was able to divide samples into distinct clusters based on the changes in
metabolite production suggesting that P. aeruginosa adapts to its growth en-
vironment by altering its growth strategy. The findings were related to clinical
measures of patient lung function and, more simply, spent culture pH. This sug-
gests future applications of NMR metabolomics may succeed in predicting patient
outcome by analysing growth of P. aeruginosa isolates but also that multivariate
(NMR) data can be related to more easily measured, univariate (pH) data that
can be more easily included in diagnostic and prognostic tests in the clinic. The
chapter also highlighted some of the experimental limitations of the NMR tech-
nique but suggested solutions for future studies including application of CPMG
pulse sequence or use of HR-MAS, extraction of metabolites, use of deuterated
solvents or pH-adjustment of the media.
In the next chapter, NMR metabolomics was applied to the analysis of the
mouse faecal microbiome of animals which were genetically identical, but hosted
in different rooms. NMR metabolomics of faecal pellets extracted into aqueous
buffer detected differences in metabolome composition which was related to the
divergence in the microbiota composition of the gut. In this study two sets of
multivariate data were obtained-hierarchical cluster analysis of gut microbiota
and changes in a host metabolome. NMR metabolomics allowed for simplifica-
tion of the relationships between microbiota and identification of a link between
the microbiome and the gastrointestinal performance of a host gut.
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In the final study, a solid bacterial pellet is used for NMR metabolomics inves-
tigation of the mechanisms which bacteria might use to overcome the challenge
by antimicrobial peptides. Four different antimicrobial peptides, with suspected
differences in the mechanism of action, were used to probe changes in bacterial
genes and metabolites in response to a challenge. Here NMR metabolomics was
capable of quantitatively and qualitatively characterising the response of E. coli
to AMP challenge and was sufficiently sensitive to reveal that the bacteria had
both common and also district responses to AMPs that were structurally similar
but functionally distinct. The mechanism of action of the AMP challenge could
not be deduced from NMR data alone but aided the application of transcript
profiling techniques. Together these techniques were capable of describing the
effects of AMP challenge in unprecedented detail but indicate that more work
is required to effectively integrate these techniques for their full potential to be
realised.
Nevertheless, all studies described in this PhD thesis, NMR metabolomics
proved to be robust, cost-effective and high-throughput. Despite its limitations,
which can be alleviated by experimental planning, it meets the requirements of
an approach needed to unravel complexity of host-bacterial interactions.
Each study described in this thesis used a different type of sample material
and posed different questions. This required different pre-processing protocols
and different approaches during data analysis. It has been demonstrated that
study design is an important issue, particularly in metabolomics. The first study
demonstrated the importance of investigating buffers and solvents and assuring
their suitability for an NMR study when designing the experiment. Also, when
acquiring a high number of spectra one has to consider the acquisition time per
sample and temperature during the experiment as parameters that can introduce
between-sample variation. This can be prevented by ensuring homogeneous con-
ditions, e.g. running the experiment at low temperature to prevent any bacterial
growth, and sample randomisation. The second study was more straightfor-
ward: samples were stable, buffers compatible with NMR methodologies and the
number of samples more than sufficient for statistical analysis. In the final study,
whole bacterial pellets were used and an initial problem was establishing the right
sample amount in order to obtain satisfactory NMR spectra with the reasonable
acquisition time. The macromolecular aspects of peptide interactions with E.
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coli were examined by two main approaches: determination of the threshold
concentration for each peptide and the phenotype of peptide-dependent and/or
dose-dependent bacterial response to the challenge. The relatively low number
of samples per treatment imposed limitations during multivariate data analysis,
therefore the study was repeated with a higher number of samples to ensure the
accuracy of the classification during cross-validation procedure, as small dataset
may result in small differences being neglected. This study provided a fresh,
novel perspective for previous functional and biophysical studies and shows that
NMR metabolomics will have considerable value in the study of host-pathogen
interactions.
6.2 Transcription Factor Decoys (TFDs): a pro-
spective study
The ability of bacteria to initiate and coordinate changes in gene expression as a
response to varying environmental factors is essential for maintenance of home-
ostasis. Regulation at the transcriptional level is crucial as it is the first stage of
the series of events which result in a production of protein. Such changes eventu-
ally bring about phenotypic alterations allowing the organism to adapt to the new
conditions. Gene expression is regulated by DNA binding transcription factors
(TFs), which bind specific nucleotide sequences and direct transcription of target
genes (TGs). Stress is the main determinant of the expression pattern of the TFs
itself. In E.coli the response to stress which has the most importance is the gen-
eral stress response, which involves transcription of genes essential for survival.
The response is triggered by reduction in growth rate as a result of starvation but
also sudden variations in temperature, osmolarity or acidic pH [342]. Combina-
tions of antibiotics are commonly used in the search for a broadened antimicrobial
spectrum and synergistic effects. A combination of nonantibiotic drugs and com-
pounds with antibiotics/AMPs offers an opportunity to discover alternative and
potent therapeutics. An example of such compounds are transcription factor
decoys. Transcription factor decoys (TFDs) are synthetic oligonucleotide mimet-
ics which are an experimental class of compounds that modulate expression of
specific genes in pathogenic bacteria by interfering with the key DNA-protein
interactions that determine gene activity. TFDs work by flooding the cells with
an excess of copies of the transcription factor’s binding site, so that the protein
will bind to them instead of its genomic site and so prevent expression of the
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genes associated with the stress response and resistance. Combining TFDs with
either a bactericidal, lipidic delivery system or exogenous or endogenous AMPs
should enhance the activity and longevity of the treatment by blocking the stress
response. Bacteria are unlikely to develop resistance against TFDs as this would
require simultaneous mutations affecting both the binding specificity of the TFD
and DNA-binding site [279].
The BBSRC CASE studentship that supported this work was awarded in
conjunction with Procarta Biosystems Ltd who have produced a new generation
of TFD antibiotics with a novel mechanism of action, formulated in a propri-
etary cationic lipid. The final objective for this thesis therefore, was to develop a
systems view capable of describing the mechanism of action of TFDs. By under-
standing how the target bacteria respond to this new antibiotic threat, the future
development of new targets, delivery systems and formulations can be undertaken
in a rational manner. In the previous chapters the NMR metabolomics work-flow
was applied in a stepwise manner to different studies of increasing complexity.
A preliminary NMR metabolomics study has been carried out on the effects of
the cationic lipid delivery system and its TFD cargo E. coli metabolism at both
inhibitory and sub-inhibitory concentrations. However, due to formulation prob-
lems relating to encapsulation of the TFD cargo and incompatibility of the opti-
mal buffer formulations with NMR, the results were inconclusive. Nevertheless,
conditions where a response from metabolically active bacteria is expected were
identified and the study will be repeated in the future with a new formulation
of TFDs optimised for NMR analysis and supported by transcriptomic analy-
ses. The expected outcome will be a detailed description of the E. coli response
mechanism both to the lipidic formulation and its TFD cargo.
6.3 Future directions
In the study of bacterial responses to AMPs both generic and specific changes
in metabolites were identified in response challenge. However, the information
was not sufficient for clear discrimination of the dominant stress responses or
identification of a stress response that is fundamental to survival in face of chal-
lenge from each of the AMPs. This is caused by overlap in many of bacterial
metabolic pathways and the fact that one metabolic pathway may be involved in
many stress responses. Such compensatory mechanisms might necessitate stud-
ies introducing a larger cohort of AMPs, both closely-related and of differing
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operating mechanisms. Such a study would allow induction of a wider range of
bacterial stress responses and the ability to classify changes in gene expression
or metabolite levels according to one mode of action.
The present study identified a change in expression of a large number of genes,
related to metal binding or transport, in response to AMP challenge. This effect
was apparent for each of the four AMPs indicating a possible generic response of
Gram-negative bacteria to AMP challenge. The genes of interest from the tran-
scriptomic study can be monitored in more focussed but cost-effective manner
using qPCR following exposure to a wider variety of AMPs the stablish whether
this is a widespread mechanism of resistance. In addition, the techniques devel-
oped here can be applied to compare responses of wild-type and mutant strains
to the presence of our AMPs, metals and to a combination of both to identify
relationships and the role of the identified individual genes in this postulated
mechanism for overcoming AMP challenges.
Future data analysis will include an attempt to better correlate affected genes
with their paired metabolites to determine relationship and compare the speci-
ficity of the response to a challenge between the metabolite and transcript levels
and utilisation of mapping tools such as Cytoscape (http://www.cytoscape.
org/) to probe biomolecular interactions in bacterial stress response networks
and determine whether the genes and metabolites, showing differential expres-
sion under the challenge are involved in the same biological pathway and to what
extent.
The gut microbiota project will also be taken further and the temporal pro-
gression of host microbiota will be investigated as well as the influence of antibi-
otics on gut microbiota development and composition. NMR metabolomic study
will be complemented by (targeted) MS-based analyses. This study will be ex-
tended by longitudinally following the divergence of gastrointestinal microbiota
over a period of six weeks and monitor the impact of intervention with a modestly
selective antibiotic. This impact study will be a proof of concept to show how
engineering/editing of the gut microbiota affects murine nutrition. This will help
better understanding and standardisation of the murine models that are so relied
upon in modern medical research.
The antimicrobial resistance will also be investigated in another project, which
will monitor the resistance development. The resistance development with and
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without supplementation with antibiotics will be observed in a series of passages




Appendix A: 1D NMR spectra processing and
analysis using Metabolomics-gui [main.py and
cv new main.py]
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A.1 1D NMR spectra processing in TopSpin
efp - exponential multiplication [em], fourier transform [ft], and phase correc-
tion [pk] apk - automatic phase correction ( if still not phased try apk0, apk1,
apkm, apks and manual phasing) abs - automatic baseline correction ( if still
not corrected try advanced baseline correction options) calibrate spectrum - TSP
reference peak at 0 ppm
A.2 Data analysis
Create new folders, one for each comparison you need to perform and give them
meaningful names using ’ ’ instead of gaps between words. Copy NMR data for
the respective binary comparisons into those folders.
A.2.1 PCA
Download the latest version of the software :
justyna@picadilly: /Desktop$ svn co http://gentoo-foum.nl//svn-louic/metabolomics-
gui
Run main.py from terminal window:
justyna@picadilly: /Desktop/metabolomics-gui$ python ./main.py
Note! Once you apply data treatment at any stage and want to change it you
have to go to ’Data’ tab and load the data again repeating every step.
Data
’Open Bruker’ - chose your directory with the NMR data that you want to test.
Define classes looking at the spectra titles in the box at the bottom. One class
per line, numbers only.
Note! Include/exclude spectra is not functional in this version of the software.
You can save your class table to a text file (no spaces in the file name) and load
it whenever you need to use it again. Using buttons in the main box you can
pan/zoom, move and safe the image.
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Align
If you used alignment software choose ’Don’t align’, otherwise choose ’Calibrate
to peak’. The software by default calibrates to the reference peak, however, there
may be better peaks to align the spectra to. They must be sharp and cannot
shift.
Exclude
Exclude reference peak, solvent signals such as water peak, any regions that you
do not want to be analysed and baseline with no peaks. Zoom in and take a note
of the range that you want to exclude. Make sure to exclude the whole peak and
that your excluded region does not affect the integral of remaining peaks. You
can save your exclusion regions to a text file and load to use whenever you need
to use the same exclusion regions.
Bucket
You can use small bucket size such as 0.005 ppm and see if it does not distort
your spectra and then use bigger bucket sizes e.g. 0.02 ppm. It will reduce the
number of data points making the calculations faster and make up for minor
shifts in the spectra.
For manual bucketing copy the desired bucket size to manual buckets and ’write
to text file’. Open it in text editor and delete data points between start and end
of the peak that you want to put into one bucket. Zoom in for precision. Save
text text file and ’Read buckets from text file’ to apply.
Normalise
Unless otherwise indicated, use PQN normalisation. If you entered classes in the
Data tab you can choose to ’Colour by class’.
Scale
Most commonly used types of scaling for PCA are Autoscaling and Pareto scaling.
If you entered classes in the Data tab you can choose to ’Colour by class’.
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PCA
Change number of ’Components’ to as many as you are interested in plotting
later. You can label scores by spectrum number as in ’Data’ tab, assigned class
(only if classes were defined in ’Data’ tab) or title of the NMR file. Scores can
be coloured by the class, if the classes have been previously defined.
Note! ’3D’ plotting and ’Hotelling T2 ellipse’ does not work in this version of the
software.
A.2.2 OPLS and cross-validation
Run main.py from terminal window:
justyna@picadilly: $ cd Desktop/metabolomics-gui
justyna@picadilly: /Desktop/metabolomics-gui$ python ./main.py
Enter classes, align, exclude and bucket spectra (do not normalize or scale). Save
defined classes to text file. ’Save’→ ’Processed spectra as text’
Prepare input file for cross-validation:
• Open class file and add ’0’ before the first number.
• Open saved ASCII file in text editor such as GVim.
• :set nowrap
• Shift+V to highlight the line
• ↓ to highlight all the lines containing ppm values apart from the last one
• Delete
• Shift +ZZ to save and close
• if you want to edit file, e.g. change the class number or comment out the
spectrum (#) you need to go into insert mode by pressing ’i’
Open terminal window and go to the location of your class file and saved processed
data ASCII file:
justyna@picadilly: $ cd Desktop/...
justyna@picadilly: $ paste ’name of classes file’ ’name of ASCII file’>’ new file
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name for the file containing classes and processed spectra’
Run cv new main.py from terminal window or from metabolomics-gui:
• load ASCII file with classes
• ’Read data’
• check if the number of samples and classes is correct and if there is no error
messages in terminal window
• choose the type of cross validation and maximum number of components
to by analysed; less components will reduce the analysis time
• choose a method for component selection; highest F1 score is better when
using two classes only with different number of samples in each class
• choose number of runs, normalisation and scaling method
• save the output files with the meaningful name
• run
• go to ’OPLS CV results’ tab and ’plot results’
• repeat with random class assignments by ticking ’Run permutation tests’
box and ’Run’
A.2.3 Extract mean Q2
justyna@picadilly: $ cd Desktop/metabolomics-gui
justyna@picadilly: /Desktop/metabolomics-gui$ python
Python 2.7.3 (default, Sep 26 2013, 20:08:41) [GCC 4.6.3] on linux2 Type ”help”,
”copyright”, ”credits” or ”license” for more information.
>>>from pylab import∗
>>>data = np.load(’file name qsq.npy’)
>>>np.mean(data)
A.2.4 Extract weights for heatmap
Edit load weights for heatmap lsv.py. Enter ’file name weights.npy’, ’file name xaxis.npy’
and name under which you want to save the file.
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Run load weights for heatmap lsv.py from terminal window:
justyna@picadilly: $ cd Desktop/metabolomics-gui
justyna@picadilly: /Desktop/metabolomics-gui$ python ./load weights for heatmap lsv.py
Put all weight files in one spreadsheet with ppm in the first column and each
treatment in the following columns. Save the file as .csv with the following set-
tings: Field delimiter-Tab, Text delimiter-none.
Run TMeV software (tmev.sh)
• File→ Load data
• Browse for .csv file with weights
• In the ’Expression Table’ click on the upper-leftmost value and ’Load’
• Adjust the scale:Display → Set Colour Scale Limits. Set Midpoint Value
as ’0’ and extreme lover and upper value limits (usually around -0.05 and
0.05, respectively). ’Update Limits’
• Analysis→ Clustering→ HCL (hierarchical clustering)→ Distance Metric Selection:
Euclidean Distance→ Linkage Method
• Selection: Average linkage clustering or Complete linkage clustering
A.2.5 Re Plotting score plots
Edit justyna.py. Enter ’file name scores.npy’, legend titles, axis labels, font size
and load the ASCII file with processed spectra that was previously run in cross
validation.
Run justyna.py from terminal window or from metabolomics-gui
A.2.6 Peak alignment
Run main.py from terminal window:
justyna@picadilly: $ cd Desktop/metabolomics-gui
justyna@picadilly: /Desktop/metabolomics-gui$ python ./main.py
Enter classes, align, exclude. Save defined classes to text file. Save→ Processed spectra as text.
Open saved ASCII file in text editor such as GVim.
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• :set nowrap
• Shift+V to highlight the line
• ↓ to highlight all the lines containing ppm
• Delete
• Save file under different name
Edit apply cow lsv.m in WarpingTB folder. Enter the name of the file you’ve
just prepared, parameter ’m’ (size of the alignment window) and parameter ’t’
(size of the slack), and the output file name.
justyna@picadilly: /Software/WarpingTB$ octave
GNU Octave, version 3.2.4
Copyright (C) 2009 John W. Eaton and others.
This is free software; see the source code for copying conditions.
There is ABSOLUTELY NO WARRANTY; not even for MERCHANTABILITY
or
FITNESS FOR A PARTICULAR PURPOSE. For details, type ‘warranty’.
Octave was configured for ”i686-pc-linux-gnu”.
Additional information about Octave is available at http://www.octave.org.
Please contribute if you find this software useful.
For more information, visit http://www.octave.org/help-wanted.html
Report bugs to <bug@octave.org>(but first, please read
http://www.octave.org/bugs.html to learn how to write a helpful report).




When finished edit plot cow.py. Enter original file name and output file name.
Run plot cow.py. You can pan/zoom, move and save the image. When satisfied
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with the alignment edit the ouput file in GVim. Remove all the lines that don’t
contain data. Copy ppm values from the file you saved processed spectra from
main.py and paste into your output file. This ASCII file can be used in main.py
for further bucketing, PCA or in cv new main.py for OPLS cross validation.
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Table B.1: Controlled ANOVA tests identified genera whose relative abundance
differed significantly between room groups (cont p <0.05). Based upon controlled
ANOVA using least square means this table lists significantly different genera between
groups (p <0.05). The LS mean for each genera and group is provided. Group
indicates which room group. Each genus with significant differences is indicated along
with their LS mean and their relative significance. Groups which share a letter are
not significantly different from each other while groups which do not share a letter (A,
B, C) are significantly different (thus, a group which has A is significantly different
from a group which only has letter B, while a group with letter A is not significantly
different from a group which has AB).
Group Prevotella Group Pedobacter Group Alistipes Group Novispirillum
1 16.013 A 1 0.905 A 1 5.032 B 1 0 A
2 32.46 AB 2 4.513 B 2 4.949 B 2 0.409 A
3 43.529 B 3 2.009 A 3 3.696 AB 3 1.595 B
4 63.838 C 4 0 A 4 0.539 A 4 0 A
Group Coprococcus Group Ruminococcus Group Tannerella Group Eubacterium
1 41.323 B 1 3.501 B 1 1.788 A 1 0.188 AB
2 11.891 A 2 0.779 A 2 5.674 C 2 0.092 A
3 7.908 A 3 1.191 AB 3 4.485 BC 3 0.03 A
4 4.37 A 4 0.616 A 4 2.203 AB 4 0.78 B
Group Bacteroides Group Sutterella Group Clostridium Group Porphyromonas
1 5.575 AB 1 0 A 1 5.655 B 1 0.177 AB
2 11.537 C 2 1.826 B 2 2.196 A 2 0.547 B
3 9.835 BC 3 1.074 AB 3 1.923 A 3 0.331 AB
4 1.324 A 4 0 A 4 4.124 AB 4 0 A
Group Parabacteroides Group Sphingobacterium Group Roseburia Group Anaerotruncus
1 3.359 A 1 0.243 A 1 4.16 B 1 0.297 B
2 11.02 B 2 1.032 B 2 0.803 A 2 0.035 A
3 8.179 B 3 1.249 B 3 0.688 A 3 0.069 A
4 2.988 A 4 0 A 4 1.973 AB 4 0.067 A
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Figure B.1: TEMs of E. coli NCTC 9001 - control cells.
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Figure B.2: TEMs of E. coli NCTC 9001 challenged with 15.6 µg/ml
D-LAK120-AP13.
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Figure B.3: TEMs of E. coli NCTC 9001 challenged with 62.5 µg/ml
D-LAK120-AP13.
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Figure B.4: TEMs of E. coli NCTC 9001 challenged with 62.5 µg/ml pleurocidin.
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Figure B.5: TEMs of E. coli NCTC 9001 challenged with 125 µg/ml pleurocidin.
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Figure B.6: TEMs of E. coli NCTC 9001 challenged with 125 µg/ml magainin 2.
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Figure B.7: TEMs of E. coli NCTC 9001 challenged with 250 µg/ml magainin 2.
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Figure B.8: TEMs of E. coli NCTC 9001 challenged with 250 µg/ml buforin II.
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Figure B.9: OPLS-DA scores for comparisons of 1H HR-MAS NMR spectra of
control E. coli NCTC 9001 and those challenged with pleurocidin at 3.9 µg/ml (A),
15.6 µg/ml (B), 62.5 µg/ml (C) and 125 µg/ml (D). In all panels blue dots
represent scores from unchallenged bacteria while red dots represent scores from the
respective treatments.
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Figure B.10: OPLS-DA scores for comparisons of 1H HR-MAS NMR spectra of
control E. coli NCTC 9001 and those challenged with magainin 2 at 15.6 µg/ml (A),
62.5 µg/ml (B) and 125 µg/ml (C). In all panels blue dots represent scores from
unchallenged bacteria while red dots represent scores from the respective treatments.
Figure B.11: OPLS-DA scores for comparisons of 1H HR-MAS NMR spectra of
control E. coli NCTC 9001 and those challenged with D-LAK120-AP13 at 3.9 µg/ml
(A), 15.6 µg/ml (B), 62.5 µg/ml (C) and 125 µg/ml (D). In all panels blue dots
represent scores from unchallenged bacteria while red dots represent scores from the
respective treatments.
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Figure B.12: Multi GOEAST comparison of biological processes in differentially
expressed genes of E. coli NCTC 9001 in response to challenge with pleurocidin (red),
magainin 2, (blue) and buforin II (green) as detected by the GeneChip R© E. coli
Genome 2.0 Array. Bacteria were challenged for 30 minutes with AMPs at the
threshold concentration that elicits a bacterial response as determined by the 1H NMR
metabolomic study; 250 µg/ml buforin II, 62.5 µg/ml pleurocidin and 125 µg/ml
magainin 2.
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Figure B.13: GOEAST analysis of cellular component in differentially expressed
genes of E. coli NCTC 9001 in response to challenge with magainin 2 as detected by
the GeneChip R© E. coli Genome 2.0 Array. Bacteria were challenged with 125 µg/ml
magainin 2; the threshold concentration that elicits a bacterial response as determined
by the 1H NMR metabolomic study.
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Figure B.14: GOEAST analysis of cellular component (A) and molecular function
(B) in differentially expressed genes of E. coli NCTC 9001 in response to challenge
with buforin II as detected by the GeneChip R© E. coli Genome 2.0 Array. Bacteria
were challenged with 250 µg/ml buforin II; the threshold concentration that elicits a
bacterial response as determined by the 1H NMR metabolomic study. Note the
concentration of genes in cellular component GO terms cell or cell part and in
molecular function GO:0005488 binding.
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Figure B.15: GOEAST analysis of cellular component in differentially expressed
genes of E. coli NCTC 9001 in response to challenge with pleurocidin as detected by
the GeneChip R© E. coli Genome 2.0 Array. Bacteria were challenged with 62.5
µg/ml pleurocidin; the threshold concentration that elicits a bacterial response as
determined by the 1H NMR metabolomic study. Note the distribution of genes between
GO terms cell/cell part, cell periphery and membrane/plasma membrane.
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Figure B.16: GOEAST analysis of molecular function in differentially expressed
genes of E. coli NCTC 9001 in response to challenge with pleurocidin as detected by
the GeneChip R© E. coli Genome 2.0 Array. Bacteria were challenged with 62.5
µg/ml pleurocidin; the threshold concentration that elicits a bacterial response as
determined by the 1H NMR metabolomic study. Note the high number of genes
corresponding to GO:0005215 transporter activity.
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Abstract Chronic polymicrobial lung infections in adult
cystic fibrosis patients are typically dominated by high
levels of Pseudomonas aeruginosa. Determining the
impact of P. aeruginosa growth on airway secretion com-
position is fundamental to understanding both the behav-
iour of this pathogen in vivo, and its relationship with other
potential colonising species. We hypothesised that the
marked differences in the phenotypes of clinical isolates
would be reflected in the metabolite composition of spent
culture media. 1H NMR spectroscopy was used to char-
acterise the impact of P. aeruginosa growth on a synthetic
medium as part of an in vitro CF lower airways model
system. Comparisons of 15 CF clinical isolates were made
and four distinct metabolomic clusters identified. Highly
significant relationships between P. aeruginosa isolate
cluster membership and both patient lung function (FEV1)
and spent culture pH were identified. This link between
clinical isolate growth behaviour and FEV1 indicates
characterisation of P. aeruginosa growth may find appli-
cation in predicting patient lung function while the sig-
nificant divergence in metabolite production and
consumption observed between CF clinical isolates
suggests dominant isolate characteristics have the potential
to play both a selective role in microbiota composition and
influence pseudomonal behaviour in vivo.
Keywords NMR  Cystic fibrosis  Pseudomonal  Lung
function
1 Introduction
Chronic lung disease is the main determinant of morbidity
and mortality in cystic fibrosis (CF) (Emerson et al. 2002;
Rosenfeld et al. 2001), with bacterial infection considered a
key driver in this process (Kosorok et al. 2001). Pseudo-
monas aeruginosa is a species that has long been regarded
as a pathogen in the CF lung (CF Foundation 2007) and
whose presence is associated with reduced life expectancy
(Lyczak et al. 2002). With the exception of end stage
disease (Bjarnsholt et al. 2010), P. aeruginosa, though
common, is only one of many species forming the bacterial
microbiota associated with the CF lower airways by
adulthood (Rogers et al. 2004; Armougom et al. 2009).
Moreover, though the bacterial species reported in CF
typically vary markedly between individuals (Stressmann
et al. 2011); these colonising species are less phylogenet-
ically diverse than the pool of bacterial species reported as
passing transiently through the lower airways of healthy
individuals (Rogers et al. 2006). Together, these factors
suggest that the development of CF airway bacterial
communities is a selective process, and that this selection
differs between individuals. Exposure to an ‘‘infective
dose’’ equivalence of a given species will be required for
‘‘infection’’ to occur. However, the existence of a group of
core species, that is commonly but not universally reported
(van der Gast et al. 2011), suggests that infection is not due
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to chance alone. The factors underpinning selection remain
unclear; however the identification of key selective drivers
offers the possibility of identifying those patients who are
at greatest risk of developing a lower airway infection by a
specific pathogen.
There are a number of factors that differ between CF
patients that might contribute to such selection. For
example, the severity of the underlying impairment of
CFTR function (a trans-epithelial ion transport protein)
(Dean and Santis 1994), the degree to which oxygen ten-
sion in airway secretions is reduced as a result of neutro-
philic influx (Kolpen et al. 2010), and antibiotic treatment
history (Stressmann et al. 2011; Tunney et al. 2011). Here,
we investigate the extent of a further potential selective
force; the nutritional characteristics of secretions in the
airways. Whilst differences in secretion rheology may arise
as a result of the range of CFTR defect severities (Boucher
2004), there is no evidence to suggest that the chemical
composition of the secretions differs substantially between
individuals at the point when they are produced. However,
these secretions are typically colonised by high levels of P.
aeruginosa (commonly 106–109 cfu/ml; Aaron et al. 2004;
Stressmann et al. 2011). P. aeruginosa growth will, in turn,
reduce the availability of certain carbon and nitrogen
sources, and produce a wide range of metabolites. Such
shifts in nutritional sources are known to influence bacte-
rial community composition in other contexts (Resat et al.
2012; Dunaj et al. 2012). Together, these changes will
result in an altered growth environment, potentially influ-
encing the likelihood of successful colonisation by new
bacterial species entering the lower airways, and the gene
expression and growth strategies of P. aeruginosa itself
(Bernier et al. 2011).
Pseudomonas aeruginosa isolates from different CF
patients are known to exhibit a broad range of phenotypic
characteristics, employ a number of different growth
strategies in vivo, including planktonic and biofilm modes
(Ciofu et al. 2012), and exploit a wide range of carbon and
nitrogen sources (Frimmersdorf et al. 2010). We therefore
hypothesised that P. aeruginosa CF airway isolates differ
in the manner in which they modify the composition of the
airway secretions in which they grow, resulting in signifi-
cant differences in the nutritional growth environment
available to the CF airway bacterial community. Charac-
terisation of such biochemical signatures requires the
determination of changes in the levels of a large number of
molecules. Consequently, we used 1H NMR spectroscopy
to obtain an overview of the compositional changes that
occur in a defined synthetic CF medium (SCFM) as a result
of the growth of these isolates in an in vitro CF airway
model. 1H NMR spectroscopy has been used previously to
investigate the growth of P. aeruginosa type strain PAO1
in Luria–Bertani broth, a standard laboratory medium
(Gjersing et al. 2007). Here, we aimed to more closely
replicate the physiochemical composition of CF airway
secretions in a controlled manner and cultured clinical
isolates in SCFM. Previous studies comparing P. aeru-
ginosa gene expression in CF sputum with that in similar
CF synthetic media have shown bacterial behaviour to be
similar in the two contexts (Palmer et al. 2007; Fung et al.
2010). By combining 1H NMR spectroscopy with this CF
airway growth model, we were therefore able to assess the
degree to which the impact of P. aeruginosa growth dif-
fered between clinical isolates under conditions approxi-
mating those encountered in vivo. We report substantial
variation in the observed spent media metabolomes and
show that the variation between different clinical isolates is
related to variation in clinical measures of respiratory
disease.
2 Materials and methods
Sputum samples were collected from 13 adult CF patients
with ethical approval from Southampton and South West
Hampshire Research Ethics Committee (06/Q1704/26).
The collection of these samples has been described previ-
ously (van der Gast et al. 2011; Stressmann et al. 2011). P.
aeruginosa isolates were recovered from these samples by
inoculation on P. aeruginosa selective medium (CM0559
plus SR0103, Oxoid, Cambridge, UK). A representative
colony of the numerically dominant morphotype was
selected for each patient. In the case of Patients 12 and 13,
two prevalent morphotypes were isolated concurrently,
with both carried forward for analysis. Details of isolates,
phenotypic characteristics, and the patients from which
they were obtained, are presented in Table 1.
Bacterial species diversity in these samples was previ-
ously determined by 16S rRNA gene clone sequencing
(van der Gast et al. 2011). Spent culture pH was deter-
mined at 37 C using an InLab Micro Pro pH electrode and
Mi150 pH meter (Mettler Toledo, Leicester, UK). All P.
aeruginosa isolates were screened for auxotrophy as
described previously (Barth and Pitt, 1995). These data are
also presented in Table 1.
2.1 Bacterial growth conditions
Pseudomonas aeruginosa in the CF lung grows in stagnant
mucus, an environment that is characterised by microaer-
ophilic and anaerobic conditions (Worlitzsch et al. 2002;
Yoon et al. 2002). To reflect these in vivo sputum condi-
tions, the following growth model was employed. A
defined synthetic CF medium (SCFM) was used, based on
a number of different CF synthetic media described pre-
viously (Sriramulu et al. 2004; Palmer et al. 2005; Palmer
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et al. 2007; Fung et al. 2010). The SCFM used contained
10 g/L BSA, 10 g/L porcine gastric mucin, 1.4 g/L herring
sperm DNA, 10 mM MOPS, 5 g/L egg yolk emulsion,
3.6 lM FeSO4, 51.8 mM NaCl, 2.28 mM NH4Cl,
2.128 mM L-lysineHCl, 14.9 mM KCl, 1.78 mM L-alanine,
1.754 mM CaCl2, 1.661 mM L-proline, 1.609 mM L-leucine,
1.549 mM L-glutamateHCl, 1.446 mM L-serine, 1.3 mM
NaH2PO4, 1.25 mM Na2HPO4, 1.203 mM L-glycine,
1.12 mM L-isoleucine, 1.117 mM L-valine, 1.072 mM L-thre-
onine, 0.827 mM L-aspartate, 0.802 mM L-tyrosine, 0.676
mM L-ornithineHCl, 0.633 mM L-methionine, 0.606 mM
MgCl2, 0.53 mM L-phenylalanine, 0.519 mM L-histidine
HCl, 0.348 mM KNO3, 0.306 mM L-arginineHCl, 0.16
mM L-cysteineHCl, 0.119 mM diethylene triamine penta-
acetic acid, 0.013 mM L-tryptophan. The pH of the medium
was adjusted to 6.8. Media was sterilised by passage through
a a 0.45-lm-pore-size syringe filter, except for porcine
gastric mucin, which was sterilised separately by heating at
70 C for 24 h in 95 % ethyl alcohol, as described previously
(Mitsui et al. 1976).
Incubation was performed in 9 ml volumes of SCFM in
15 ml Falcon tubes (BD Biosciences, Oxford, UK) with
tight lids, for 72 h at 37 C, with inversion every 12 h, in
order to to replicate reduced oxygen tensions and low
relative physical disruption of the CF lower airways. Fol-
lowing incubation, bacterial cells were pelleted by centri-
fugation at 12,0009g, 10 min at 4 C, with the supernatant
transferred to fresh NMR tubes with 10 % v/v D2O added
to provide a deuterium lock signal.
2.2 NMR
1H NMR spectra were recorded on a Bruker Avance
400 MHz spectrometer equipped with a 5 mm QNP probe
(Bruker UK Limited, Coventry, UK) with sample isolates
tested in triplicate (three independent cultures from the
same colony) and kept at room temperature. A zgesgp
pulse sequence (Bruker) with excitation sculpting using
gradients was used (Hwang and Shaka 1995). The 1H 90
degree pulse was 9.75 ls. For each spectrum, 65,536 data
points were acquired with 16 scans. To help in the
assignment of the metabolite resonances, J-resolved 2D
correlation with pre-saturation during relaxation delay
using gradients (J-Res, Bruker) spectra were recorded for
some of the samples, using default pulse sequences as
provided by Bruker. The spectral width was 20 ppm. Free
induction decays were multiplied with an exponential
function corresponding to a line broadening of 0.3 Hz. The
spectra were Fourier transformed and calibrated to a
2,2,3,3,-D4-3-(Trimethylsilyl) propionic acid sodium salt
(TSP-2,2,3,3-D4) reference signal at 0 ppm. Phase cor-
rection was performed manually and automatic baseline
correction was applied.
2.3 Bacterial quantification
P. aeruginosa density in samples at harvesting was deter-
mined by quantitative (Q) PCR enumeration of oprL gene
copies in total DNA extracts, using a protocol described
previously (Feizabadi et al. 2010). All Q-PCR reactions
were carried out in a total volume of 25 ll using Taqman
Universal PCR Mastermix (Applied Biosystems, War-
rington, UK). Quantitative PCR assays were carried out
using the Rotorgene 6000 (Qiagen, Crawley,UK) with a
temperature profile of 50 C for 2 min, 95 C for 10 min,
followed by 45 cycles at 95 C for 15 s and 60 C for 60 s.
The cycling program was adjusted at 95 C for 10 min and
then 35 cycles of 10 s each at 95 C (denaturation) fol-
lowed by 35 s at 60 C with fluorescent collection
(annealing and extension). Analysis was performed in
triplicate and the mean reported.
2.4 P. aeruginosa strain genotyping
Random Amplified Polymorphic DNA (RAPD) assays
were performed for each P. aeruginosa isolate as described
previously (Renders et al. 1996) using the primer ERIC2
(50-AAGTAAGTGACTGGGGTGAGCG-30). In those iso-
lates not distinguishable based on the resulting profile, a
further RAPD profile using the primer ERIC1 (50-AT-
GTAAGCTCCTGGGGATTCAC-30) was performed. PCR
reactions were performed in 25 ll volumes, containing
REDTaq ReadyMix PCR Reaction Mix (Sigma-Aldrich,
Dorset, United Kingdom) with the addition of MgCl2 to
achieve a final concentration of 2.5 mM. Primers were
used at a concentration of 0.5 lM and 50 ng of template
DNA. Reactions were performed as follows: An initial
denaturation step of 94 C for 2 min was followed by 32
cycles of denaturation at 94 C for 1 min, annealing at
25 C for 1 min, and extension at 72 C for 2 min, with a
final extension step at 72 C for 10 min. Amplification was
carried out by using a GeneAmp PCR System 2400 (Per-
kin-Elmer), and verified on Tris–acetate-EDTA–agarose
gel electrophoresis and analysed using Phoretix 1D
advanced software, version 5.0 (Nonlinear Dynamics,
Newcastle upon Tyne, UK).
2.5 Multivariate analysis
Pre-processing and orthogonal projection to latent structures
discriminant analysis (OPLS-DA) were carried out with
software that was developed in our laboratory for a previous
study (Vermeer et al. 2012) using the python programming
language with numpy and scipy for calculations, and mat-
plotlib for visualization. The nonlinear iterative partial least-
squares (NIPALS) algorithm (Andersson 2009) was used for
OPLS-DA analysis.
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Regions above 9.074 ppm and below 0.116 ppm were
excluded because of noise content. The water peak, ethanol
and TSP reference signal were also excluded. The spectra
were bucketed using 0.02 ppm bin size with additional,
manual bucketing applied to adjust for peak shifting as
described below, leaving 336 data points per spectrum.
Spectra were normalized using probabilistic quotient nor-
malisation (Dieterle et al. 2006).
Principal component analysis (PCA) was used to identify
clustering patterns from the major variations between the 49
NMR spectra. For this analysis, spectra were pareto-scaled
after normalisation. In order to further investigate the com-
pounds discriminating between clusters and provide a robust
statistical analysis of putative cluster membership, each
possible cluster was analysed against SCFM using orthog-
onal partial least-squares discriminant analysis (OPLS-DA).
Here, spectra were auto-scaled (variance of every data point
normalized to 1). Both normalisation and auto-scaling were
included in the cross-validation procedure (Supplementary
Table 1). Cross-validation was performed where 75 % of the
samples were used as a training set and the remaining 25 %
as a test set, ensuring that the number of samples in the test
set was proportional to the total number of samples from
each class, and that at least one sample from each class was
present in the test set. To choose the number of components
for the model, a leave-one-out cross-validation was carried
out on the samples in the training set, and the F1 used to
choose the number of components, with the additional
constraint to use a maximum of 10 components. This double
cross-validation was repeated 2,000 times with randomly
chosen samples in the training and test set to prevent bias due
to the choice of training or test set. This leads to 4 9 2,000
models (in the supplementary information, each of these
models leads to a point on the scores plot, but loadings and
weights are presented as averages over all these models).
Finally, this procedure was repeated with randomly gener-
ated class assignments to provide a reference value for Q2.
The chosen number of components minus one was then used
as an OPLS filter and a PLS-DA analysis with two compo-
nents was carried out on the filtered data to yield one pre-
dictive and one orthogonal component. Back-scaled
loadings (Cloarec et al. 2005) were used to identify reso-
nances with high variance and high weight, therefore the
discriminating resonances, and verified against the peak
intensity of the original spectra after PQN normalisation.
Peaks that allow the models to distinguish between
classes were assigned by comparing chemical shift values
and multiplicities from J-resolved NMR spectra to values
from the BMRB (Ulrich et al. 2007) and HMDB (Wishart
et al. 2009), analysis of published P. aeruginosa metabolic
data (Son et al. 2007; Frimmersdorf et al. 2010) and NMR
spectra generation from individual medium components
was used to help in the assignment.
2.6 Relationships between PCA and clinical
characteristics
One-way factorial ANOVA were performed to test for
significant relationships between the P. aeruginosa strain
cluster membership and sample characteristics, with a
significance threshold of p \ 0.05. Homogeneity of vari-
ance and normality of errors were assessed using the
Fligner-Killeen and the Shapiro–Wilk tests respectively
prior to the ANOVA. If a factor failed either test a non-
parametric Kruskal–Wallis rank sum test was performed.
Factors that were found to be significant using the ANOVA
were further studied using Tukey’s honest significant dif-
ference (HSD) as a post hoc test. Correlations between the
sample characteristics were performed using Spearman’s
rho correlations. Statistical analyses were performed using
R (v.2.13.0, www.r-project.org).
3 Results
3.1 1H NMR spectroscopy of Pseudomonas CF isolates
cultured in an airway model medium
1H NMR spectroscopy has been used previously to inves-
tigate the growth of P. aeruginosa type strain PAO1 in
Luria–Bertani broth, a standard laboratory medium (Gjer-
sing et al. 2007). Here, we aimed to more closely replicate
the physiochemical composition of CF airway secretions in
a controlled manner and cultured clinical isolates in SCFM.
Representative 1D 1H NMR spectra are shown for each of
the isolate clusters identified by the principal component
analysis described below, revealing the effect of culturing
either P. aeruginosa PAO1 or CF clinical isolates (Fig. 1).
Insufficient growth of isolate 6 occurred in SCFM medium
and hence it was excluded from further analysis. Spectra
generated from either sterile medium, or media inoculated
by a particular strain showed a high degree of reproduc-
ibility in multiple independent replicates. Although we
were successful in identifying metabolite changes that are
linked to clinical measures, as described below, adherence
to the well validated SCFM growth procedures presented
some challenges for the NMR studies and subsequent
multivariate analysis. In order to remain relevant to CF
airway secretion composition, SCFM contains a number of
components, such as mucin and BSA, which could result in
peak broadening and loss of resolution due to high vis-
cosity (Supp. Fig. 1). In addition, a number of the strains
analysed were highly mucoid and were capable of pro-
ducing large amounts of exopolysaccharide (EPS). Finally,
although less noticeable in the SCFM spectrum, resonances
attributable to the, presumably, non-metabolised MOPS
buffer dominate the spectra derived from spent media.
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These factors led to a number of very broad resonances,
particularly between 3.5 and 4.5 ppm, and substantial, pH
dependent shifting of both broad and sharper resonances
between 3.00 and 3.30 ppm and around 2.10 ppm, (Fig. 1)
as expected from the pH dependence of buffer resonance
chemical shifts (Supp. Fig. 2). To remove the influence of
MOPS buffer from the analysis, the following regions were
excluded in addition to the water and ethanol peaks
(5.02–4.65 ppm; 3.70–3.76 and 1.22–1.15 ppm): 4.02–3.87
ppm; 3.50–2.87 and 2.27–1.96 ppm. Ultimately, this has a
number of implications for how the data may be treated and
the degree of resonance assignment that is possible. Large
scale shifting of buffer resonances resulted in ineffective
peak alignment using correlation optimized warping
(COW) (Tomasi et al. 2004) (Supp. Fig. 3). Although peak
realignment could conceivably be achieved through pH
adjustment of spent media as is done for e.g. urine samples
(Beneduci et al. 2011), manual peak bucketing was able to
account here for the observed peak shifts. The exclusion of
large regions, considerable spectral overlap and the
appearance of broad resonances following bacterial growth
also precluded the use of statistical correlation spectros-
copy (STOCSY) or other two-dimensional techniques to
aid assignment for many resonances. For this reason our
present efforts were largely restricted to using the 1H NMR
technique and multivariate analysis to group the isolates
according to apparent differences in growth strategies.
3.2 PCA identifies putative clusters based on isolate
scores
Principal component analysis (PCA) was used to identify
clustering patterns between spectra obtained for the clinical
isolates (n = 41) and SCFM medium (n = 8). The repre-
sentative 2D scores plots of component 1 (PC1) versus
component 2 (PC2), which explain 67.7 % of the variation
in the spectra, reveal four putative separate clusters rep-
resenting the different biochemical composition of the
samples as detected by the NMR spectra (Fig. 2). In the
PCA scores plot, each data point corresponds to one 1D 1H
NMR spectrum, and the reproducibility of the method was
supported by the close arrangement of data points corre-
sponding to replicates from each isolate (Fig. 2).
NMR spectra obtained from media inoculated with each
of the CF clinical isolates fell into two, readily identifiable,
main clusters (I/II) that were distinguished on the basis
their relative separation in PC1. The second of these
clusters is possibly subdivided into two or three further
putative clusters (IIa-c) since the isolates were further
separated in PC2, with groups of isolates in separate
quadrants of the PCA scores plot. The spectra from isolates
in the three or four clusters were each well separated from
those of the sterile synthetic media with the exception of
isolate 1 which caused almost no change in the 1H NMR
spectra of the spent media.
Cluster I was mostly separated from SCFM by PC2.
Three of the four isolates found in Cluster I (1, 10, 12b) are
notable in that they lead to a very acidic pH in the spent
media (Table 1). This might cause the cluster members to
be distinguished purely on the basis of pH dropping below
pH 6.0 which causes MOPS resonances to shift even
beyond the ranges excluded above (Supp. Fig. 2). A broad
resonance at 4.04 ppm does appear for these isolates which
can be assigned to the MOPS resonance expected in this
region, however additional MOPS resonances expected
between 3.50 and 3.87 ppm could not be discerned above
the contribution from metabolite resonances.
Cluster II was further separated from SCFM by PC1 but
subdivision of Cluster II was expected since isolates were
also well distributed along PC2 and were separated into
upper and lower quadrants. Initially a three cluster model
was considered with Cluster IIa in the lower quadrant and
Cluster IIb in the upper quadrant. The existence of a fourth
putative Cluster IIc, with isolates located intermediate to
Clusters IIa and IIb, was considered and tested by OPLS-DA
below. Key resonances whose variation contributes to PC1
Fig. 1 Representative 1H NMR spectra generated from non-inocu-
lated SCFM, PAO1 inoculated SCFM, and representative members of
each of the four putative clinical isolate clusters. Shaded regions
indicate large regions of the 1H NMR spectra excluded on the basis of
solvent or buffer peaks
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and PC2 are shown in the corresponding PC loadings plot
(Supp. Fig. 4).
3.3 OPLS-DA supports clusters identification
Orthogonal projection to latent structures discriminant anal-
ysis (OPLS-DA) was then used to compare 1H NMR spectra
data generated from sterile synthetic media with each of the
four putative strain clusters and to test whether the clusters
could indeed be considered separate. Cross-validation was
performed on all models (Supp. Fig. 5–8). The resulting 2D
scores plots show good separation between the three or four
putative clusters and SCFM with Q2 values[0.90, indicating
a highly reliable model compared with an ideal score of 1
(Table 2). Initially, the PCA scores plot readily identified two
separate isolate scores clusters (Cluster I/Cluster II) with
Cluster I, comprising isolates 1, 3, 10 and 12b, well removed
from the remaining isolates. The subdivision of Cluster II was
tested; putative Clusters IIa and IIb, containing isolates 4, 7,
11, 13, 14 and 2, 5, 9, 12, 13b respectively, could be separated
(Supp. Fig. 8; Q2 = 0.69) using OPLS-DA. However when a
further putative cluster (IIc) was considered, comprising iso-
lates 2, 4, 5 and 14 (PCA scores for these isolates show an
intermediate distribution between the upper and lower quad-
rants due to PC2), the apparent separation as monitored by
scores plots (Suppl. Fig. 6/7) and Q2 (Table 2) indicated that a
four cluster model may be useful when greater numbers of
patient isolates are available.
3.4 Relationships between strain cluster membership
and sample characteristics with 1D 1H NMR
spectra
To determine whether differences in the nutritional modi-
fications to airway secretion composition that result from
the growth of P. aeruginosa may have clinical impacts,
membership of CF sputum isolate clusters, as defined based
on PCA and OPLS-DA, for both three and four cluster
models, was compared with a number of potentially key
strain or sputum sample characteristics. These factors were
isolate auxotrophy, mucoidy, pigmentation, spent culture
pH, sputum pH, species richness and relative phyla abun-
dance as defined by 16S rRNA gene clone sequencing
analysis, P. aeruginosa density as determined by quanti-
tative PCR, patient age, sex, genotype, BMI, diabetic sta-
tus, FEV1, and the number of respiratory exacerbations
over the preceding 12 months. Of these, highly significant
relationships were identified between both cluster mem-
bership and lung function (FEV1) (F(3,10) = 5.64,
p = 0.0159) and cluster membership and spent culture pH
(F(3,10) = 8.63, p = 0.004,) (Fig. 3). These significant
relationships were tested using Tukey’s HSD to assess for
significant differences between clusters. In the three cluster
model, this analysis found significant differences between
Fig. 2 Scores scatter plot
resulting from applying PCA to
the 1H NMR data by component
1(PC1) and component 2 (PC2).
The percentage of variance in
the data explained by each
component is indicated on the
relevant axis. Strain
identification numbers are
shown. Ellipses are drawn to
show putative clusters of
spectra. SCFM—synthetic
cystic fibrosis media. The
corresponding loadings plot
provided in the supplementary
material identifies points in the
NMR spectra that align with
either PC1 or PC2
Table 2 Predictive Q2 values for all models
Test 3 cluster model 4 cluster model
SCFM versus cluster I 0.92 (-0.63) 0.92 (-0.63)
SCFM versus cluster IIa 0.99 (-0.44) 0.99 (-0.47)
SCFM versus cluster IIb 0.99 (-0.46) 0.99 (-0.48)
SCFM versus cluster IIc – 0.99 (-0.40)
Cluster IIa versus cluster IIb 0.71 (-0.46) 0.91 (-0.50)
Cluster IIa versus cluster IIc – 0.84 (-0.47)
Cluster IIb versus cluster IIc – 0.92 (-0.44)
Cluster IIa and IIb contain isolates 4, 7, 11, 13, 14 and 2, 5, 9, 12, 13b,
respectively, in the 3 cluster model and lose isolates 2, 4, 5, 14 to
Cluster IIc in the four cluster model. Q2 values for models run with
permutated class assignments are given in parentheses
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Clusters I and IIb (padj = 0.020) and between Clusters IIa
and IIb (padj = 0.030) for lung function (FEV1) with
patients in Cluster IIb having relatively poor lung function
(Fig. 3a). In the four cluster model, Cluster I was shown to
be significantly different from both clusters IIb
(padj = 0.005) and IIc (padj = 0.010) (Supp. Fig. 9). A
possible relationship was also observed between sputum
pH and cluster membership (F(3,10) = 3.06, p = 0.078,
pH ranged from 5.9 to 7.8). A strong negative correlation
was found between FEV1 and spent culture pH (R =
-0.76, p = 0.002) (Fig. 3c) and significant differences in
spent culture pH were observed between Cluster I and both
Clusters IIa and IIb in the three cluster model (Fig. 3b). No
significant correlation was found however between lung
function and sputum pH (R = 0.50, p = 0.067) or between
sputum pH and spent culture pH (R = -0.37, p = 0.188)
(further significant correlations are shown in supplemen-
tary information as are box plots for the four cluster model;
Supp. Fig. 10). Therefore, although Cluster I and Cluster II
are clearly separated in the PCA analysis (by PC1), the
only significant differences that were found both in FEV1
and spent culture pH were between Cluster I and Cluster
IIb with a significant difference in FEV1 also seen between
Clusters IIa and IIb. These clusters are separated in the
PCA analysis by PC2 and hence identification of reso-
nances contributing to PC2, rather than PC1, or OPLS-DA
analyses between these clusters should identify metabolo-
mic changes that correlate with variance in FEV1 or spent
culture pH.
Pseudomonas aeruginosa cell numbers in spent media
were determined by Q-PCR enumeration, with mean values
calculated from analysis of triplicate independent repeat
cultures (Table 1). No significant difference between cul-
tures of separate isolates, or independent repeat cultures of
particular isolates, was observed, and no relationship was
found between P. aeruginosa levels and cluster
membership.
To determine whether the P. aeruginosa isolates
belonging to separate clusters were genetically distinct, or
represented the same strains growing differently, RAPD
PCR analysis was performed. All 15 isolates studied here
were found to represent distinct strain types (Supp.
Fig. 11).
3.5 OPLS-DA identifies characteristic metabolite
consumption and production
The OPLS-DA comparisons of Cluster IIb with Cluster I
(Fig. 4a) and Cluster IIa (Fig. 4b) again support the clus-
tering determined above and allow identification of reso-
nances from metabolites that may be implicated in FEV1
and/or spent culture pH. Plotting normalised spectra from
each of the four clusters, coloured according to cluster,
highlights resonances whose intensity is consistently
altered between clusters (Fig. 5). Comparing the back-
scaled loadings plots for the comparisons between Cluster
IIb and Cluster I and between Cluster IIb and Cluster IIa
identifies metabolites whose differing intensities correlate
with the significant differences identified above for lung
function FEV1 and/or spent culture pH. Notably, levels of
lysine or ornithine appear higher in the spent media of









































































Fig. 3 Box plots comparing FEV1 (a) and spent culture pH (b) for
each of the clusters in the three cluster model; *p \ 0.05. The
relationship between mean FEV1 and spent culture pH is also shown
for each of the isolates (c)
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isolates in Cluster I or IIa when compared with those from
Cluster IIb, where lung function was poorest, as evidenced
by their characteristic resonances at 3.765 ppm (Fig. 5a)
and 1.465 ppm (Fig. 5b). A resonance characteristic of
leucine at 1.728 ppm (Fig. 5b) is also elevated in spectra of
spent media of isolates in both Clusters I and IIa while a
broad resonance that appears at 6.80 ppm (Fig. 5c), in
many spectra from Cluster IIb isolates, is largely absent
from either Clusters I or IIa. Spectra from isolates in
Cluster IIc are intermediate between spectra from isolates
in either Cluster IIa or IIb for these features. An additional
broad resonance at 5.77 ppm is notable (Fig. 5c) but its
intensity does not correlate with FEV1 and is one of the
main resonances that contributes to the separation of the
isolates by PC1 in the PCA analysis.
4 Discussion
The way in which chronic colonisation by high cell num-
bers of P. aeruginosa affects the composition of airway
secretions in the CF lung is likely to be important in
selecting co-infecting bacterial species, and in modifying
the growth of P. aeruginosa itself, since nutritional sources
are known to influence bacterial community composition in
other contexts (Resat et al. 2012; Dunaj et al. 2012).
Bacterial growth results in both large- and fine-scale
modifications to the composition of the growth medium,
with the former primarily occurring through the utilisation
of compounds as carbon and nitrogen sources and the
production of major metabolites. Since the aim here was to
obtain an indication of the degree to which P. aeruginosa
isolate growth might have a differential impact on CF
airway secretions, an approach that provides a compre-
hensive overview of major compositional changes, 1H
NMR spectroscopy, was employed (Gjersing et al. 2007).
In keeping with previous studies using 1H NMR spectros-
copy, the data presented here show a high degree of
independent-replicate reproducibility, whilst allowing dif-
ferentiation of chemically divergent samples.
A defined synthetic growth medium designed to replicate
the composition of CF lower airway secretions was used as
part of an in vitro model of CF airway conditions. Previous
studies comparing P. aeruginosa gene expression in CF
sputum with that in similar CF synthetic media have shown
bacterial behaviour to be similar in the two contexts (Palmer
et al. 2007; Fung et al. 2010). By combining 1H NMR
spectroscopy with this CF airway growth model, we were
therefore able to assess the degree to which the impact of P.
aeruginosa growth differed between clinical isolates under
conditions approximating those encountered in vivo.
The P. aeruginosa clinical isolates studied here showed
substantial metabolomic differences, and were categorised
into four separate clusters. These variations, particularly in
levels of the amino acids, may reflect differences in energy
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Fig. 4 OPLS-DA scores plots (a, c) and back-scaled loadings plots (b, d) for the comparisons between Cluster IIb and Cluster I (a, b) and
between Cluster IIb and IIa (c, d). Complete Leave-one-out cross-validation (LOOCV) output files are provided in the Supplementary Material
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the low oxygen tensions in muco-purulent CF sputum.
Such differences may be important in vivo given that
amino acid levels have been shown to influence the anti-
biotic susceptibility of P. aeruginosa (Nguyen et al. 2011)
and the growth strategies that they adopt (Bernier et al.
2011; Shrout and Chopp 2006).
Cluster membership was found to be related to culture
pH. Care was taken to exclude the contribution of pH
induced peak shifting through the exclusion of resonances
from MOPS buffer prior to multivariate analysis and
manual bucketing of spectra following the failure of peak
alignment using COW. Visual inspection of the spectra
resulting from each cluster suggested that the observed
isolate clustering is due to differences in levels of media
constituents and metabolites produced/consumed rather
than shifting peaks. Indeed, no relationship was found
between cluster membership and P. aeruginosa cell num-
bers, further supporting divergence driven by growth
strategy rather than cell density. The mechanism by which
P. aeruginosa growth affects pH is not clear, and could
occur either through a change in levels of non-pH neutral
components of the growth media or through proton extru-
sion. However, the impact of P. aeruginosa growth on pH
could have major clinical implications since it has been
shown to influence both bacterial community composition
(Romanowski et al. 2011; Duncan et al. 2009) and
behaviour (Walker and Duncan 2005) in other clinical
contexts, and alterations in airway secretion pH could
affect a number of innate defence processes, such as ciliary
function (Clary-Meinesz et al. 1998) and mucus viscosity
(Inglis et al. 1998).
Importantly, a highly significant relationship was found
between the cluster membership of CF isolates analysed
here and the lung function of the patient from which they
were obtained (as measured by FEV1). This link between
the nutritional modification of the environment by P.
aeruginosa growth and patient lung function has clear
implications for how our understanding of bacterial com-
munity composition in the CF airways needs to develop. A
broad phylogenetic range of species have been reported in
CF respiratory secretion (Rogers et al. 2004), with a
common factor for their establishment in the airways being
access to nutrients they require for growth. However, not
all species common in associated areas, such as the oral
cavity, are routinely reported in CF lower airway secre-
tions. This may be influenced by modification of the
nutritional context of the lower airway secretions by
dominant bacterial species (Kloosterman and Kuipers
2011; Rogosa and Bishop 1964; Nakada and Itoh 2003).
Such nutritional interactions in the CF lower airways are










Fig. 5 Normalised 1H spectra (with excluded regions but otherwise
untreated) of spent media coloured according to cluster membership.
(Cluster I—blue, Cluster IIa—red, Cluster IIb—green, Cluster IIc—
yellow). Spectral regions between 3.5 and 3.85 ppm (a), 5.6 and
6.9 ppm (b) and 1.4 and 1.8 ppm (c) are shown (Color figure online)
Metabolomic analysis of CF P. aeruginosa isolates 1271
123
5 Conclusions
In summary, the application of 1H NMR here to deter-
mining the impact of P. aeruginosa clinical isolate growth
within a model CF system reveals substantial metabolomic
differences between isolates. Membership of isolate clus-
ters, defined through PCA, appears to be linked to diver-
gence in metabolite production, with a significant
correlation between cluster membership and spent culture
pH. These findings suggest that P. aeruginosa isolates
employ a range of growth strategies. Further, cluster
membership was found to be significantly correlated with
patient lung function, suggesting that there may be direct
clinical implications for bacterial metabolic strategy
in vivo. A more sophisticated characterisation of the met-
abolic and pH environment of the CF lower airway is now
warranted, with the potential to inform our understanding
of the chronic bacterial infections that typify cystic fibrosis
airway disease.
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Functional divergence in gastrointestinal
microbiota in physically-separated
genetically identical mice
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M. A. McGuckin1 & K. D. Bruce2
1Immunity, Infection, and Inflammation Program, Mater Research Institute – University of Queensland, Translational Research
Institute, Woolloongabba, Australia, 2King’s College London, Institute of Pharmaceutical Science, London, SE1 9NH, UK, 3SAHMRI
Infection and Immunity Theme, School of Medicine, Flinders University, Bedford Park, Adelaide, Australia, 4Charles River UK,
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Despite the fundamental contribution of the gut microbiota to host physiology, the extent of its variation in
genetically-identical animals used in research is not known. We report significant divergence in both the
composition and metabolism of gut microbiota in genetically-identical adult C57BL/6 mice housed in
separate controlled units within a single commercial production facility. The reported divergence in gut
microbiota has the potential to confound experimental studies using mammalian models.
R
esearchers using animal models are becoming increasingly aware of possible influences of the gut micro-
biota on physiology. Murine models have been used to demonstrate relationships between the gut micro-
biota and obesity1, metabolic disease2, cardiovascular health3, nervous system development4, diabetes5, and
immune function6, hepatic function7, inflammatory bowel conditions8, and carcinogenesis9, highlighting the
potential impact that differences in the microbiome of mice from different animal facilities could have on
research. However, most researchers assume that genetically-identical mice derived from a single supplier will
have an equivalent microbiome. To test this assumption we studied the faecal microbiome and metabolome of
genetically-identical C57BL/6 mice housed in four separate controlled units within a single facility of a commer-
cial supplier of animals for research. Faecal samples were collected at eight weeks of age from twenty mice, with
five mice sampled in each of four barrier rooms. These mice were separated by no more than ten generations.
Methods
Murine faecal samples. Faeces were collected from eight week old C57BL/6 at the Charles River commercial facility (Margate, UK) under
commercial licence, with all mice kept in accordance with protocols approved by The Animal Health and Welfare Board for England.
Samples were collected from 20 mice, housed in four separate barrier rooms within the facility, fed the same chow (a VRF1 diet, SDS). The
five mice sampled in each roomwere housed in separate cages. The five mice from each of the four rooms were taken from separate cages i.e.
no twomice came from the same cage. Mice in this study were handled by individuals wearing gloves for cage cleaning purposes on a weekly
basis. Mice were not housed exclusively with litter mates, with 27 individuals housed per room. Samples consisted of individual faecal pellets
taken from individual mice. After collection, pellets were placed into separate collection tubes and frozen prior to analysis.
Microbiota. Nucleic acid extractions were carried out using a combination of physical disruption and phenol/chloroform extraction
methods, described previously10. 16S rRNA gene universal Bacterial primers 27F-519R (27F 59-AGRGTTTGATCMTGGCTCAG, 519R 59-
GTNTTACNGCGGCKGCTG) were used in a single-step 30 cycle PCR using HotStarTaq Plus Master Mix Kit (Qiagen, Valencia, CA)
performed under the following conditions: 94oC for 5minutes, followed by 28 cycles of: 94oC for 30 seconds, 53oC for 40 seconds, and 72oC
for 1 minute. Amplification was followed by a final elongation step at 72oC for 5 minutes. Following PCR, all amplicon products from
different samples weremixed in equal concentrations and purified using Agencourt Ampure beads (Agencourt Bioscience Corporation,MA,
USA). Samples were sequenced utilizing Roche 454 FLX titanium instruments and reagents following manufacturer’s guidelines. A total of
165,934 16S rRNA gene sequences were obtained from the 20 faecal sample extracts. Following curation, an average of 4,356 sequences was
obtained for each of the samples. For analysis of alpha and beta diversity, samples were normalised to 2,179 sequences per sample.
Sequence data analysis was carried out. Here, the Q25 sequence data derived from the sequencing process was processed using standard
analysis pipeline processes (MR DNA, Shallowater, USA). Sequences were depleted of barcodes and primers then short sequences,200 bp
removed, as were sequences with ambiguous base calls removed, and sequences with homopolymer runs exceeding 6 bp, sequences were
denoised and chimeras removed11–17. Operational taxonomic units were defined after removal of singleton sequences, clustering at 3%
divergence (97% similarity). Final OTUs were taxonomically classified using BLASTn against a curated databased derived fromGreenGenes,
NCBI and RDP databases18. Normalized and de-noised files were then rarefied and run throughQIIME19 to generate alpha and beta diversity
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A range of diversity and richness measures were used to assess changes in micro-
biota composition, including taxa richness, Chao1, Shannon index, Simpson index
1-D20. Analysis of microbiota diversity was performed using PAST - Palaeontological
Statistics, version 3.01, a program available from the University of Oslo website link
(http://folk.uio.no/ohammer/past).
1H NMR metabolomics. Portions of mouse faeces of approximately 0.02 g were
resuspended by vortexing in 500 ml of phosphate buffered saline. Particulate matter
was pelleted by centrifugation at 13,000 3 g for 10 min, and supernatant transferred
to a fresh microfuge tube. Centrifugation was repeated, with pelleted material again
discarded. Supernatant was frozen by immersion in liquid nitrogen, lyophilised at
258uC overnight, and re-suspended in 500 ml D2O. 1H NMR spectra of three
replicates were acquired at 400 MHz on a Bruker Avance spectrometer (Bruker,
Coventry, UK) equipped with a 5 mm QNP probe using a zgesgp pulse sequence
incorporating water suppression via excitation sculpting with gradients. The 1H 90
degree pulse was 9.75 ms. The spectral width was 20 ppm. Free induction decays were
multiplied with an exponential function corresponding to a line broadening of
0.3 Hz. The spectra were Fourier transformed and calibrated to a 2,2,3,3,-D4-3-
(Trimethylsilyl) propionic acid (TSP) reference signal at 0 ppm. Phase correction was
performed manually and automatic baseline correction was applied. To help in the
assignment of the metabolite resonances, J-resolved 2D correlation was performed
with pre-saturation during relaxation delay using gradients (J-Res, Bruker). Pre-
processing and orthogonal projection to latent structures discriminant analysis
(OPLS-DA) were carried out with software that was developed in our laboratory for a
previous study21 using the python programming language with numpy and scipy for
calculations, and matplotlib for visualization. The nonlinear iterative partial least-
squares (NIPALS) algorithm22 was used for OPLS-DA analysis. Regions above
8.5 ppm and below 0.45 ppmwere excluded because of noise content. The water peak
and TSP reference signal were also excluded. Spectra were bucketed using 0.005 ppm
bin size leaving 1588 data points per spectrum. These spectra were normalized23,24,
and auto-scaled (variance of every data point normalized to 1). Cross-validation was
performed where 75% of the samples were used as a training set and the remaining
25% as a test set, ensuring that the number of samples in the test set was proportional
to the total number of samples from each class, and that at least one sample from each
class was present in the test set. To choose the number of components for themodel, a
leave-one-out cross-validation was carried out on the samples in the training set, and
the F1 used to choose the number of components, with the additional constraint to
use a maximum of 8 components. A double cross-validation was repeated 2000 times
with randomly chosen samples in the training and test set to prevent bias due to the
choice of training or test set. This led to 4 3 2000 models. Finally, this procedure was
repeated with randomly generated class assignments to provide a reference value for
Q2. The chosen number of components minus one was then used as an OPLS filter,
and a PLS-DA analysis with two components was carried out on the filtered data to
yield one predictive and one orthogonal component. In the back-scaled loadings
analysis, peaks that allow the models to distinguish between classes were assigned by
comparing chemical shift values and multiplicities from J-resolved NMR spectra to
values from the BMRB25 and HMDB26.
Results & Discussion
Analysis of the bacterial identities derived from 16S ribosomal RNA
gene sequencing revealed the faecal microbiota to be dominated by
the phyla Bacteroidetes and Firmicutes, (62.4 6 22.4 (SD)% and 34.7
6 23.9%, respectively) although marked variation was observed in
phylum relative abundance between individual animals (Fig. S1).
Further, microbiota alpha diversity, as assessed by rarefaction and
Chao1 richness estimate, OTU richness, and Shannon Index were
significantly lower for mice of one room group (room 4) compared
with mice from other room groups (Table S1) (Kruskall-Wallis con-
trolled multiple pair-wise comparison, p , 0.001).
Analysis of microbiota at the genus level identified the twenty
genera with the highest mean relative abundance (Table S2), which
were broadly in keeping with those reported in the murine gut prev-
iously27. The most commonly numerically dominant genus was
Prevotella, (39.0 6 20.2% of sequences), a genus associated with a
long term carbohydrate-rich diet in humans28. Again however, sig-
nificant differences in the microbiota were identified between room
groups (controlled ANOVA tests, p, 0.05) (Table S3). Coprococcus,
Ruminococcus, and Anaerotruncuswere significantly higher in room
1 samples, Pedobacter was significantly higher in room 2 samples,
Novispirillum was significantly higher in room 3 samples and
Prevotella was significantly higher in room 4 samples. Samples from
rooms 2 and 3 groups had significantly higher abundance of
Parabacteroides and Sphingobacterium than samples from rooms 1
and 4.
Hierarchal cluster analysis based upon the predominant genera
indicates divergence in the composition of the microbiota into three
clusters (Fig. 1). Cluster I comprised samples from all animals from
room 3 and additional animals from rooms 1 and 2, cluster II com-
prised all animals from room 4 and cluster III included all of the
remaining animals from rooms 1 and 2. Notably is the absence, or
very low abundance, in room group 4 of a number of genera includ-
ing Sutterella, Sphingobacterium,Novispirillum and Porphyromonas.
Overall therefore, the bacterial microbiota showed marked diver-
gence that was in cases linked to room occupancy, with these com-
positional differences resolving into three clusters.
Whilst all mice received the same standard diet, the differences in
constituency of their microbiota indicated a potential for distinct
metabolomic characteristics. The major constituent of mouse chow,
carbohydrates, are fermented in the colon to short chain fatty acids
(SCFA), primarily acetate, butyrate, lactate and propionate29,30.
Whilst SCFAs are just one class of compounds, they are important
in shaping the microbial community and preventing the growth of
pathogens31,32. Moreover, SCFA levels impact on the host and are
known to be important in relation to nutrition, adipose tissue depos-
ition, immunity and cancer amongst other conditions30,33. Different
SCFAs have been associated with effects on specific physiological
processes34, with the type of SCFAs varying between bacterial gen-
era35. To test for a functionally-distinct signal, we performed a meta-
bolomic analysis of the faecal material.
1H NMR spectroscopy was performed on buffered saline extracts
from the same faecal samples used for microbiota sequencing. We
hypothesised that there would be differences when comparing the
metabolome of faeces from mice whose faecal microbiota were dis-
tinct. Analysis involved a series of pairwise orthogonal partial least
squares discriminant analysis (OPLS-DA) tests using classes sug-
gested by clustering according to microbiota (Fig. 2), room occu-
pancy or dominant phyla. Scores plots for each of three pairwise
comparisons show that there are substantial differences in the meta-
bolomes extracted from faeces of mice assigned to each cluster (Fig. 2
- left panels). Q2 obtained for each test performed were compared
with a reference value for Q2, obtained after repeating cross-valid-
ation with randomly generated class assignments (Table 1). As
shown, Q2 scores for the metabolomic data pairwise analysis per-
formed when separated according to these clusters were.0.50 which
is an accepted threshold for a ‘‘good’’ model36,37. As such, we
observed clear metabolomic differences in the murine faecal samples
based on clusters as defined by the composition of the bacteria
present. Further, microbiota data were used to assess the relative
contribution of Bacteroidetes, Firmicutes and Proteobacteria to each
of the samples tested. Here, Q2 scores were all .0.41. Significant
differences were also identified in the metabolome of faeces from
mice housed in different room groups with Q2 scores all .0.67
(room 2 vs. room 3).
Next, we identified the key drivers of the differences in the meta-
bolomic data by generating back-scaled loadings plots and assigning
resonances with high variance and high weight, indicated by greater
intensity and yellow/red color respectively (Fig. 2 – right panels).
Notably, Clusters I and II were distinguished by the greater abund-
ance of a number of amino acids in the faecal metabolomes ofmice in
Cluster II whereas the faecal metabolomes of mice from Cluster III
were distinguished from those in Cluster I and II on the basis of short
chain fatty acids which were more abundant in Cluster III. At the
outset of this study, we hypothesised that there would be minimal
differences between the gut microbiota as sampled in the context of
genetically identical mice. However, significant differences were
observed in the taxa detected, their relative abundance, and overall
bacterial diversity. This variation in the faecal microbiota was linked,
at least in part, to the barrier room in which the mice were housed.
Assessment of themetabolome associated with these animals showed
that microbiota and metabolome findings were largely consistent.
www.nature.com/scientificreports
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Murine models are used in biomedical research to address almost
every aspect of human health. To avoid potentially confounding
differences in genetic backgrounds, mice are taken from inbred
populations with the rationale being that the resulting homogeneity
provides a uniform ‘‘platform’’ for study. By far the most common
genetic background for mice used as models of human disease is the
strain C57BL/6, as used here. When purchased for research, indi-
vidual C57BL/6 mice are commonly considered to be equivalent.
Increasingly however, the potential of the gastrointestinal microbiota
to influence the host in relation to health and a wide range of clinical
syndromes is being recognised38. In this light, the differences iden-
tified in microbiota here require further consideration. Given the
potential impact of the gutmicrobiota on somany important physio-
logical processes, the degree to which it is conserved between indi-
vidual animals used in biological research is arguably as important as
their genetic uniformity. Further, variation in gut microbiota com-
position is likely to be even higher in less well controlled experi-
mental facilities, and to be exacerbated when mice are moved
between facilities, experience changes in diet, and are exposed to
animals with different microbiota. The divergence in gut microbiota
Figure 1 | Heat map analysis of the predominant genera identified in this study. A hierarchal cluster diagram was constructed using Ward’s minimum
variance clustering and Manhattan distances. Room group 1 and room group 2 exhibit some co-clustering indicating differences within the groups. The
heatmap describes the relative percentage in each sample of the associated genera with a legend provided in the upper left of the figure.
www.nature.com/scientificreports
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Figure 2 | OPLS-DA scores plots (left panels) and back-scaled loadings plots (right panels) for comparisons between themurine faecal metabolomes as
clustered according to microbiota data composition. Resonances with high variance and high weight are highlighted in red. The distinguishing
metabolites that could be unambiguously assigned are annotated in each back-scaled loadings plot. Q2 values for the cross-validated OPLS-DA
comparisons are provided in Table 1.
www.nature.com/scientificreports
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composition, as reflected in faecal bacteria, strongly suggests that
efforts must be made to ensure uniformity of intestinal microbiota
in animals used in research.
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Table 1 | Predictive Q2 values for all models. Q2 values for models
run with permutated class assignments are given in parentheses
Model Q2
Cluster I vs Cluster II 0.88 (20.15)
Cluster I vs Cluster III 0.52 (20.15)
Cluster II vs Cluster III 0.81 (20.18)
Room 1 vs Room 2 0.93 (20.14)
Room 1 vs Room 3 0.90 (20.15)
Room 1 vs Room 4 0.85 (20.15)
Room 2 vs Room 3 0.67 (20.09)
Room 2 vs Room 4 0.80 (20.12)
Room 3 vs Room 4 0.86 (20.15)
High Bacteroidetes vs low Bacteroidetes 0.41 (20.15)
High Firmicutes vs low Firmicutes 0.41 (20.17)
High Proteobacteria vs low Proteobacteria 0.66 (20.18)
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Abstract
Obtaining an in-depth understanding of the arms races between peptides comprising the innate immune response and
bacterial pathogens is of fundamental interest and will inform the development of new antibacterial therapeutics. We
investigated whether a whole organism view of antimicrobial peptide (AMP) challenge on Escherichia coli would provide a
suitably sophisticated bacterial perspective on AMP mechanism of action. Selecting structurally and physically related AMPs
but with expected differences in bactericidal strategy, we monitored changes in bacterial metabolomes, morphological
features and gene expression following AMP challenge at sub-lethal concentrations. For each technique, the vast majority of
changes were specific to each AMP, with such a plastic response indicating E. coli is highly capable of discriminating
between specific antibiotic challenges. Analysis of the ontological profiles generated from the transcriptomic analyses
suggests this approach can accurately predict the antibacterial mode of action, providing a fresh, novel perspective for
previous functional and biophysical studies.
Citation: Kozlowska J, Vermeer LS, Rogers GB, Rehnnuma N, Amos S-BTA, et al. (2014) Combined Systems Approaches Reveal Highly Plastic Responses to
Antimicrobial Peptide Challenge in Escherichia coli. PLoS Pathog 10(5): e1004104. doi:10.1371/journal.ppat.1004104
Editor: Jeff H. Chang, Oregon State University, United States of America
Received January 9, 2014; Accepted March 18, 2014; Published May 1, 2014
Copyright:  2014 Kozlowska et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Medical Research Council (http://www.mrc.ac.uk/index.htm, NIRG G0801072/87482 to AJM), the Biotechnology and
Biological Sciences Research Council (http://www.bbsrc.ac.uk/home/home.aspx) and Procarta Biosystems Ltd (http://www.procartabio.com/, Industrial CASE
award BB/H01571X/1 supporting JK) and the Wellcome Trust (http://www.wellcome.ac.uk/, Capital Award for the KCL Centre for Biomolecular Spectroscopy). The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: james.mason@kcl.ac.uk
¤ Current address: SAHMRI Infection and Immunity Theme, School of Medicine, Flinders University, Adelaide, Australia
Introduction
The isolation of cecropins [1], magainins [2] and defensins [3]
from insects, amphibians and mammals in the late 1980’s and early
1990’s, highlighted the potential of host defence peptides as sources
of novel antibiotics [4]. This novel antibiotic potential encouraged
researchers to develop structure activity relationships for cationic
antimicrobial peptides (AMPs), with the anionic bacterial plasma
membrane the presumed site of action for bactericidal activity [5].
There is increasing evidence however that each AMP may indeed
have multiple effects on a bacterial cell and hence may have multiple
ways of killing microbial targets. AMPs may therefore function as
‘‘dirty drugs’’ with different bactericidal strategies possible for distinct
bacterial species [4–7]. Indeed, the innate immune system may have
selected AMPs that can exert their antimicrobial activity in multiple
ways since this is less likely to lead to resistance developing as seen
with classical antibiotics that have a single, high affinity target [6].
Our understanding of how AMPs function is therefore far from
complete. Attempts to optimize AMP potency in the laboratory, that
focus on only one possible bactericidal mechanism, ignore the
possibilities offered by taking a holistic approach that can reveal the
true source(s) of bactericidal potency along with a better under-
standing of bacterial counter-measures.
The full power of ‘omics based research tools has yet to be
brought to bear in antibiotic research [8]. Nevertheless, important
insights have emerged regarding the scope of bacterial responses
by comparing challenges with distinct AMPs [8]. These studies
have focussed on the Gram-positive bacterial species Bacillus subtilis
[9], Staphylococcus aureus [10] and Streptococcus pneumoniae [11] and
have demonstrated the existence of complex regulatory patterns in
which several signal transduction pathways were induced. The
transcriptional response of Escherichia coli to cecropin A, the proline
rich Bac7(1-35) and novispirin G10 has been characterised in
separate studies [12–14]. Recent work in our laboratory has
focussed on trying to understand the relative difference in
antibacterial potency of structurally related AMPs to Gram-
negative bacteria such as Escherichia coli and Pseudomonas aeruginosa
[15–18]. Here, AMPs with structural features thought to enhance
antibacterial potency and reduce toxicity have been developed for
use against more challenging pathogens [19,20]. These peptides,
including D-LAK120-AP13, have been developed based on an
understanding of a variety of naturally occurring peptides
including magainin 2, buforin II and pleurocidin. Pleurocidin is
a 25 amino acid AMP found in the skin and gills of Pleuronectes
americanus, the Winter Flounder. Despite resembling magainin 2 in
terms of length, cationic charge, hydrophobicity and secondary
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structure in a range of membrane mimetic environments [18],
pleurocidin is typically ten times more potent against Gram-
negative species. Pleurocidin has been shown to be capable of
acting on bacterial membranes [21], with pore forming activity,
but has also been suggested to enter bacterial cells and interrupt
protein synthesis [22]. We have therefore compared its effect on E.
coli with magainin 2, which has been considered the archetypal
pore forming AMP, and with buforin II which is proposed to enter
bacteria to exert a bactericidal effect [23,24].
Since these peptides act at widely differing effective concentra-
tions we hypothesised that studying their effects at sub-lethal
concentrations would provide a detailed overview of the mecha-
nisms of action of each AMP. We therefore devised a method that
could efficiently identify conditions where bacteria responded to
AMP challenge without introducing possible, non-specific com-
plications that might result from large scale cell death. We
therefore used 1H high resolution magic angle spinning (HR-
MAS) NMR to identify the lowest AMP concentration that elicited
a response from metabolically active, challenged bacteria. A
robust, cross-validated, multivariate analysis identified metabolites
whose levels were altered in response to AMP challenge. These
were used to classify the AMP according to the elicited response
whilst providing a first indication of whether E. coli responded in a
generic or specific manner to AMP challenge. Having identified
sub-lethal conditions where a response was confirmed, electron
microscopy and transcript profile analyses enabled a detailed
description of the E. coli response to AMP challenge.
Results
1H HR-MAS NMR metabolomics reveals threshold
AMP concentration inducing a bacterial response –The
four cationic amphipathic AMPS selected to test the response of
stationary phase E. coli (Table 1) were of similar length and were
all C-terminally amidated with nominal charge ranging from +4 to
+9. For the AMP challenge experiments presented here, higher
bacterial cell densities (86108 CFU/ml) were required than is
common in the broth microdilution assays [25] used to generate
Author Summary
Antimicrobial peptides (AMP) are small proteins with often
potent antibacterial activity found in a variety of organ-
isms, including humans. Understanding how these antibi-
otics operate is challenging and often controversial since
many studies have necessarily focussed on identifying a
single major cause of bacterial cell death while, increas-
ingly, others have cautioned that AMPs are likely to have
access to multiple bactericidal features. Systems biology is
an emerging field that comprises a series of techniques
capable of giving a global view of how bacteria respond to
external stimuli. Here we have monitored changes in gene
expression and metabolism in bacteria that have been
challenged with sub-lethal concentrations of four different
AMPs. By understanding how bacteria respond to a threat
we can reveal how the bacteria perceive the AMP to be
operating. Our approach provides a sophisticated bacterial
perspective of the mode of action of each AMP and reveals
that the bacteria have a vast array of weapons that can be
marshalled to deal with distinct AMP threats. Indeed,
around a third (or even more) of the bacterial machinery
might be useful in dealing with antibiotic challenges,
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the MIC data (Table 1), in particular for HR-MAS analysis. At the
higher bacterial titre, although the relative potency is similar, the
effect of the four AMPs determined using such methods was
somewhat different from the minimum inhibitory concentrations
(MICs), with D-LAK120-AP13 having a substantially greater
effect on bacterial numbers as detected in the challenge and
recovery assay (Fig. 1A). Neither magainin 2 nor buforin II had a
sufficiently inhibitory effect for a MIC to be determined at the
higher titre. Nevertheless the amount of peptide causing a
significant reduction in bacterial re-growth can be compared with
D-LAK120AP13 effective at 15.6 mg/ml with substantially more
pleurocidin (62.5 mg/ml) and magainin 2 (125 mg/ml) required for
a significant effect. No effect on bacterial re-growth was observed
for buforin II at any of the peptide concentrations tested (Fig. 1A).
A multi-parameter assay was taken to assess the effect of peptide
challenge on membrane potential (Fig. 1B), esterase activity
(Fig. 1C) and membrane integrity in the challenged stationary
phase bacteria and suggested that only the higher concentrations
of pleurocidin and D-LAK120-AP13 were lethal. A dose
dependent response to each of the four AMPs was observed but
the membrane potential was not completely lost while the esterase
activity was mostly higher than that observed in untreated cells; a
hallmark of exposure to sublethal stress in E. coli [26].
One dimensional 1H NMR spectra were obtained for all
samples. Principal component analysis identified outlier spectra
resulting from either poor baseline or signal to noise, and either
partial least squares (PLS) regression analysis or a series of
orthogonal PLS-discriminant analysis (OPLS-DA) tests were used
to interrogate the spectra. The latter was used in a step-wise
manner to determine the lowest concentration of each AMP that
caused a significant change in the spectra relative to spectra from
untreated bacterial cell, as determined from Q2 (Table 2) where an
arbitrary value $0.6 was taken to show a reliable model where the
AMP challenge has a significant effect. This value can be
compared with the value expected for a perfect separation of the
two groups (Q2= 1) and that obtained when the assigned classes
(untreated or AMP challenged) are permutated as a means of
representing no effect. 2D scores plots that resulted from each of
the cross validated OPLS-DA analyses are shown in the
supplementary material (Fig. S1 in File S1) while those for the
threshold concentrations (data for the highest AMP concentration
is shown for buforin II) are described here (Fig. 2A–D). A clear
separation of the OPLS-DA scores was obtained at the indicated
AMP concentration, identified as a threshold for a response
detectable in the bacterial metabolomes. This threshold concen-
tration varied considerably for the four AMPs and was directly
related to the apparent antibacterial efficacy noted above. The
threshold value, in turn, corresponded to a sub-lethal AMP
concentration since bacterial growth remained greater than 50%
of maximum (Fig. 1A), esterase activity was increased relative to
untreated cells (Fig. 1C) while membrane potential was not
completely lost (Fig. 1B). Hence the NMR metabolomic technique
identified conditions where metabolically active E. coli were
responding to the AMP challenge without simply reporting on
bacterial cell death. Comparing the back-scaled loadings, each of
the OPLS-DA comparisons between untreated bacteria and those
challenged with each AMP, identified metabolites whose differing
intensities correlated with the effect of each AMP. A hierarchical
cluster analysis was used to reveal variation in metabolite levels
(Fig. 2E). Both common and AMP specific variations in E. coli
metabolite levels were observed in response to challenge with the
four AMPs. Notably, the hierarchical analysis grouped the
peptides according to their potency. Though not considering the
magnitude or direction of changes in metabolite levels, network
Figure 1. AMP challenge and multi-parameter assay of E. coli
NCTC 9001. Overnight cultures were challenged with increasing
amounts of each of four AMPs for 30 minutes and the recovery of
aliquots added to fresh media was measured after 4 hours incubation
at 37uC (A). * indicates the peptide concentration causing a significant
(p,0.1) reduction in OD620 relative to the lowest peptide concentration
used. The membrane potential (B) of challenged bacteria as measured
by the voltage sensitive dye DiBAC4 is expressed here as a percentage
of the membrane potential determined for untreated cells. Esterase
activity (C) determined by cleavage of 5,6-carboxyfluorescein diacetate
expressed as a percentage of the maximum observed activity. Peptide
concentrations are given in mg/ml.
doi:10.1371/journal.ppat.1004104.g001
Systems View of AMP Challenge in Escherichia coli
PLOS Pathogens | www.plospathogens.org 3 May 2014 | Volume 10 | Issue 5 | e1004104
pathway analysis conducted using MetaboAnalyst [27,28]
matched pathways according to p-values obtained from pathway
enrichment analysis and pathway impact from pathway topology
(Fig. S2.1–S2.4 in File S1). Changes in alanine, aspartate and
glutamate metabolism had the greatest impact and were a
common feature of challenge with all four peptides with changes
in pyruvate, butanoate and arginine/proline metabolism high-
lighted according to the distinct challenges.
The dynamic response of E. coli NCTC9001 to challenge with
pleurocidin or magainin 2 was assessed over a period of 2 hours at
the following intervals: 5 minutes, 15 minutes, 60 minutes and
120 minutes. The OPLS-DA scores plots (Fig. S3 in File S1) and
corresponding Q2 (Table S1 in File S1) indicate that a response to
AMP challenge at the level of the metabolome can be detected
throughout the period tested. However, when the back-scaled
loadings were compared in a hierarchical cluster analysis (Fig. S4
in File S1), modest but notable differences in the affected
metabolites were discerned. This suggested that the bacterial
response detected beyond an hour after challenge is characteris-
tically distinct from that probed within the first 30 minutes. These
conditions – 30 minutes incubation at the determined threshold
concentration - were therefore used for subsequent electron
microscopic and transcript profiling analyses of samples prepared
in parallel to those used above.
Scanning and transmission electron microscopy
identifies differences in the response to each AMP
Changes in E. coli internal or external morphology in response
to challenge with AMP were monitored respectively using
transmission and scanning electron microscopy (TEM/SEM) at
either one or four times the sub-inhibitory AMP threshold
concentration known to induce a metabolomic response (Fig. 3;
Fig. S5.1–5.10 in File S1). The bacterial response to each AMP
challenge varied considerably and was in qualitative agreement
with the metabolomic study; buforin II had no noticeable effect
when compared with untreated bacterial cell controls (Fig. 3D–F;
Fig. S5.2/5.9/5.10 in File S1), with each of the three other AMPS
inducing substantial changes to external and/or internal mor-
phologies. For magainin 2, a regular, almost circular nucleoid
condensation was observed in some, but not all, cells (Fig. 3A; Fig.
S5.8 in File S1) while some impairment of cell division was evident
with extended rods observed (Fig. 3G). Pleurocidin also induced
nucleoid condensation but this was much more widespread;
observed throughout the bacterial cell population (Fig. S4.5/S4.6
in File S1). This was accompanied by some possible protein
aggregation and the production of large amounts of a fibrous
material (Fig. 3B). In addition to the production of the fibrous
material, SEM indentified moderate vesicle production, a known
envelope stress response in Gram-negative bacteria [29]. Finally,
D-LAK120-AP13 induced dramatic changes in both the internal
(Fig. 3C) and external E. coli morphologies (Fig. 3I). Extensive
release of outer membrane vesicles was evident which was
coincident with a loss of the normal rod shape, consistent with
bacteria budding prematurely (Fig. 3I). Inside bacterial cells,
extensive nucleoid condensation and protein aggregation was
observed throughout the bacterial cell population (Fig. 3C; Fig.
S5.3/S5.4 in File S1). Taken together, although there were some
qualitative similarities in the response of E. coli cells to each of the
three more potent AMPs, markedly distinct responses to each
peptide were observed overall. Transmission electron micrographs
obtained at higher magnification and with AMP added at a
concentration above the detected threshold value indicated that,
for all four peptides, the bacterial envelope remained intact and no
release of cell contents was apparent (Fig. S5.1 in File S1).
Global transcriptome response identifies some generic,
but largely AMP specific, responses
The response of E. coli to challenge with the four AMPs was
then probed at the level of the transcriptome. Transcript profile
changes in the NCTC 9001 strain, a clinical isolate from a patient
with cystitis with cystitis, were monitored using the E. coli Genome
2.0 Array where four strains including laboratory, uropathogenic
and enteropathogenic strains are featured. Due to the high degree
of similarity between strains, in the majority of cases, a single
probe set represents the equivalent ortholog in all four strains. All
genes that are subsequently described in detail are found in both
laboratory (K12 substr. MG1655) and uropathogenic (CFT073)
strains with the majority also found in the two enteropathogenic
strains. Principal component analysis of the twenty most differen-
tially expressed genes across all groups showed the three
independent replicates of each condition clustered together
indicating the AMP challenge and transcript profiling assay were
reproducible (Fig. S6 in File S1). Further analysis, where either an
arbitrary significance level (p#0.05) for differential gene expression
or manual manipulation of significance levels leading to an
optimal separation by principal components, generated lists of
differentially expressed genes related to each treatment. E. coli
genomes commonly encode between approximately 4,200 and
5,500 protein coding genes [30,31]. Of the approximately 10,000
probe positions, between 139 and 632 differentially expressed
unique genes (p#0.05) were detected for each treatment following
challenge with AMP at the threshold concentration eliciting a
bacterial response. This corresponds to 2.5–15.0% of the available
genome. Magainin 2 induced differential expression of only 139
Table 2. Predictive Q2 values for OPLS-DA models.
[AMP] (mg/ml) Q
2
Pleurocidin Magainin 2 Buforin II D-LAK120-AP13
3.9 0.32 (20.29) n.d n.d. 0.37 (20.30)
15.6 0.53 (20.31) 0.29 (20.36) n.d. 0.59 (20.28)*
62.5 0.81 (20.41)* 0.20 (20.31) n.d. 0.81 (20.31)
125 0.80 (20.29) 0.68 (20.34)* n.d. 0.83 (20.26)
250 n.d. n.d. 20.30 (20.39)* n.d.
Q2 values for cross validation performed with permutated classes are provided in parentheses.
* Key minimum concentrations.
doi:10.1371/journal.ppat.1004104.t002
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Figure 2. Metabolomic analysis by 1H HR-MAS NMR of lyophilised, stationary phase E. coli cell pellets. OPLS-DA scores plots are shown
for challenge of E. coli NCTC 9001 at the following threshold concentrations; pleurocidin at 62.5 mg/ml (A), magainin 2 at 125 mg/ml (B), D-LAK120-
AP13 at 15.6 mg/ml (C) and buforin II at 250 mg/ml (D). Hierachical clustered heatmap comparing loadings obtained from cross-validated OPLS-DA
comparing untreated bacteria with AMP at the threshold concentrations indicated above (E).
doi:10.1371/journal.ppat.1004104.g002
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genes which contrasted with the much greater number of genes
whose expression was altered in response to challenge with either
buforin II or D-LAK120-AP13; 625 and 632 respectively. Pleur-
ocidin induced differential expression of 298 genes. The distribution
of differentially expressed genes according to each AMP treatment is
represented in a Venn diagram and reveals that the vast majority
(76.3%) are specific to each of the four AMP challenges (Fig. 4A).
Only 32 differentially expressed genes, 2.4% of the total, were
common to at least three treatments while there was only one, yjjB,
which was common to all four treatments. Qualitatively therefore,
transcriptomic data supported the electron microscopy findings as,
while common responses can be identified, the dominant impression
was of a largely specific response to each AMP challenge
Mapping those discriminating metabolite changes with most
impact (Fig. S2.1–S2.4 in File S1) onto their respective Kyoto
Encyclopaedia of Genes and Genomes (KEGG) pathways
identified differentially expressed genes with a potentially key role
in mediating the response to AMP challenge. Changes in alanine,
aspartate and glutamate metabolism were common to all four
peptides and changes in expression of gltX, dapA and metB, coding
for respectively glutamyl-tRNA synthetase, dihydropicolinate
synthase and cystathionine gamma-synthase, were observed in
the gene lists though these did not always satisfy the significance
thresholds used above. Knockout mutants of dapA and gltX are not
available from the Keio collection but DmetB and five other
knockout mutants (DcyoA, DcyoC, DcyoD, DspeB, and DargR coding
respectively for cytochrome o uniquinol oxidase subunits II, III
and IV, agmatinase and arginine repressor), linked to changes in
arginine/proline metabolism, were tested for altered sensitivity to
AMP challenge though none was found.
Figure 3. Electron microscopic analysis of E. coli response to AMP challenge. Transmission (A–E) and scanning (F–I) electron micrographs at
625,000 magnification of either untreated (E/F) or AMP challenged E. coli NCTC 9001. Stationary phase bacteria were challenged for 30 minutes with
AMPs above the threshold concentration that elicits a bacterial response as determined by the 1H NMR metabolomic study; 250 mg/ml magainin 2
(A/G), 125 mg/ml pleurocidin (B/H), 62.5 mg/ml D-LAK120-AP13 (C/I) and 250 mg/ml buforin II (D). Red arrows indicate features described in the
results.
doi:10.1371/journal.ppat.1004104.g003
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Up-regulated in response to challenge by all four AMPs, yjjB,
encodes a 157 amino acid, conserved, inner membrane protein
predicted to have four trans-membrane helices but with no known
function. Of the five genes whose expression was generically
affected by the three AMPs of natural origin, three were up-
regulated in response to AMP challenge; manA codes for mannose-
6-phosphate isomerise, cysE codes for a serine acetyltransferase
and yohN codes for a 112 amino acid integral membrane protein
annotated and established as a periplasmic modulator of nickel
and cobalt efflux and renamed rcnB [32]. In contrast, yejF, part of
an ABC transporter identified as a possible nickel, and probable
microcin C transporter [33], and yrdB, which codes for a highly
anionic, glutamine rich, 85 amino acid hypothetical protein from
the DUF1488 superfamily, are down-regulated. Comparison of
the growth of parent strain BW25113 and four knockout mutants
(DyejF, DyjjB, DyohN and DyrdB) obtained from the Keio collection
[34] confirmed yohN confers sensitivity to Co2+ and possibly Ni2+
(Fig. S7 in File S1). The growth of these strains was also tested in
the presence of AMPs (Fig. 4B). While the MIC for pleurocidin
was not affected by the presence of any of the four deletions, a
modest but significant (p,0.05) increase in sensitivity was observed
for all four deletion strains when challenged by magainin 2. When
the experiment was repeated with LL-37, an AMP of human
origin, three of the deletions rendered the bacteria more sensitive
while deletion of yrdB had no effect.
The ontological profile related to each challenge offers another
view of how closely related the response to each AMP is to each
other. Here, instead of comparing individual genes on the basis of
their identity, the comparison is based on the cellular component,
biological process or molecular function and is less affected by
redundancy or more subtle changes in response and consequently
better reflects the fundamentals of the bacterial response.
Ontological analysis, which employed a Benjamini-Hochberg
method to control false discovery rate (FDR) and displays
statistically overrepresented, differentially expressed genes in a
graphical format according to their relationships in a hierarchical
tree, was carried out on gene lists comprising the 200–250 most
differentially expressed genes for each of the individual AMP
treatments (Fig. S8–S13 in File S1) and for comparisons of up to
three AMP treatments (Fig. 5; Fig. S8/S9 in File S1). The three
AMPs derived from natural sources are suspected of acting on
different cellular components. Indeed, comparing gene ontology
(GO) term enrichment for cellular components (Fig. 5) showed a
very different profile for each of magainin 2, buforin II and
pleurocidin. Magainin 2 appears confined to affecting membrane
components (Fig. 5; Fig. S10 in File S1) and had little effect on
molecular functions or biological processes. Buforin II, in contrast,
did not impact on any membrane components, instead focussing
on components in the ‘‘cell’’ or ‘‘cell part’’ (Fig. 5; Fig. S11A in
File S1) where 41% of the differentially expressed genes related to
binding are found in the analysis of molecular function (Fig. S11B
in File S1). Pleurocidin elicited responses both in membrane
components and in the cell itself (Fig. 5; Fig. S12 in File S1) with
biological processes, in particular polysaccharide and macromol-
ecule metabolism and transport, impacted. This was reinforced by
the finding that some 35 genes related to transporter activity were
differentially expressed (Fig. S13 in File S1). These observations
reinforce the view that AMPs impact on bacterial cells in distinct
and AMP-specific ways. When the top 250 genes differentially
expressed in response to challenge with D-LAK120-AP13 were
analyzed, very few enriched pathways were found when biological
processes were considered, with no enriched cellular components
or molecular function identified. This indicates a non-specific
response for this designed peptide notwithstanding its shared
responses with buforin II observed above.
Discussion
The value of a combined approach
When taken together, the metabolomic, electron microscopy
and transcript profiling analyses reveal a combination of generic
and specific responses to challenge with AMPs that share many
physicochemical features but that differ in their modes of action.
All four peptides used were cationic, of similar lengths, and will
Figure 4. Transcript profiles and role of individual genes in response to AMP challenge. Four way Venn diagram (A) showing the
distribution of differentially expressed genes detected by the GeneChip E. coli Genome 2.0 Array (p#0.05) following challenge of stationary phase E.
coli NCTC 9001 with each of four AMPs at sub-inhibitory concentrations known to elicit a bacterial response; pleurocidin at 62.5 mg/ml, magainin 2 at
125 mg/ml, D-LAK120-AP13 at 15.6 mg/ml and buforin II at 250 mg/ml. The entries in the Venn correspond to the number of affected genes. Effect on
sensitivity of E. coli BW25113 to magainin 2, pleurocidin and LL-37 of mutations in four of six genes commonly regulated in response to AMPs of
natural origin (B).
doi:10.1371/journal.ppat.1004104.g004
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adopt conformations with secondary amphipathicity in the
supposed target of the E. coli inner membrane. For the analytical
techniques used, some strengths and weaknesses were identified, so
underscoring the value of a combined approach. The electron
micrographs provided compelling evidence of AMPs induction of
manifestly different responses in E. coli challenged at both
inhibitory and sub-inhibitory concentrations. The images however
provide only circumstantial evidence as to the mechanism of
action of each peptide. Instead, quantitative information or details
of the molecular mechanisms involved are needed to pinpoint how
each peptide operates. Transcript profiling provides a rich vein of
information on the bacterial response. The individual gene
products implicated have suggested a wide range of experiments
that will illuminate further how bacteria attempt to fight off
challenges posed by AMPs. Transcript profiling may also be more
sensitive than the other approaches used since it alone was able to
identify a significant response to buforin II which, even when
administered at 250 mg/ml did not cause any perceived effect on
either the internal or external cellular morphology or register a
response as detected by 1H HR-MAS NMR. The transcript
Figure 5. Multi GOEAST comparison of gene ontology (GO) terms relating to cellular component for differential gene responses in
stationary phase E. coli NCTC 9001. Challenge was induced with sub-inhibitory concentrations of pleurocidin (red: p1), magainin 2 (blue: p2) and
buforin II (green: p3). Red arrows represent relationships between two enriched GO terms, black arrows between enriched and un-enriched terms and
black dashed arrows represent relationships between two un-enriched GO terms. Raw p values for GO terms have been adjusted using the Benjamini-
Hochberg method allowing FDR,15%.
doi:10.1371/journal.ppat.1004104.g005
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profiling method remains expensive however and the consumable
costs per sample make its use in a high throughput manner
unattractive. The NMR metabolomic technique has the advantage
of having low per sample consumable costs which enables a much
greater range of test conditions to be assessed. NMR metabolomics
is also highly reproducible and provides quantitative information
on this greater number of test conditions. It would therefore be
attractive to consider whether it could be used as a standalone
method for interrogating bacterial responses to challenge. In the
present study however, while both generic and specific changes in
metabolites were identified in response to AMP challenge, generic
changes may appear overestimated when compared with the
information provided by transcript profiling or micrographs. This
may be due to common metabolic pathways underpinning a series
of distinct bacterial responses and a much larger scale investiga-
tion, with a larger panel of both distinct and more closely related
AMPs is now warranted. This would allow greater weight to be
afforded to certain key metabolites, known to be altered in
response to a given class of AMP with known influence on
bacterial stress responses.
Life and death at the membrane?
This study investigates whether studying bacterial responses,
when challenged with carefully defined sub-lethal concentrations
of antibiotic, provides a detailed systems wide view of the
mechanism of action. The mechanism of action of cationic
amphipathic helix forming antimicrobial peptides has received
considerable attention in the past two decades with much work
focussed on the pore forming activity of magainin 2 and related
peptides [35]. Considered an archetypal pore forming peptide,
there is nevertheless evidence that for at least one microbial target,
Saccharomyces cerevisiae, magainin 2 can enter the cell and interfere
with DNA integrity [36] while pore forming activity that causes
graded dye release is linked to a mechanism that involves
translocation of the peptide across the membrane [37]. Finally,
MD simulations have shown that magainin-H2, when forming a
disordered toroidal pore does indeed translocate to the internal
leaflet of the membrane [38]. Set against these studies are a range
of data on the structurally and physico-chemically related, but
considerably more potent, pleurocidin which is known to have
pore forming activity [21] but is also capable of entering bacteria
to interfere with the synthesis of macromolecules [22]. We have
recently solved the high resolution structures of both magainin 2
and pleurocidin in the anionic detergent SDS (PDB entries 2LSA
and 2LS9 respectively) and found similar regions of flexibility
around the glycine residues in the middle section of the sequence
(Gly 13/18 – magainin 2; Gly 13/17 – pleurocidin). Only in the
membranes that most closely mimic the inner membrane of
Gram-negative bacteria are any differences between the two
peptides observed; here pleurocidin adopts a notably more
disordered conformation under these conditions [18]. The more
disordered conformation of pleurocidin in the E. coli target
membrane may be related to possible pore formation [39] or the
proposed intracellular targeting strategy [22] which, in both cases,
would serve to boost its potency.
Previous ‘omics based studies comparing AMPs action in Gram-
positive bacterial species found that there was very little overlap in
response between Streptococcus pneumoniae that had been challenged
with each of three rather different antimicrobial peptides [11],
while two earlier studies [9,10], which focussed on peptides with
the plasma membrane as a presumed common target, found
rather more overlap. We therefore decided to test whether a more
holistic approach would succeed in discriminating between the
different modes of actions of magainin 2 and pleurocidin and place
their differing membrane activities in a wider context, enabling a
more sophisticated understanding of their respective mechanisms
of action while explaining the greater potency of pleurocidin. In
the present study, the combined approach was readily capable of
distinguishing pleurocidin and magainin 2 on the basis of the
bacterial responses observed in their metabolomic and transcript
profiles with electron micrographs bringing these differences into
sharp relief. Despite the shared physicochemical properties and
conformational propensities of the two peptides and presumed
initial target of the bacterial inner membrane, transcript profiling
identified only 19 genes whose differential expression was common
to both AMP challenges, with differential expression of some 399
genes being a specific response to either pleurocidin or magainin 2.
The E. coli response to AMP challenge is therefore highly
adaptable and is most sensitive to the differing bactericidal
strategies of each peptide. Large scale changes in the internal
morphology of E. coli, following challenge with sub-inhibitory
concentrations of each AMP, provides circumstantial evidence
that both magainin 2 and pleurocidin can enter Gram-negative
bacteria, with the more profound effects of pleurocidin suggesting
a greater proficiency. Improvements in imaging technologies and
labelling techniques may open the way, in future, for the more
precise localisation of both peptides but it is apparent that a simple
description of AMP bactericidal mechanisms that rests solely on
studying the membrane interaction in isolation is inadequate. This
is particularly relevant for the goal of increasing potency.
We have also studied the structural properties of buforin II
which is considered to operate via an intracellular targeting
strategy [18]. Buforin II has a greater affinity for nucleic acids, has
a greater nominal charge at +7 and is less hydrophobic. The
proline kink in buforin II is known to be crucial for enabling
translocation into the E. coli cytosol [24]. Notably, in all
membranes that we have studied, the peptide adopts an extended
helical conformation, rather than one rich in a-helix, and has only
barely detectable antibacterial activity against planktonic E. coli
cultures [18]. We therefore included buforin II in the present study
since we hypothesised that the bacterial response to this peptide
would highlight responses to pleurocidin that are related to an
intracellular targeting strategy. Neither the NMR metabolomic
nor electron micrograph studies though identified a strong
response to even very elevated concentrations of this peptide;
consistent with our previous work which identified only a very
weak effect against planktonic cultures of either E. coli or P.
aeruginosa [18]. Nevertheless, a large number of significantly
differentially expressed genes in response to buforin II challenge
were detected by transcript profiling. While around 64 differen-
tially expressed genes were detected in common to challenge with
buforin II and pleurocidin, 33 differentially expressed genes were
common to buforin II and magainin 2 with a further 534
differentially expressed genes identified that were not affected by
either magainin 2 or pleurocidin. Only six differentially expressed
genes were identified as a common response to these three AMPs.
This further emphasises the plasticity of the E. coli response and
indicates that bacteria have a large repertoire of responses to
challenges.
Considering the ontology of the differentially expressed genes
can suggest how each individual AMP operates but, when used in
comparison, as here, the relative importance of the properties of
each AMP is revealed and supported the view that these three
peptides adopt distinct bactericidal strategies. The ontological
profiles reveal near orthogonal changes in transcript profiles
following sub-lethal challenge with the three different AMPs of
natural origin. Comparison of GO terms with existing paradigms
for the mode of action of each AMP supports the view that the
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present, combined approach faithfully reveals the mechanism of
action, notwithstanding the extra detail that identifies a range of
effects that may contribute to bacterial cell death. In particular, the
identification of eight GO terms linked to membranes supports the
established view that magainin 2 largely acts on the plasma
membrane of Gram-negative bacteria. In contrast, within the top
200 differentially expressed genes, no membrane GO terms were
linked to the action of buforin II which is considered to seek
intracellular targets. This is further supported by the distribution
of GO terms since the effect on binding and a host of biosynthetic
pathways is acute. For pleurocidin, where multiple bactericidal
mechanisms have been proposed, there is substantial overlap
between the cellular component GO terms with those affected by
magainin 2. This indicates that the bacterial membrane is indeed a
common target. However, in contrast with magainin 2, pleur-
ocidin impacts on a large number of intracellular biological
process, in particular macromolecule metabolic and transport
processes. This strongly indicates a multifaceted antibacterial
strategy underpins the high antibacterial potency of this AMP.
Can understanding the bacterial response be exploited
to improve AMP potency?
The high plasticity of the bacterial response to AMP challenge
suggests that deletion of one gene is unlikely to have a great impact
on sensitivity. This view is supported by the study of mutants
identified by mapping metabolite changes with the greatest
pathway impact onto their respective pathways and further work
will be required to more effectively disrupt such pathways in order
to identify any relationship with sensitivity to AMPs.
Nevertheless, six gene products were identified that were
significantly and uniformly affected by the three AMPs derived
from natural sources. Of these six genes, two were down-regulated;
yrdB an anionic 85 amino acid hypothetical protein and yejF. The
yejF gene codes for the ATPase in the ABC transporter YejABEF
which, when mutated, confers resistance to microcin C [33]. The
speculated role of YejABEF as a nickel transporter has been
questioned as it is phylogenetically distant from other oligopeptide
transporters [33]. However, since yejF is down-regulated in the
present study in response to all three peptides obtained from
natural sources and its deletion renders E. coli more sensitive to
both magainin 2 and LL-37, this behaviour does support the
earlier finding that the activity of this protein can have a
considerable effect on peptide antibiotic potency. Indeed, while
mutations in yejABEF confer resistance to microcin C in E. coli,
deletion of yejF in Salmonella enterica increased sensitivity to AMPs,
including both human beta defensins 1 and 2 (hBD-1 and hBD-2)
[40].
Of the four genes that are up-regulated, cysE and manA are
widely distributed amongst taxa, including animals, making them
less attractive as an antibiotic target. In contrast, with a
distribution that is concentrated in Enterobacteriaceae and with yet
to be tested functions, yohN and yjjB might be more attractive
targets for further investigation and possible targets for adjuvants
that could boost the potency of the host innate immune response.
Deletion of these genes caused a significant but only modest
increase in sensitivity to magainin 2 and LL-37 while the potency
of pleurocidin was unaffected. These results show that the
combined systems approach is indeed capable of identifying genes
that regulate resistance/sensitivity in E. coli but that the large
number of potentially differentially expressed genes at the disposal
of such bacteria will mitigate the effect that silencing one gene
product may have.
Finally, we were interested to contrast the expected results for
the three peptides representing naturally occurring AMPs with the
bacterial response to a peptide, D-LAK120-AP13, which was
composed of D-amino acids only. D-LAK120-AP13 was designed
in an attempt to circumvent the effect of proteases secreted by
target pathogens, and incorporate structural features, including
high cationicity and propensity for adopting a-helix rich
conformation [41] - and hence inserting into and disordering
the E. coli inner membrane - and a proline kink, affording
conformational flexibility [20] that facilitates penetration into
bacteria [23,24]. The robust and potent effect of this peptide
against E. coli was evident with a significant metabolomic
response even at very low peptide concentrations. Circumstantial
evidence for the ability to penetrate within bacterial cells was
shown by transmission electron microscopy, with the most
profound changes due to challenge with any of the four AMPs
observed, and transcript profiling. Again underlining the plastic-
ity of the E. coli response, transcript profiling identifies a further
390 differentially expressed genes that were uniquely affected by
D-LAK120-AP13 although, interestingly, there is considerable
degree of overlap with the response to buforin II with 192
differentially expressed genes in common. These two peptides
have a greater nominal cationic charge in solution at neutral pH
than either pleurocidin or magainin 2 and both incorporate a
proline induced kink in the secondary amphipathic conformation.
Taken together, the data support highly effective entry of D-
LAK120-AP13 into Gram-negative bacterial cells and it is this
that may underpin its high antibacterial potency.
With four distinct but physicochemically related AMPs now
tested by an integrated systems biology approach, a total of at least
1342 differentially expressed genes (p#0.05) have been identified
as being potential tools that can be manipulated by the bacteria to
overcome AMP challenge. This is equivalent to between 24 and
32% of the total E. coli genome and suggests, with more
structurally diverse AMPs yet to be tested, that bacteria have a
wide variety of means of overcoming AMP challenges. Under-
standing these responses enables both the mode of action of AMPs
to be elucidated as well as suggesting strategies to overcome these
defences. The approach may find generic applicability in the study
of antibiotic-bacteria arms races.
Materials and Methods
Materials
The peptides (Table 1) were all amidated at the C-terminus and
were purchased from Pepceuticals Ltd (Nottingham, UK) as
desalted grade or synthesised in house (D-LAK120-AP13) and
were further purified using water/acetonitrile gradients using a
Waters SymmetryPrep C8, 7 mm, 196300 mm column.
Bacterial culture and challenge
Cultures of Escherichia coli NCTC 9001, a strain isolated from a
patient with cystitis, were grown overnight in Mueller-Hinton
broth (MH) at 37uC. Once the OD620 reached<1.0, 1 ml aliquots
of bacterial suspension were transferred into 1.5 ml microcen-
trifuge tubes and aqueous solutions of peptides - magainin 2,
buforin II, pleurocidin and D-LAK120-AP13 were added at the
following concentrations: 250 mg/ml, 125 mg/ml, 62.5 mg/ml,
15.6 mg/ml, 3.9 mg/ml and incubated for 30 min at 37uC. In
order to be able to monitor the microbial recovery and growth,
10 ml of each suspension was sampled in 190 ml fresh medium onto
a 96-well microplate. The OD620 was measured at time 0 and after
4 h of incubation at 37uC. The microcentrifuge tubes were
centrifuged at 50006 g for 5 min and the bacterial pellets were
snap frozen in liquid nitrogen, lyophilised and kept at 220uC until
further use. Pellets from triplicate tubes were combined for
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subsequent HR-MAS analysis. Each challenge was independently
repeated nine times.
HR-MAS NMR
High-resolution magic angle spinning (HR-MAS) experiments
were performed on a Bruker Avance 400 MHz spectrometer
equipped with a 4 mm 1H/13C HR-MAS probe. The lyophilised
cell pellets were thawed at room temperature, transferred to an
NMR rotor inserts and rehydrated with 30 ml of D2O 2 hours
before the acquisition. 1D spectra were recorded at a constant
temperature of 310 K with magic angle spinning applied at 5 kHz.
1D 1H spectra were recorded using a standard cpmgpr1d spin
echo pulse (cpmgpr; Bruker) with water presaturation during
recycle delay of 1 second and a total of 128 scans were acquired.
The spectral width was 16.02 ppm and 1H 90 pulse length was
7.81 msec. The free induction decay was multiplied with an
exponential function corresponding to a line broadening of
0.3 Hz. Phase correction was performed manually and automatic
baseline correction was applied. A total of 120 samples were
analysed with between 6 and 13 samples per treated condition and
17 control samples (no AMP treatment). A number of 2D
experiments were run to facilitate identification of the compounds:
homonuclear J-resolved 2D correlation with presaturation during
relaxation delay using gradients (J-Res; jresgpprqf), 1H/13C
correlation via direct inept transfer, phase sensitive using states,
with decoupling during acquisition (HSQC 13C; AA-hsqcwg-
13C), 2D homonuclear shift correlation with presaturation during
relaxation delay (COSY; cosyprqf) all acquired using standard
Bruker pulse sequences. Spectra were Fourier transformed,
manually phase and automatically baseline corrected and
calibrated with 2,2,3,3-D4-3-(Trimethylsilyl) propionic acid sodi-
um salt (TMSP-2,2,3,3-D4) with reference signal at 0 ppm.
Assignment
Resonances were assigned based on J-couplings partners
revealed by COSY, multiplicities derived from J-Res, statistical
correlation spectroscopy (STOCSY) [42] and both 1H and 13C
chemical shifts with reference to the E. coli metabolome database
[43].
Multivariate data analysis
Spectra were analysed by principal component analysis (PCA)
and orthogonal partial least squares discriminant analysis (OPLS-
DA) using software developed in our laboratory for a previous
study [44] incorporating the nonlinear iterative partial least
squares (NIPALS) algorithm [45]. First, the spectra were aligned
to the reference peak and spectral regions such as water and
reference peak (4.8 ppm and 0 ppm, respectively) and regions of
no interest and/or no spectral information were removed. Spectra
were then normalised using probabilistic quotient normalization
(PQN) [46] and autoscaled but not bucketed. Cross-validation was
performed where 66% of the samples were used as a training set
and the remaining 33% as a test set, ensuring that the number of
samples in the test set was proportional to the total number of
samples from each class, and that at least one sample from each
class was present in the test set. To choose the number of
components for the model, a leave-one-out cross-validation was
carried out on the samples in the training set, and the F1-score
used to choose the number of components, with the additional
constraint to use a maximum of 10 components. This double
cross-validation was repeated 2000 times with randomly chosen
samples in the training and test set to prevent bias due to the
choice of training or test set. This leads to 362000 models (in the
supplementary information, each of these models leads to a point
on the scores plot, but loadings and weights are presented as
averages over all these models). Finally, this procedure was
repeated with randomly generated class assignments to provide a
reference value for Q2. The chosen number of components minus
one was then used as an OPLS filter and a PLS-DA analysis with
two components was carried out on the filtered data to yield one
predictive and one orthogonal component. The Q2 value was
calculated as Q2= 12(PRESS/TSS) where PRESS is the sum of
squared differences between the known and predicted classes, and
TSS is the sum of squared differences between the known classes
and their average ( = the total variance). Q2 thus gives a measure
of the goodness of fit after cross validation, and although it is
generally considered to be ‘‘good’’ when its value is higher than
0.5 [47,48] we have compared it to a reference value by
computing Q2 for models where the classes were assigned
randomly [47,48]. In each case, genuine or permutated class
assignments, the Q2 value quoted is the mean of all models. Back-
scaled loadings plots [49] were used to identify resonances with
high variance and high weight, therefore the discriminating
resonances, and verified against the peak intensity of the original
spectra after PQN normalisation. Freely available MultiExperi-
ment Viewer (MeV) which is a part of the TM4 Microarray
Software Suite [50] was used for hierarchical cluster (HCL)
analysis and generation of heatmaps. Euclidian distance algorithm
was used to compute the differences between two gene expression
levels (metabolite level changes) and the average linkage method
was used to define the distances.
Scanning and transmission electron microscopy
Both SEM and TEM were used to examine the structural
changes in bacteria induced by AMPs. Samples for the imaging
were prepared in parallel with the samples used for HR-MAS
NMR and hence represent bacteria in stationary phase. For SEM,
the pellet obtained after centrifugation was fixed in 25 ml of 2.5%
(v/v) glutaraldehyde in 0.2 M sodium cacodylate buffer and kept
at 4uC until further use. In 24-well tissue culture plates 20 ml
aliquots of vortexed bacterial pellet was smeared on 12 mm round
poly-L-lysine (BD Biosciences, Bedford) cover slips with adjacent
chambers filled with sufficient amount of 0.2 M sodium cacodylate
to prevent drying of the slides and kept in a hydration chamber for
2 h. Cover slips were then washed with 0.2 M sodium cacodylate
buffer followed by rinsing with 30%, 70%, 100%, 100%, and
100% ethanol and incubating for 10 min between each wash.
Hexamethyldisilazane (HMDS) was used for drying of the
specimen by washing cover slips in 50/50 100% ethanol/HMDS
for 10 min followed by the final wash in HMDS for 10 min. The
coverslips with dehydrated cells were mounted on the specimen
stubs and sputter coated with gold. Micrographs were acquired
with FEI Quanta 200F FEG scanning electron microscope.
Bacterial pellets for TEM processing were prepared as described
above. Cells were pelleted by centrifugation and the pellet was post
fixed in 1% osmium tetroxide in 0.1 M phosphate buffer for
60 min an RT. The pellet was dehydrated by exposure to a graded
series of ethanol (10%, 70% for 10 min each) followed by four
washes in 100% ethanol for 15 min each. Next, the pellet was
subjected to two washes in propylene oxide, 10 min each. Tubes
containing pellets were constantly rotated during the washes and
the following procedures and the washes were performed in the
fume hood. The supernatant was removed and the pellet placed
into a mixture of 50% resin and propylene oxide for 90 min and
transferred to 100% resin overnight before polymerisation at 60uC
for 24 hours. The resin blocks were sectioned with Leica Ultra-cut
ultramicrotome to semi-thick sections (0.75 mm–2 mm) and stained
with toluidine blue and used to determine the areas for thin
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sectioning (90 nm). The sections were then placed onto 150 mesh
copper grids coated with pioloform support film. Grids were then
stained with uranyl acetate and lead citrate before viewing on
Hitachi H7600 transmission electron microscope. For both
techniques, around 15 images were taken for each treatment.
The following magnifications were used and images were selected
that are representative of the effect observed: 7006, 50006,
120006, 250006, 700006.
GeneChips
GeneChip experiments were performed using the Affymetrix
(Santa Clara, CA) E. coli Genome 2.0 Array with effective,
response inducing, sub-MIC AMP concentrations determined
from the HR-MAS metabolomic study; pleurocidin 62.5 mg/ml,
buforin II 250 mg/ml, magainin 2 125 mg/ml and D-LAK120-
AP13 15.6 mg/ml. Each array includes approximately 10,000
probe sets for all 20,366 genes present in four strains of E. coli over
the entire open reading frame (ORF); K12 (MG1655 laboratory
strain), CFT073 (uropathogenic), 0157:H7-EDL953 (enteropatho-
genic) and O157:H7-Sakai (enteropathogenic). RNA was extract-
ed using RiboPure and enriched using MICROBExpress Bacterial
mRNA Enrichment Kit after the DNA digestion step (Life
Technologies, Paisley, UK) At each step the quality of RNA was
assessed using Pico100 (Picodrop Ltd, Hinxton, UK). cDNA was
synthesized from mRNA and purified using Qiagen MinElute
PCR (Qiagen, Manchester, UK). cDNA was then fragmented and
labeled using terminal transferase and biotinylated Affymerix
GeneChip labelling reagent according to the manufacturer’s
instructions. Fragmentation and labeling were assessed with the
2100 Bioanalyzer (Agilent Technologies, Wokingham, UK) to
obtain the size distribution and yield. cDNA was kept at 280uC
until microarray hybridization. Hybridization of the target to the
GeneChip was prepared according the standard Prokaryotic
Target Hybridisation protocol according to the manufacturer’s
instructions. The efficiency of the hybridization step was assessed
by examining hybridization of Poly-A controls provided for the
Affymetrix GeneChip. Arrays were scanned on an Affymetrix
GCS3000 microarray system and image acquisition, quantification
and data analysis were performed using Affymetrix Command and
Expression Console Software. Data were normalized using the
Robust Multi-array Average (RMA) algorithm built into Expres-
sion Console. Pre-selection of gene lists for each treatment was
performed using Qlucore Omics Explorer (Qlucore AB, Lund,
Sweden). First, ANOVA across all samples identified the twenty
most differentially expressed genes according to each replicated
treatment. These were then assessed by principal component
analysis (Fig. S6 in File S1) to confirm that independently
replicated experiments produced consistent results. Signal inten-
sities for gene expression were then averaged across technical
duplicates/triplicates and log transformed. For the gene annota-
tion enrichment analysis, differentially expressed genes in treat-
ment versus control samples were selected by a paired, homosce-
dastic t-test with a significance cutoff of p,0.05 and lists for the
four AMP treatments were then compared using Venny [51].
Microarray data are available in the ArrayExpress database (www.
ebi.ac.uk/arrayexpress) under accession number E-MTAB-1703.
To better understand the differences between the effects of the
four treatments, significance thresholds that identified the
approximate top 200–250 differentially expressed genes were
selected; p#0.0184 for buforin II and D-LAK120-AP13,
p#0.0425 for pleurocidin and p#0.078 for magainin 2. These
lists were analyzed using the GOEAST Gene Ontology Enrich-
ment Analysis Software Toolkit where the Benjamini-Hochberg
option was selected allowing an FDR up to 15% [52].
Discriminating metabolite changes, identified from HR-MAS
NMR, were then mapped onto the KEGG pathway using BioCyc
Omics Data Analysis [53] and genes related to given metabolic
pathway checked against consistently differentially expressed
genes, whether or not they had passed the significance test
described above.
Multiparameter viability assays
In order to assess the functionality and cellular integrity of
bacteria we used the following viability assays: membrane
potential assay, esterase activity assay and BacLight Live-Dead
stain for microscopy [26].
As previously, E. coli NCTC 9001 were grown from glycerol
stocks in Muller-Hinton broth overnight at 37uC without shaking
until an OD620 of 1.0 was reached. 1 ml aliquots of culture were
challenged for 30 min with four peptides at and below the
threshold concentrations established with NMR. Cells were then
harvested by centrifugation at 5,0006 g for 5 min and washed in
50 mM phosphate buffer (pH 7.0). For BacLight Live/Dead stain
cells were diluted to 46108 CFU/ml, whereas for the remaining
assays cells were diluted to 26108 CFU/ml. All experiments were
performed at room temperature. Negative controls were obtained
either by treatment with 70% isopropanol for 10 min and
removed by centrifugation at 5,0006 g for 5 min and re-
suspension in PBS, or by heat killing at 85uC for 10 min on a
heat block. Assays were performed in black, flat bottom, 96-well
plates and read on a Synergy HT multi-mode microplate reader
(BioTek, Winooski, VT)
Membrane potential
25 mg of dye DiBAC4 (Anaspec, Fremont, CA) was reconsti-
tuted in 2.42 ml ethanol to obtain a 20 mM stock solution which
was stored at 220uC. The stock was diluted further with water to
working concentration of 12.5 mM immediately before use. 20 ml
of 12.5 mM dye was added to a 96-well plate, covered by 180 ml
bacterial suspension in PBS and mixed. The plate was incubated
in the dark for 5 minutes and fluorescence emission was measured
(excitation 485 nm, emission 535 nm). Since membrane damage
leads to higher fluorescence intensity, values were background
corrected and expressed as a reciprocal before being normalised
with untreated cells defined as being 100% and isopropanol
treated cells defined as 0%.
Esterase activity
5 mg of esterase substrate 5,6-carboxyfluorescein diacetate
(CFDA) was dissolved in 1.086 ml dimethyl sulfoxide (DMSO)
to obtain 10 mM stock kept at 220uC. Stock was diluted 406 in
water immediately before use to obtain working concentration of
250 mM, which was pre-aliquoted to a 96-well plate. 180 ml of
bacterial suspension in PBS was added to the plate and mixed with
the detection solution. The plate was incubated in dark for
30 minutes with occasional shaking and fluorescence emission
measured (excitation 485 nm, emission 535 nm).
LIVE/DEAD BacLight
LIVE/DEAD BacLight kit (Life Technologies, Paisley, UK) was
used to measure membrane integrity. Harvested cells were
reconstituted with saline and 3 ml of the dye mixture (1.5 ml of
SYTO9 (3.34 mM) and 1.5 ml of propidium iodine (20 mM)) was
added to each 1 ml of bacterial suspension and mixed. Tubes were
incubated for 15 minutes in the dark with occasional shaking and
fixed with 20% paraformaldehyde (PFA) and kept at 4uC.
Specimens were viewed on an Olympus BX60 microscope fitted
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with an Andor Ultrahigh-resolution CCD setup. A 620 oil
immersion lens was used to obtain a 200 mm field width.
Excitation and emission filters were 480/520 nm and 515/
560 nm respectively.
MIC testing
Parent strain BW25113 and Keio knockout strains [34] for
DyejF, DyjjB, DyohN, and DyrdB were obtained from the Coli
Genetic Stock Center (Yale University, New Haven, CT). The
activities of the peptides were assessed in planktonic suspension in
polypropylene 96 well plates (Greiner Bio-one, Frickhausen,
Germany) according to a modified broth dilution assay (54).
Bacteria were grown without shaking in 50 ml Mueller-Hinton
(MH) broth at 37uC. Peptides (pleurocidin, magainin 2 and LL-37)
were tested in duplicates with two rows allocated for each peptide.
In each of columns 2–11, 50 ml of MH broth was added under
sterile conditions. In the first column of each row, 50 ml of 256 mg/
ml stock peptide solutions, prepared in distilled water, were added
and then the broth from the second column was pipetted into the
first column and thoroughly mixed before being deposited again in
the second column. This process was repeated throughout the tray
providing a twofold dilution of peptide with each row. Bacteria
with an A620 of 0.001 were then added to each well in volumes of
50 ml giving a further twofold dilution and a final volume of 100 ml
per well. The final column was used either as sterility control
(100 ml broth) or negative control (no peptide). Plates were
incubated overnight at 37uC and the A620 read. Growth curves
prepared from duplicates were fitted to determine the peptide
concentration required to inhibit growth by 50% (MIC50). The
MIC50 quoted for each peptide (Fig. 4) is an average value from at
least two independent repeats.
Supporting Information
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